

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 265/10, 261/02, 413/12, 413/06, A61K 31/535, 31/42	A1	(11) International Publication Number: WO 00/00481 (43) International Publication Date: 6 January 2000 (06.01.00)
(21) International Application Number: PCT/US99/14392 (22) International Filing Date: 25 June 1999 (25.06.99) (30) Priority Data: 60/091,030 29 June 1998 (29.06.98) US (71) Applicant: DU PONT PHARMACEUTICALS COMPANY [US/US]; 974 Centre Road, WR-1ST18, Wilmington, DE 19807 (US). (72) Inventors: JIN, Fuqiang; Apartment F9, 3120 Naamans Road, Wilmington, DE 19810 (US). CONFALONE, Pasquale, N.; 303 Centennial Circle, Greenville, DE 19807 (US). (74) Agent: LARSEN, Scott, K.; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		(81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: CYCLIC CARBAMATES AND ISOXAZOLIDINES AS IIB/IIIA ANTAGONISTS <div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div> (57) Abstract <p>The present invention relates generally to cyclic carbamates and isoxazolidines of Formula (I) or their pharmaceutically acceptable salts thereof, which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Title

Cyclic Carbamates and Isoxazolidines as IIB/IIIA Antagonists

Field of the Invention

5 The present invention relates generally to cyclic carbamates and isoxazolidines which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to
10 methods of using these compounds for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

Background of the Invention

15 Hemostasis is the normal physiological process in which bleeding from an injured blood vessel is arrested. It is a dynamic and complex process in which platelets play a key role. Within seconds of vessel injury, resting platelets become activated and are bound to the exposed matrix of the
20 injured area by a phenomenon called platelet adhesion. Activated platelets also bind to each other in a process called platelet aggregation to form a platelet plug. The platelet plug can stop bleeding quickly, but it must be reinforced by fibrin for long-term effectiveness, until the
25 vessel injury can be permanently repaired.

 Thrombosis may be regarded as the pathological condition wherein improper activity of the hemostatic mechanism results in intravascular thrombus formation. Activation of platelets and the resulting platelet aggregation and platelet factor
30 secretion has been associated with a variety of pathophysiological conditions including cardiovascular and cerebrovascular thromboembolic disorders, for example, the thromboembolic disorders associated with unstable angina, myocardial infarction, transient ischemic attack, stroke,
35 atherosclerosis and diabetes. The contribution of platelets to these disease processes stems from their ability to form aggregates, or platelet thrombi, especially in the arterial wall following injury.

Platelets are activated by a wide variety of agonists resulting in platelet shape change, secretion of granular contents and aggregation. Aggregation of platelets serves to further focus clot formation by concentrating activated clotting factors at the site of injury. Several endogenous agonists including adenosine diphosphate (ADP), serotonin, arachidonic acid, thrombin, and collagen, have been identified. Because of the involvement of several endogenous agonists in activating platelet function and aggregation, an inhibitor which acts against all agonists would represent a more efficacious antiplatelet agent than currently available antiplatelet drugs, which are agonist-specific.


Current antiplatelet drugs are effective against only one type of agonist; these include aspirin, which acts against arachidonic acid; ticlopidine, which acts against ADP; thromboxane A₂ synthetase inhibitors or receptor antagonists, which act against thromboxane A₂; and hirudin, which acts against thrombin.

Recently, a common pathway for all known agonists has been identified, namely platelet glycoprotein IIb/IIIa complex (GPIIb/IIIa), which is the membrane protein mediating platelet aggregation. A recent review of GPIIb/IIIa is provided by Phillips et al. Cell (1991) 65: 359-362. The development of a GPIIb/IIIa antagonist represents a promising new approach for antiplatelet therapy.


GPIIb/IIIa does not bind soluble proteins on unstimulated platelets, but GPIIb/IIIa in activated platelets is known to bind four soluble adhesive proteins, namely fibrinogen, von Willebrand factor, fibronectin, and vitronectin. The binding of fibrinogen and von Willebrand factor to GPIIb/IIIa causes platelets to aggregate. The binding of fibrinogen is mediated in part by the Arg-Gly-Asp (RGD) recognition sequence which is common to the adhesive proteins that bind GPIIb/IIIa.

Several RGD-peptidomimetic compounds have been reported which block fibrinogen binding and prevent the formation of platelet thrombi.


European Patent Application Publication Number 478363
relates to compounds having the general formula:




5 European Patent Application Publication Number 478328
relates to compounds having the general formula:




European Patent Application Publication Number 525629
10 (corresponds to Canadian Patent Application Publication
Number 2,074,685) discloses compounds having the general
formula:




15 PCT Patent Application 9307867 relates to compounds
having the general formula:



European Patent Application Publication Number 4512831
20 relates to compounds having the general formula:




Copending commonly assigned US patent application (USSN 08/337,920, filed 11/10/94, Wityak et al.; published as WO95/13155, 6/1/95) discloses compounds having the general formula:



which are useful as IIB/IIIA antagonists.

Copending commonly assigned US patent application (USSN 08/455,768, filed 5/31/95, Voss et al.) discloses compounds having the general formula:



which are useful as $\alpha_v\beta_3$ antagonists.

None of the above references teaches or suggests the compounds of the present invention which are described in detail below.

Summary of the Invention

One aspect of this invention provides novel compounds of Formula (I) (described below) which are useful as antagonists of the platelet glycoprotein IIb/IIIa complex. The compounds of the present invention inhibit the binding of fibrinogen to platelet glycoprotein IIb/IIIa complex and inhibit the aggregation of platelets. The present invention also includes pharmaceutical compositions containing such compounds of Formula (I), and methods of using such compounds for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.


The present invention also includes methods of treating cardiovascular disease, thrombosis or harmful platelet aggregation, reocclusion following thrombolysis, reperfusion injury, or restenosis by administering a compound of Formula (I) alone or in combination with one or more additional therapeutic agents selected from: anti-coagulants such as

warfarin or heparin; anti-platelet agents such as aspirin, piroxicam or ticlopidine; thrombin inhibitors such as boroarginine derivatives, hirudin or argatroban; or thrombolytic agents such as tissue plasminogen activator, anistreplase, urokinase or streptokinase; or combinations thereof.

Also included in the present invention are pharmaceutical kits comprising one or more containers containing pharmaceutical dosage units comprising a compound of Formula (I), for the treatment of cell adhesion related disorders, including but not limited to thromboembolic disorders.

Detailed Description of the Invention

This invention relates to novel compounds the Formula (I):



(I)

or their pharmaceutically acceptable salts thereof, wherein:

20

A is selected from R¹;

phenyl substituted with R¹ and 0-2 R⁶;

piperidinyl substituted with 0-1 R¹ and 0-2 R⁶; and

pyridyl substituted with 0-1 R¹ and 0-2 R⁶;

25

R¹ is -NHR², -C(=NR²)NHR², -Z(CH₂)_qNHR², -Z(CH₂)_qC(=NR²)NHR², -N(R²)C(=NR²)NHR², -C(=O)NHR², -C(=NR²)N(OR^{2A})R², or -C(=NOR^{2A})NHR²;

30 q is 1, 2, or 3;

Z is a bond, O, S, S(=O), or S(=O)₂;

R² is, independently at each occurrence, H, C₁-C₄ alkyl, C₂-C₆ alkenyl, C₁-C₁₀ alkoxy carbonyl, or aryl(C₁-C₁₀ alkoxy) carbonyl;

5 R^{2A} is H or C₁-C₁₀ alkyl substituted with 0-1 R⁴;

R³ is H,

C₁-C₆ alkyl substituted with 0-1 R⁶,
C₂-C₆ alkenyl substituted with 0-1 R⁶,
10 C₂-C₆ alkynyl substituted with 0-1 R⁶,
C₃-C₇ cycloalkyl substituted with 0-2 R^{6A},
phenyl substituted with 0-2 R^{6A}, or
pyridyl substituted with 0-2 R^{6A};

15 X is -C(=O)- or a single bond;

R⁴ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl, C₇-C₁₄ bicycloalkyl, hydroxy, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ alkylsulfonyl, nitro, C₁-C₆ alkylcarbonyl, C₆-C₁₀ aryl, 20 -N(R¹²)R¹³; halo, CF₃, CN, NO₂, C₁-C₆ alkoxy carbonyl, carboxy, piperidinyl, morpholinyl, or pyridinyl;

R⁵ is H or C₁-C₁₀ alkyl substituted with 0-1 R⁴;

25

R⁶ is C₃-C₇ cycloalkyl substituted with 0-2 R^{6A} or 0-1 R¹;
phenyl substituted with 0-2 R^{6A} or 0-1 R¹; or
pyridyl substituted with 0-2 R^{6A} or 0-1 R¹;

30 R^{6A} is C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, CF₃, NO₂ or NR¹²R¹³;

U is -C(R⁷)(R^{7A})- or -N(R⁷)-;

R⁷ is selected from:

35

H,
C₁-C₄ alkyl substituted with 0-2 R¹⁶,
C₂-C₄ alkenyl substituted with 0-2 R¹⁶,
C₂-C₄ alkynyl substituted with 0-2 R¹⁶,

- C₃-C₆ cycloalkyl substituted with 0-2 R¹⁶,
C₃-C₆ cycloalkyl(C₁-C₄ alkyl) substituted with 0-2 R¹⁶,
aryl substituted with 0-4 R¹⁶,
aryl(C₁-C₄ alkyl) substituted with 0-4 R¹⁶,
5 a 5-6 membered heterocyclic ring system having 1-3
heteroatoms selected independently from O, S, and N,
said heterocyclic ring being substituted with 0-4
R¹⁶, and
C₁-C₄ alkyl substituted with a 5-6 membered heterocyclic
10 ring system having 1-3 heteroatoms selected
independently from O, S, and N, said heterocyclic
ring being substituted with 0-4 R¹⁶;
- alternatively, R⁵ and R⁷ are taken together to form a 5-6
15 membered heterocyclic ring system having 1 or 2 nitrogen
atoms;
- R^{7A} is selected from:
- H,
20 C₁-C₄ alkyl substituted with 0-2 R¹⁶,
C₂-C₄ alkenyl substituted with 0-2 R¹⁶, and
C₂-C₄ alkynyl substituted with 0-2 R¹⁶;
- R⁸ is selected from:
- 25 H,
-C(=O)N(R²⁰)₂,
C₁-C₆ alkyl substituted with 0-2 R¹⁶,
C₂-C₄ alkenyl substituted with 0-2 R¹⁶,
C₂-C₄ alkynyl substituted with 0-2 R¹⁶,
30 C₃-C₆ cycloalkyl substituted with 0-2 R¹⁶,
aryl substituted with 0-4 R¹⁶,
aryl(C₁-C₄ alkyl) substituted with 0-4 R¹⁶,
a 5-6 membered heterocyclic ring system having 1-3
heteroatoms selected independently from O, S, and N,
35 said heterocyclic ring being substituted with 0-4
R¹⁶, and
C₁-C₄ alkyl substituted with a 5-10 membered heterocyclic
ring system having 1-3 heteroatoms selected

independently from O, S, and N, said heterocyclic ring being substituted with 0-4 R¹⁶;

alternatively, R⁵ and R⁸ are taken together to form a
5 piperidinyl or a pyrrolidinyl ring;

alternatively, R⁷ and R⁸ are taken together to form a 5-6
membered carbocyclic ring, wherein said carbocyclic ring
is either saturated, partially unsaturated or aromatic;
10

R^{8A} is selected from:

H,
C₁-C₄ alkyl substituted with 0-2 R¹⁶,
C₂-C₄ alkenyl substituted with 0-2 R¹⁶, and
15 C₂-C₄ alkynyl substituted with 0-2 R¹⁶;

k is 0 or 1;

j is 0, 1, 2, or 3;
20

V is O, NH, or a single bond;

Q is -C(=O)Y, -SO₃H, or -PO₃H;

25 Y is hydroxy,

C₁-C₁₀ alkyloxy,
C₃-C₁₁ cycloalkyloxy,
C₆-C₁₀ aryloxy,
C₇-C₁₁ aralkyloxy,
30 C₃-C₁₀ alkylcarbonyloxyalkyloxy,
C₃-C₁₀ alkoxycarbonyloxyalkyloxy,
C₂-C₁₀ alkoxycarbonylalkyloxy,
C₅-C₁₀ cycloalkylcarbonyloxyalkyloxy,
C₅-C₁₀ cycloalkoxycarbonyloxyalkyloxy,
35 C₅-C₁₀ cycloalkoxycarbonylalkyloxy,
C₇-C₁₁ aryloxycarbonylalkyloxy,
C₈-C₁₂ aryloxycarbonyloxyalkyloxy,
C₈-C₁₂ arylcarbonyloxyalkyloxy,

C₅-C₁₀ alkoxyalkylcarbonyloxyalkyloxy,
C₅-C₁₀ (5-alkyl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy,
C₁₀-C₁₄ (5-aryl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy,
or

5 (R²)HN-(C₁-C₁₀ alkyl)oxy;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

10

R⁹ and R¹⁰ are each independently H, C₁-C₆ alkyl, C₂-C₆
alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl,
phenyl substituted with 0-2 R^{6A}, or
pyridyl substituted with 0-2 R^{6A};

15

R¹² and R¹³ are each independently H, C₁-C₁₀ alkyl, C₁-C₁₀
alkoxycarbonyl, C₁-C₁₀ alkylcarbonyl, C₁-C₁₀
alkylsulfonyl, heteroaryl(C₁-C₄ alkyl)sulfonyl,
aryl(C₁-C₁₀ alkyl)sulfonyl, arylsulfonyl, aryl,
20 heteroarylcarbonyl, heteroarylsulfonyl, or
heteroarylalkylcarbonyl, wherein said aryls and
heteroaryls are optionally substituted with 0-3
substituents selected from the group consisting of C₁-C₄
alkyl, C₁-C₄ alkoxy, halo, CF₃, and NO₂;

25

R¹⁶ is H, halogen, -CF₃, -CN, -NO₂, -NR¹⁷R¹⁸, methyl, ethyl,
propyl, butyl, cyclopropyl, methoxy, ethoxy, propoxy,
butoxy, or C₁-C₄ alkoxycarbonyl;

30 R¹⁷ and R¹⁸ are each independently H, methyl, ethyl, propyl,
or butyl;

alternatively, R¹⁷ and R¹⁸ can be taken together to form
-(CH₂)₄-, -(CH₂)₅-, or -CH₂CH₂NHCH₂CH₂-;

35

R²⁰ is selected from:

H,

C₁-C₄ alkyl substituted with 0-1 R²¹,

C₃-C₆ cycloalkyl substituted with 0-2 R²¹,
aryl substituted with 0-3 R²¹, and
aryl(C₁-C₄ alkyl) substituted with 0-4 R²¹; and

5 R²¹ is H, halogen, -CF₃, -CN, -NR¹⁷R¹⁸, methyl, ethyl, propyl,
butyl, cyclopropyl, methoxy, ethoxy, propoxy, or butoxy;

provided that m and n are chosen such that the number of
atoms connecting R¹ and Y is in the range of 10-18.

10

Preferred compounds of the present invention are
compounds wherein:

A is selected from R¹;

15 phenyl substituted with R¹ and 0-2 R⁶;
piperidinyl substituted with 0-1 R¹ and 0-2 R⁶; and
pyridyl substituted with 0-1 R¹ and 0-2 R⁶;

20 R¹ is -NHR², -C(=NR²)NHR², -Z(CH₂)_qNHR², -Z(CH₂)_qC(=NR²)NHR²,
-N(R²)C(=NR²)NHR², -C(=NR²)N(OR^{2A})R², or -C(=NOR^{2A})NHR²;

q is 1, 2 or, 3;

Z is a bond or O;

25

R² is, independently at each occurrence, H, C₁-C₄ alkyl, C₂-C₄
alkenyl, C₁-C₆ alkoxy carbonyl, or aryl(C₁-C₆
alkoxy)carbonyl;

30 R^{2A} is H or C₁-C₆ alkyl substituted with 0-1 R⁴;

R³ is H,

35 C₁-C₄ alkyl substituted with 0-1 R⁶,
C₂-C₄ alkenyl substituted with 0-1 R⁶,
C₂-C₄ alkynyl substituted with 0-1 R⁶,
C₃-C₆ cycloalkyl substituted with 0-2 R^{6A},
phenyl substituted with 0-2 R^{6A}, or
pyridyl substituted with 0-2 R^{6A};

X is -C(=O)-;

5 R⁴ is C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆ cycloalkyl, C₇-C₁₂ bicycloalkyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, nitro, C₁-C₄ alkylcarbonyl, C₆-C₁₀ aryl, -N(R¹²)R¹³; halo, CF₃, CN, NO₂, C₁-C₅ alkoxy carbonyl, carboxy, piperidinyl, morpholinyl, or pyridinyl;

10

R⁵ is H or C₁-C₆ alkyl substituted with 0-1 R⁴;

R⁶ is C₃-C₇ cycloalkyl substituted with 0-2 R^{6A} or 0-1 R¹; phenyl substituted with 0-2 R^{6A} or 0-1 R¹; or
15 pyridyl substituted with 0-2 R^{6A} or 0-1 R¹;

R^{6A} is C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, CF₃, NO₂, or NR¹²R¹³;

20 U is -C(R⁷)(R^{7A})- or -N(R⁷)-;

20

R⁷ is selected from:

H,
C₁-C₄ alkyl substituted with 0-1 R¹⁶,
C₂-C₄ alkenyl substituted with 0-1 R¹⁶,
25 C₂-C₄ alkynyl substituted with 0-1 R¹⁶,
C₃-C₆ cycloalkyl substituted with 0-2 R¹⁶,
C₃-C₆ cycloalkyl(C₁-C₄ alkyl) substituted with 0-1 R¹⁶,
aryl substituted with 0-4 R¹⁶, and
aryl(C₁-C₄ alkyl) substituted with 0-4 R¹⁶;

30

alternatively, R⁵ and R⁷ are taken together to form a piperidinyl, pyrrolidinyl, or piperazinyl ring;

R^{7A} is H;

35

R⁸ is selected from:

H,
-C(=O)NHR²⁰,

- C₁-C₆ alkyl substituted with 0-1 R¹⁶,
C₂-C₄ alkenyl substituted with 0-1 R¹⁶,
C₂-C₄ alkynyl substituted with 0-1 R¹⁶,
C₃-C₆ cycloalkyl substituted with 0-2 R¹⁶,
5 aryl substituted with 0-4 R¹⁶,
aryl(C₁-C₄ alkyl) substituted with 0-4 R¹⁶,
a 5-6 membered heterocyclic ring system having 1-3
heteroatoms selected independently from O, S, and N,
said heterocyclic ring being substituted with 0-4
10 R¹⁶, and
C₁-C₄ alkyl substituted with a 5-10 membered heterocyclic
ring system having 1-3 heteroatoms selected
independently from O, S, and N, said heterocyclic
ring being substituted with 0-4 R¹⁶;
15 alternatively, R⁵ and R⁸ are taken together to form a
piperidiny1 or a pyrrolidinyl ring;
alternatively, R⁷ and R⁸ are taken together to form a 5-6
20 membered carbocyclic ring, wherein said carbocyclic ring
is selected from phenyl, cyclohexyl, cyclopentyl,
cyclohexenyl, or cyclopentenyl;
R^{8A} is H or C₁-C₄ alkyl substituted with 0-1 R¹⁶;
25 k is 0 or 1;
j is 0, 1, or 2;
30 V is O or a single bond;
Q is -C(=O)Y or -SO₃H;
Y is hydroxy,
35 C₁-C₁₀ alkyloxy,
C₃-C₁₁ cycloalkyloxy,
C₆-C₁₀ aryloxy,
C₇-C₁₁ aralkyloxy,

- C₃-C₁₀ alkylcarbonyloxyalkyloxy,
C₃-C₁₀ alkoxycarbonyloxyalkyloxy,
C₂-C₁₀ alkoxycarbonylalkyloxy,
C₅-C₁₀ cycloalkylcarbonyloxyalkyloxy,
5 C₅-C₁₀ cycloalkoxycarbonyloxyalkyloxy,
C₅-C₁₀ cycloalkoxycarbonylalkyloxy,
C₇-C₁₁ aryloxycarbonylalkyloxy,
C₈-C₁₂ aryloxycarbonyloxyalkyloxy,
C₈-C₁₂ arylcarbonyloxyalkyloxy,
10 C₅-C₁₀ alkoxyalkylcarbonyloxyalkyloxy,
C₅-C₁₀ (5-alkyl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy,
C₁₀-C₁₄ (5-aryl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy,
or
(R²)HN-(C₁-C₁₀ alkyl)oxy;
15
m is 0, 1, or 2;

n is 0, 1, 2, or 3;

20 R⁹ is H, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆
cycloalkyl, phenyl substituted with 0-2 R^{6A}, or pyridyl
substituted with 0-2 R^{6A};

R¹⁰ is H, methyl, ethyl, propyl, or butyl;
25
R¹² and R¹³ are each independently H, C₁-C₆ alkyl, C₁-C₆
alkoxycarbonyl, C₁-C₆ alkylcarbonyl, C₁-C₆ alkylsulfonyl,
heteroaryl(C₁-C₄ alkyl)sulfonyl,
aryl(C₁-C₆ alkyl)sulfonyl, arylsulfonyl, aryl,
30 heteroarylcarbonyl, heteroarylsulfonyl, or
heteroarylalkylcarbonyl, wherein said aryls and
heteroaryls are optionally substituted with 0-3
substituents selected from the group consisting of C₁-C₄
alkyl, C₁-C₄ alkoxy, halo, CF₃, and NO₂;
35
R¹⁶ is H, halogen, -CF₃, -CN, -NO₂, -NR¹⁷R¹⁸, methyl, ethyl,
propyl, butyl, cyclopropyl, methoxy, ethoxy, propoxy,
butoxy, or C₁-C₄ alkoxycarbonyl;

R¹⁷ and R¹⁸ are each independently H, methyl, ethyl, propyl, or butyl;

- 5 alternatively, R¹⁷ and R¹⁸ can be taken together to form
-(CH₂)₄-, -(CH₂)₅-, or -CH₂CH₂NHCH₂CH₂-;

R²⁰ is selected from:

- H,
10 C₁-C₄ alkyl substituted with 0-1 R²¹,
C₃-C₆ cycloalkyl substituted with 0-2 R²¹,
aryl substituted with 0-3 R²¹, and
aryl(C₁-C₄ alkyl) substituted with 0-3 R²¹; and
15 R²¹ is H, halogen, -CF₃, -CN, -NR¹⁷R¹⁸, methyl, ethyl, propyl,
butyl, cyclopropyl, methoxy, ethoxy, propoxy, or butoxy;

provided that m and n are chosen such that the number of
atoms connecting R¹ and Y is in the range of 10-18.

20

More preferred compounds of the present invention are
compounds, wherein:

- A is phenyl substituted with R¹ and 0-1 R⁶, or
25 piperidinyl substituted with 0-1 R⁶;

R¹ is -NHR², -C(=NR²)NHR², -(CH₂)_qNHR², -(CH₂)_qC(=NR²)NHR², or
-N(R²)C(=NR²)NHR²;

- 30 q is 1, 2, or 3;

R² is, independently at each occurrence, H, methyl, ethyl,
propyl, butyl, or C₂-C₄ alkenyl;

- 35 R³ is H,
C₁-C₄ alkyl substituted with 0-1 R⁶ or
C₂-C₄ alkenyl substituted with 0-1 R⁶;

X is -C(=O)-;

R⁴ is methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy,
or butoxy, fluoro, chloro, bromo, iodo, CF₃, NO₂, NH₂,
5 or N(CH₃)₂;

R⁵ is H or C₁-C₂ alkyl substituted with 0-1 R⁴;

R⁶ is C₃-C₆ cycloalkyl substituted with 0-2 R^{6A};
10 phenyl substituted with 0-2 R^{6A}; or
pyridyl substituted with 0-2 R^{6A};

R^{6A} is methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy,
or butoxy, fluoro, chloro, bromo, iodo, CF₃, NO₂, NH₂,
15 N(CH₃)₂, or N(CH₂CH₃)₂;

U is -C(R⁷)(R^{7A})- or -N(R⁷)-;

R⁷ is selected from:
20 H, methyl, ethyl, propyl, and butyl;

R^{7A} is H;

R⁸ is selected from:
25 H,
-C(=O)NHR²⁰,
C₁-C₆ alkyl substituted with 0-1 R¹⁶,
C₂-C₄ alkenyl substituted with 0-1 R¹⁶,
C₂-C₄ alkynyl substituted with 0-1 R¹⁶,
30 C₃-C₆ cycloalkyl substituted with 0-2 R¹⁶,
aryl substituted with 0-4 R¹⁶,
aryl(C₁-C₄ alkyl) substituted with 0-2 R¹⁶,
a 5-6 membered heterocyclic ring system having 1-3
heteroatoms selected independently from O, S, and N,
35 said heterocyclic ring being substituted with 0-2
R¹⁶, and
C₁-C₄ alkyl substituted with a 5-10 membered heterocyclic
ring system having 1-3 heteroatoms selected

independently from O, S, and N, said heterocyclic ring being substituted with 0-2 R¹⁶;

R^{8A} is H, methyl, ethyl, propyl, or butyl;

5

k is 0;

j is 0;

10 V is a single bond;

Q is -C(=O)Y;

Y is hydroxy-,

15

C₁-C₄ alkoxy-,

methylcarbonyloxymethoxy-,

ethylcarbonyloxymethoxy-,

t-butylcarbonyloxymethoxy-,

cyclohexylcarbonyloxymethoxy-,

20

1-(methylcarbonyloxy)ethoxy-,

1-(ethylcarbonyloxy)ethoxy-,

1-(t-butylcarbonyloxy)ethoxy-,

1-(cyclohexylcarbonyloxy)ethoxy-,

t-butyloxy carbonyloxymethoxy-,

25

i-propyloxy carbonyloxymethoxy-,

1-(i-propyloxy carbonyloxy)ethoxy-,

1-(cyclohexyloxy carbonyloxy)ethoxy-,

1-(t-butyloxy carbonyloxy)ethoxy-,

dimethylaminoethoxy-,

30

diethylaminoethoxy-,

(5-methyl-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,

(5-(t-butyl)-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,

(1,3-dioxo-5-phenyl-cyclopenten-2-on-4-yl)methoxy-,

1-(2-(2-methoxypropyl)carbonyloxy)ethoxy-,

35

(R²)HN-(C₁-C₆ alkyl)oxy-, morpholinoethoxy-, or

pyrrolidinoethoxy;

m is 0 or 1;

n is 0 or 1;

R^9 is H, methyl, ethyl, propyl, butyl, phenyl substituted with
5 0-2 R^6 , or pyridyl substituted with 0-2 R^6 ;

R^{10} is H;

R^{16} is H, halogen, $-CF_3$, $-CN$, $-NO_2$, $-NR^{17}R^{18}$, methyl, ethyl,
10 propyl, butyl, cyclopropyl, methoxy, ethoxy, propoxy or
butoxy;

R^{17} and R^{18} are each independently H, methyl, ethyl, propyl or
butyl.

15


R^{20} is selected from:

H,
C₁-C₃ alkyl substituted with 0-1 R^{21} ,
C₃-C₆ cycloalkyl substituted with 0-1 R^{21} ,
20 aryl substituted with 0-2 R^{21} , and
aryl(C₁-C₂ alkyl) substituted with 0-2 R^{21} ; and

R^{21} is H, F, Cl, Br, I, $-CF_3$, $-CN$, NH_2 , $N(CH_3)_2$, $N(CH_2CH_3)_2$,
methyl, ethyl, cyclopropyl, methoxy, or ethoxy.

25

Even more preferred compounds of the present invention
are compounds of Formula (Ia),




30

(Ia)

wherein:

R^1 is $-C(=NR^2)NHR^2$, $-(CH_2)_qC(=NR^2)NHR^2$ or



q is 1 or 2;

5 R^2 is, independently at each occurrence, H, methyl or ethyl;

R^3 is H,

methyl substituted with 0-1 R^6 , or

ethyl substituted with 0-1 R^6 ;

10

R^5 is H, methyl or ethyl;

R^6 is C_3 - C_6 cycloalkyl substituted with 0-2 R^{6A} ;

phenyl substituted with 0-2 R^{6A} ; or

15

pyridyl substituted with 0-2 R^{6A} ;

R^{6A} is methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy,

or butoxy, fluoro, chloro, bromo, iodo, CF_3 , NO_2 , NH_2 or

$N(CH_3)_2$;

20

R^8 is selected from:

H,

$-C(=O)NHCH_2R^{21}$,

$-C(=O)NH(CH_2)_2R^{21}$,

25

$-C(=O)NH(CH_2)_3R^{21}$,

methyl substituted with 0-1 R^{16} ,

ethyl substituted with 0-1 R^{16} ,

phenyl substituted with 0-2 R^{16} ,

phenyl(CH_2)- substituted with 0-2 R^{16} ,

30

phenyl(CH_2CH_2)- substituted with 0-2 R^{16} ,

a 5-6 membered heterocyclic ring system selected from

pyrrolyl, indolyl, 2-isobenzazoly-, indazolyl,

isoindazolyl, pyridinyl, quinolinyl, isoquinolinyl,

and piperidinyl;

35

methyl substituted with a 5-6 membered heterocyclic ring system selected from pyrrolyl, indolyl, 2-

isobenzazoly-, indazolyl, isoindazolyl, pyridinyl,

quinolinyl, isoquinolinyl, and piperidinyl; and

ethyl substituted with a 5-6 membered heterocyclic ring system selected from pyrrolyl, indolyl, 2-isobenzazolyl-, indazolyl, isoindazolyl, pyridinyl, quinolinyl, isoquinolinyl, and piperidinyl;

5

Y is hydroxy-, methoxy-, ethoxy-, n-butoxy-, isopropoxy-, isobutoxy-, benzyloxy-, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, tert-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy-,
10 tert-butyloxy carbonyloxymethoxy-, dimethylaminoethoxy-, diethylaminoethoxy-, morpholinoethoxy-, or pyrrolidinoethoxy-;

R¹⁶ is H, halogen, -CF₃, methyl, ethyl, methoxy, ethoxy, -NH₂,
15 -N(CH₃)₂, or -N(CH₂CH₃)₂;

R¹⁷ and R¹⁸ are each independently H, methyl, or ethyl; and

R²¹ is H, F, Cl, Br, I, -CF₃, -CN, NH₂, N(CH₃)₂, N(CH₂CH₃)₂,
20 methyl, ethyl, cyclopropyl, methoxy, or ethoxy.

In a further preferred embodiment compounds of the present invention are selected from

25 3-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminopropionic acid;

3-[[4(R)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(S)-yl]acetyl]amino propionic acid;

30

Trans-3-[[4-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6-yl]acetyl]amino propionic acid;

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminobutyric acid;

35

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-phenylvaleric acid;

5 3(S)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-3-(pyridin-3-yl)propionic acid;

10 3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-3-(pyridin-3-yl)propionic acid;

15 3(S)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-3-phenylpropionic acid;

20 3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-3-phenylpropionic acid;

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-4-[(3-dimethylamino)propyl]amino-4-oxobutanoic acid;

25 3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-indole-3-valeric acid;

30 3-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminopropionic acid;

3-[[4(R)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(S)-yl]acetyl]aminopropionic acid;

35 3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminobutyric acid;

[N-[[4(S)-[4-(N-butylaminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]piperidin-4-yl]acetic acid;

- 5 3(R)-[[4(S)-[4-(N-butylaminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-phenylvaleric acid;


- 3-[[2-methyl-3(S)-[4-(aminoiminomethyl)phenyl]-isoxazolidin-10 5(R)-yl]acetyl]aminopropionic acid;

3-[[2-methyl-3(R)-[4-(aminoiminomethyl)phenyl]-isoxazolidin-5(S)-yl]acetyl]aminopropionic acid;

- 15 3(R)-[[2-methyl-3(R)-[4-(aminoiminomethyl)phenyl]-isoxazolidin-5(S)-yl]acetyl]aminobutyric acid; and

- [N-[[4(S)-[4-(N-butylaminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]piperidin-4-20 yl]acetic acid.


A second embodiment of the present invention relates to novel compounds of the Formula (II):



(II)

or their pharmaceutically acceptable salts thereof.


- Preferred compounds of the present invention are
30 compounds of Formula (IIa):



(IIa)

or their pharmaceutically acceptable salts thereof.

- 5 A third embodiment of the present invention relates to novel compounds of the Formula (III):



(III)

- 10 or their pharmaceutically acceptable salts thereof.

A fourth embodiment of the present invention relates to a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically effective amount of a compound
15 of the present invention.

A fifth embodiment of the present invention relates to a method in inhibiting the aggregation of blood platelets which comprises administering to a host in need of such inhibition
20 a therapeutically effective amount of a compound of the present invention.

A sixth embodiment of the present invention relates to a method of treating thromboembolic disorders selected from
25 thrombus or embolus formation, harmful platelet aggregaion, reocclusion following thrombolysis, reperfusion injury, restenosis, atherosclerosis, stroke myocardial infarction, and unstable angina, which comprises administering to a host in need of such treatment a therapeutically effective amount
30 of a compound of the present invention.

A seventh embodiment of the present invention relates to a method of treating metastatic cancer which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of the present invention.

The compounds of Formula (I) of the present invention are useful for the treatment (including prevention) of thromboembolic disorders. The term "thromboembolic disorders" as used herein includes conditions involving platelet activation and aggregation, such as arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, thrombosis, unstable angina, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, myocardial infarction, cerebral embolism, kidney embolisms, pulmonary embolisms, or such disorders associated with diabetes, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the invention described above.

The compounds of Formula (I) of the present invention are useful for inhibiting the binding of fibrinogen to blood platelets, inhibiting aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal. The compounds of the invention may be used as a medicament for blocking fibrinogen from acting at its receptor site in a mammal.

Compounds of the invention may be administered to patients where prevention of thrombosis by inhibiting binding of fibrinogen to the platelet membrane glycoprotein complex IIb/IIIa receptor is desired. They are useful in surgery on peripheral arteries (arterial grafts, carotid endarterectomy) and in cardiovascular surgery where manipulation of arteries

and organs, and/or the interaction of platelets with artificial surfaces, leads to platelet aggregation and consumption, and where the aggregated platelets may form thrombi and thromboemboli. The compounds of the present invention may be administered to these surgical patients to prevent the formation of thrombi and thromboemboli.

Extracorporeal circulation is routinely used during cardiovascular surgery in order to oxygenate blood. Platelets adhere to surfaces of the extracorporeal circuit. Adhesion is dependent on the interaction between GPIIb/IIIa on the platelet membranes and fibrinogen adsorbed to the surface of the extracorporeal circuit. Platelets released from artificial surfaces show impaired homeostatic function. The compounds of the invention may be administered to prevent such ex vivo adhesion.

The compounds of the present invention may be used for other ex vivo applications to prevent cellular adhesion in biological samples.

Other applications of these compounds include prevention of platelet thrombosis, thromboembolism, and reocclusion during and after thrombolytic therapy and prevention of platelet thrombosis, thromboembolism and reocclusion after angioplasty of coronary and other arteries and after coronary artery bypass procedures. The compounds of the present invention may also be used to prevent myocardial infarction. The compounds of the present invention are useful as thrombolytics for the treatment of thromboembolic disorders.

The compounds of the present invention can also be administered in combination with one or more additional therapeutic agents selected from: anti-coagulant or coagulation inhibitory agents, such as heparin or warfarin; anti-platelet or platelet inhibitory agents, such as aspirin, piroxicam, or ticlopidine; thrombin inhibitors such as boro peptides, hirudin or argatroban; or thrombolytic or fibrinolytic agents, such as plasminogen activators, anistreplase, urokinase, or streptokinase.

The compounds of Formula (I) of the present invention can be administered in combination with one or more of the

foregoing additional therapeutic agents, thereby to reduce the doses of each drug required to achieve the desired therapeutic effect. Thus, the combination treatment of the present invention permits the use of lower doses of each component, with reduced adverse, toxic effects of each component. A lower dosage minimizes the potential of side effects of the compounds, thereby providing an increased margin of safety relative to the margin of safety for each component when used as a single agent. Such combination therapies may be employed to achieve synergistic or additive therapeutic effects for the treatment of thromboembolic disorders.

By "therapeutically effective amount" it is meant an amount of a compound of the invention that when administered alone or in combination with an additional therapeutic agent to a cell or mammal is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease.

By "administered in combination" or "combination therapy" it is meant that the compound of the present invention and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect.

The term anti-coagulant agents (or coagulation inhibitory agents), as used herein, denotes agents that inhibit blood coagulation. Such agents include warfarin (available as CoumadinTM) and heparin.

The term anti-platelet agents (or platelet inhibitory agents), as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include the various known non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and

piroxicam, including pharmaceutically acceptable salts or prodrugs thereof. Of the NSAIDS, aspirin (acetylsalicylic acid or ASA), and piroxicam. Piroxicam is commercially available from Pfizer Inc. (New York, NY), as FeldaneTM.

- 5 Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof. Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include
10 thromboxane-A₂-receptor antagonists and thromboxane-A₂-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof.

- The phrase thrombin inhibitors (or anti-thrombin agents), as used herein, denotes inhibitors of the serine
15 protease thrombin and other inhibitors of thrombin synthesis such as Factor XA. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the granular secretion of plasminogen
20 activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. Such inhibitors include boroarginine derivatives and boro peptides, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof. Boroarginine derivatives and boro peptides
25 include N-acetyl and peptide derivatives of boronic acid, such as C-terminal α -aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiuronium analogs thereof. The term hirudin, as used herein, includes suitable derivatives or analogs of hirudin,
30 referred to herein as hirulogs, such as disulfatohirudin. Boro peptide thrombin inhibitors include compounds described in Kettner et al., U.S. Patent No. 5,187,157 and European Patent Application Publication Number 293 881 A2, the disclosures of which are hereby incorporated herein by
35 reference. Other suitable boroarginine derivatives and boro peptide thrombin inhibitors include those disclosed in PCT Application Publication Number 92/07869 and European Patent Application Publication Number 471 651 A2, the

disclosures of which are hereby incorporated herein by reference, in their entirety.

The phrase thrombolytics (or fibrinolytic) agents (or thrombolytics or fibrinolytics), as used herein, denotes agents that lyse blood clots (thrombi). Such agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof. Tissue plasminogen activator (tPA) is commercially available from Genentech Inc., South San Francisco, California. The term anistreplase, as used herein, refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosures of which are hereby incorporated herein by reference herein, in their entirety. Anistreplase is commercially available as EminaseTM. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase.

Administration of the compounds of Formula (I) in combination with such additional therapeutic agent, may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety.

GPIIb/IIIa is known to be overexpressed in metastatic tumor cells. The compounds or combination products of the present invention may also be useful for the treatment, including prevention, of metastatic cancer.

The compounds herein described may have asymmetric centers. Unless otherwise indicated, all chiral, diastereomeric and racemic forms are included in the present invention. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. It will be appreciated that compounds of the present invention that contain asymmetrically substituted carbon atoms may be isolated in optically active or racemic forms. It is well

known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis, from optically active starting materials. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated.

When any variable (for example but not limited to, R^2 , R^4 , R^{6A} , R^{12} , R^{13} , etc.) occurs more than one time in any constituent or in any formula, its definition on each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R^6 , then said group may optionally be substituted with up to two R^6 and R^6 at each occurrence is selected independently from the defined list of possible R^6 .

When a bond to a substituent is shown to cross the bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a bond joining a substituent to another group is not specifically shown or the atom in such other group to which the bond joins is not specifically shown, then such substituent may form a bond with any atom on such other group.

When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of Formula (I), then such substituent may be bonded via any atom in such substituent. For example, when the substituent is piperidinyl, or morpholinyl, unless specified otherwise, said piperidinyl or morpholinyl, tetrazolyl group may be bonded to the rest of the compound of Formula (I) via any atom in such piperidinyl or morpholinyl, tetrazolyl group.

Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By stable compound or stable structure it is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

The term "substituted", as used herein, means that any one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that
5 the substitution results in a stable compound. When a substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.

As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon
10 groups having the specified number of carbon atoms (for example, "C₁-C₁₀" denotes alkyl having 1 to 10 carbon atoms); "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "cycloalkyl" is intended to include saturated ring groups, including mono-
15 , bi-, or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and adamantyl and so forth. "Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds
20 which may occur in any stable point along the chain, such as ethenyl, propenyl and the like; and "alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as
25 ethynyl, propynyl and the like.

The terms "alkylene", "alkenylene", "phenylene", and the like, refer to alkyl, alkenyl, and phenyl groups, respectively, which are connected by two bonds to the rest of the structure of Formula (I). Such "alkylene", "alkenylene",
30 "phenylene", and the like, may alternatively and equivalently be denoted herein as "--(alkyl)--", "--(alkenyl)--" and "--(phenyl)--", and the like.

"Halo" or "halogen" as used herein refers to fluoro, chloro, bromo and iodo; and "counterion" is used to represent
35 a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate and the like.

As used herein, "aryl" or "aromatic residue" is intended to mean phenyl or naphthyl optionally substituted with 0-3

groups independently selected from methyl, methoxy, amino, hydroxy, halogen, C₁-C₆ alkoxy, C₁-C₆ alkyl, CF₃, SCH₃, S(O)CH₃, SO₂CH₃, -N(CH₃)₂, C₁-C₄ haloalkyl, methylenedioxydiyl, ethylenedioxydiyl; the term "arylalkyl" represents an aryl group attached through an alkyl bridge.

As used herein, the terms "heterocycle", "heterocyclic ring" or "heterocyclic ring system" are intended to mean a stable 5-6 membered monocyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic or "heteroaryl") and which consists of carbon atoms and from 1 to 3 heteroatoms independently selected from the group consisting of N, O and S. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds one, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than one.

As used herein, the term "heteroaryl" refers to aromatic heterocyclic groups. Such heteroaryl groups are preferably 5-6 membered monocyclic groups or 8-10 membered fused bicyclic groups. Examples of such heteroaryl groups include, but are not limited to pyridyl (pyridinyl), pyrimidinyl, furanyl (furyl), thiazolyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, isoxazolyl, oxazolyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothienyl, benzimidazolyl, quinolinyl, or isoquinolinyl.

As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound of Formula (I) is modified by making acid or base salts of the compound of Formula (I). Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues

such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.

"Prodrugs" are considered to be any covalently bonded carriers which release the active parent drug according to Formula (I) *in vivo* when such prodrug is administered to a mammalian subject. Prodrugs of the compounds of Formula (I) are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compounds. Prodrugs include compounds of Formula (I) wherein hydroxyl, amino, sulfhydryl, or carboxyl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, sulfhydryl, or carboxyl group respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of Formula (I), and the like. Examples of the prodrug forms of the compounds of the present invention include the following esters: methyl; ethyl; isopropyl; n-butyl; i-butyl; methylcarbonyloxymethyl-; ethylcarbonyloxymethyl-; t-butylcarbonyloxymethyl-; cyclohexylcarbonyloxymethyl-; 1-(methylcarbonyloxy)ethyl-; 1-(ethylcarbonyloxy)ethyl-; 1-(t-butylcarbonyloxy)ethyl-; 1-(cyclohexylcarbonyloxy)ethyl-; i-propyloxy carbonyloxymethyl-; cyclohexylcarbonyloxymethyl-; t-butyloxy carbonyloxymethyl-; 1-(i-propyloxy carbonyloxy)ethyl-; 1-(cyclohexyloxy carbonyloxy)ethyl-; 1-(t-butyloxy carbonyloxy)-ethyl-; dimethylaminoethyl-; diethylaminoethyl-; (5-methyl-1,3-dioxacyclopenten-2-on-4-yl)methyl-; (5-(t-butyl)-1,3-dioxacyclopenten-2-on-4-yl)methyl-; (1,3-dioxo-5-phenyl-cyclopenten-2-on-4-yl)methyl-; 1-(2-(2-methoxypropyl)-carbonyloxy)ethyl-.

The pharmaceutically acceptable salts of the compounds of Formula (I) include the conventional non-toxic salts or the quaternary ammonium salts of the compounds of Formula (I) formed, for example, from non-toxic inorganic or organic

acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of Formula (I) which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.

The pharmaceutically acceptable salts of the acids of Formula (I) can be formed with an appropriate amount of a base, such as an alkali or alkaline earth metal hydroxide e.g. sodium, potassium, lithium, calcium, or magnesium, or an organic base such as an amine, e.g., dibenzylethylenediamine, trimethylamine, piperidine, pyrrolidine, benzylamine and the like, or a quaternary ammonium hydroxide such as tetramethylammonium hydroxide and the like.

As discussed above, pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid, respectively, in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.

The disclosures of all of the references cited herein are hereby incorporated herein by reference in their entirety.

5





Synthesis

The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below,
10 together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by
15 reference.

The following abbreviations are used herein:

	Boc	tert-butyloxycarbonyl
	Boc ₂ O	di-tert-butyl dicarbonate
20	CDI	1,1'-carbonyldiimidazole
	DCE	dichloroethane
	DDQ	2,3-dichloro-5,6-dicyano-1,4-benzoquinone
	DIBAL-H	diisobutylaluminum hydride
	DIEA	diisopropylethylamine
25	DMAP	4-dimethylaminopyridine
	DMF	N,N-dimethylformamide
	EtOAc	ethyl acetate
	EtOH	ethyl alcohol
	IBCF	isobutylchloroformate
30	NMM	N-methylmorpholine
	pyr	pyridine
	PyBOP	benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphoniumhexafluorophosphate
	TEA	triethyl amine
35	TFA	trifluoroacetic acid
	THF	tetrahydrofuran

In general, the compounds of this invention can be prepared by a coupling of one of the following key acid intermediates of type 1, 2 or 3 with an amino acid such as a β -amino acid or an amino acid of type 4 followed by suitable chemical transformations.




(R^{1a} represents a precursor of R¹; could be a protected R¹, cyano, etc)

10

The acid intermediate of type 1 can be prepared via a dipolar cycloaddition of a nitron with an appropriate dipolarophile as we disclosed in the application WO98/06707. Scheme I represents a general example.


15

Scheme I




- 5 Cycloaddition of a nitrile oxide, which is prepared from hydroxylamines by treatment with NCS in DMF (Liu, et al. J. Org. Chem. 1980, 45, 3916) followed by in situ dehydration in the presence of TEA, with a suitably substituted alkene affords an isoxazoline. Hydrolysis of the isoxazoline gives
- 10 an acid of type 2 (Scheme II).

Scheme II



Scheme III




5

The acid intermediate of type 3 can be prepared either from the acid of type 1 or type 2. tert-Butyl esterification of 1 using the method developed by Deccico, et al (J. Org. Chem. 1995, 60, 4782) followed by treatment with Zn/HOAc affords 1,3-aminoalcohol 10. Ring closure of 10 on treatment with CDI or phosgene gives cyclic carbamate 12, which is saponificated in the presence of TFA to form 3 (Scheme III).

15 Scheme IV outlines a synthesis of type 3 acid from 2. Similarly, 2 is first converted to the corresponding tert-butyl ester which forms 1,3-aminoalcohol 12 on treatment with Zn/HOAc. Reductive amination of 12 with an aldehyde or ketone in the presence of a reducing reagent such as NaB(AcO)₃H, NaBCNH₃ or NaBH₄ gives 10, which is then transformed to 3.


20

Scheme IV



- 5 Alternatively, the type 1 acid may also be prepared from **2**. Thus, **2** is first converted to an ester, for example, methyl ester. On treatment with an alkylating reagent, this ester forms a salt **13**, which affords an isoxazolidine **14** on reaction with a variety of reducing reagents such as NaBH₄.
- 10 Basic hydrolysis of **14** furnishes the transformation (Scheme V).

Scheme V




5 The geometrically pure version of the acids of type 1 or type 3 can be obtained by chromatography or by controlling reaction conditions or by choosing suitable reagents at some stage in the synthesis of these two types of acids.

10 A variety of methods are applied to the synthesis of enantiomerically pure acids of type 1, 2 or 3, including chiral chromatography separation, chemical resolution and enzymatic resolution. Scheme VI shows two examples of


15

Scheme VI

Method 1 (See, Zhang, *et al* Tetrahedron Lett. 1996, 37, 4455.)




Method 2



- 5 Depending on the availability of the starting materials, the compatibility of the functional groups in the molecule and other factors, compounds of this invention can be prepared by a coupling reaction of an acid of either type 1, 2 or 3 with an amino acid. Scheme VII illustrates a general synthetic sequence starting with the type 1 acid. Coupling of an acid of type 1 with an amino ester of type 4 using standard coupling reagents, such as DCC/HOBt or PyBOP, affords a nitrile-amide 15. The isoxazolidine ring is expanded to a cyclic carbamate ring by a sequential treatment with Zn/HOAc and CDI to yield 16. The transformation of the cyano group to an amidine is effected via the corresponding imidate, or thioimidate, or amidoxime. Saponification of the resulting amidine gives the final compound 17.


Scheme VII



5 Scheme VIII describes a synthetic sequence for the
 compounds of this invention starting with an acid of type 2.
 Coupling of 2 with a β -amino ester followed by a Zn-promoted
 reductive ring cleavage affords 1,3-aminoalcohol 18. This
 1,3-aminoalcohol is transformed to 19 through a reductive
 10 amination and ring closure. Compound 19 is then converted to
 the final product 20 the same way as 16 to 17.

15 Compounds of Formula (I) wherein X is a single bond may
 be prepared from intermediates such as 15 by conversion of
 the cyano group to an amidine followed by saponification.

Scheme VIII



5 Compounds of Formula (I) wherein R^1 is $\text{R}^2\text{HN}(\text{R}^2\text{N}=\text{CN}(\text{R}^2))$ - may be prepared by a transformation of the amine to the guanidine, which is brought about by using the method described by Kim, et al (Tetrahedron Lett. 1993, 48, 7677).

10 Compounds of Formula (I) wherein R^1 is $\text{R}^2\text{HNC}(\text{O})$ - may be prepared by reaction of the corresponding nitrile with an appropriate alcohol under acidic conditions (J. Med. Chem. 1991, 34, 851) or with hydrogen peroxide under basic conditions (J. Am. Chem. Soc. 1958, 80, 2257).


15 Compounds of Formula (I) wherein R^1 is $\text{R}^2(\text{R}^5\text{O})\text{N}(\text{R}^2\text{N}=\text{C})$ - or $\text{R}^2\text{HN}(\text{R}^5\text{ON}=\text{C})$ - may be prepared by reaction of the corresponding nitrile with an appropriately substituted hydroxyamine.

20 The appropriately substituted racemic b-amino acids may be purchased commercially or, as is shown in Scheme IX, Method 1, prepared from the appropriate aldehyde, malonic acid and ammonium acetate according to the procedure of


Johnson and Livak (J. Am. Chem. Soc. 1936, 58, 299). Racemic b-substituted-b-amino esters may be prepared through the reaction of dialkylcuprates or alkyllithiums with 4-benzoyloxy-2-azetidinone followed by treatment with anhydrous ethanol (Scheme IX, Method 2) or by reductive amination of b-keto esters as is described in W09316038. (Also see Rico et al., J. Org. Chem. 1993, 58, 7948-51.) Enantiomerically pure b-substituted-b-amino acids can be obtained through the optical resolution of the racemic mixture or can be prepared using numerous methods, including: Arndt-Eistert homologation of the corresponding a-amino acids as shown in Scheme IX, Method 3 (see Meier, and Zeller, Angew. Chem. Int. Ed. Engl. 1975, 14, 32; Rodriguez, et al. Tetrahedron Lett. 1990, 31, 5153; Greenlee, J. Med. Chem. 1985, 28, 434 and references cited within); and through an enantioselective hydrogenation of a dehydroamino acid as is shown in Scheme VI, Method 4 (see Asymmetric Synthesis, Vol. 5, (Morrison, ed.) Academic Press, New York, 1985). A comprehensive treatise on the preparation of b-amino acid derivatives may be found in patent application WO 9307867, the disclosure of which is hereby incorporated by reference.

Scheme IX


Method 1




Method 2



Method 3



Method 4



5 The compounds of this invention and their preparation can be further understood by the following procedures and examples, which exemplify but do not constitute a limit of their invention.

10

Example 1

3-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminopropionic acid HCl salt

15

Part A. C-(4-Cyanophenyl)-N-methylnitrone

A mixture of 4-cyanobenzaldehyde(3.3g, 25.2mmol), N-methylhydroxyamine hydrogen chloride and sodium bicarbonate (4.23g, 50.4mmol) in dry methylene chloride(80ml) was stirred at rt for 5hrs. The solid portion was filtered off and the
20 filtrate was concentrated to give the product as white solid(98%yield). ¹H NMR(300MHz, CDCl₃) δ 3.94(s, 3H), 7.46(s,

1H), 7.72(d, J=8Hz, 2H), 8.32(d, J=8Hz, 2H). MS(NH₃-CI) Calc. for (M+1)⁺: 161. Found: 161.

Part B. Isobutyl cis-[2-methyl-3-(4-cyanophenyl)isoxazolidin-5-yl]acetate

A solution of C-(4-cyanophenyl)-N-methylnitrone(1g, 6.3mmol) in vinyl acetate isobutyl ester(10ml) was heated at 100 °C for 20hrs, and then concentrated. The residue was chromatographed with CH₂Cl₂/MeOH as eluent to give the cis isomer(880mg, 46% yield) and the trans(50mg, 2.6%), along with a cis and trans mixture(630mg, 33%). ¹H NMR(300MHz, CDCl₃) δ 0.90 (d, J=6, 6H), 1.98(m, 2H), 2.60(m, 1H), 2.62(s, 3H), 2.90(m, 2H), 3.68(t, J=5, 1H), 3.90(m, 2H), 4.68(m, 1H); MS(NH₃-CI) Calc. for (M+1)⁺: 303. Found: 303.

15

Part C. [2-methyl-3(S)-(4-cyanophenyl)isoxazolidin-5(R)-yl]acetic acid

The above cis racemic ester(5.0 g) was slurred in 360 ml of phosphate buffer(PH=7.2) at 50 °C with 2.5 g of Lipase AK. After 24hrs, additional 3.0 g of Lipase AK was added. After stirring at 50 °C for additional 24hrs, the mixture was acidified to a PH of 2.0, and then filtered. The aqueous solution was extracted with EtOAc. The combined EtOAc solution was extracted with saturated NaHCO₃, washed with brine, then dried over Na₂SO₄. After concentration, 2.50g of isobutyl 2-[2-methyl-3(R)-(4-cyanophenyl)isoxazolidin-5(S)-yl]acetate with an e.e. of >85% was obtained as a thick oil. The aqueous NaHCO₃ solution was acidified to a PH of 3.0 and then extracted with EtOAc. The organic phase was dried over Na₂SO₄. After concentration, 1.4 g of 2-[2-methyl-3((S)-(4-cyanophenyl)-isoxazolidin-5(R)-yl]acetic acid with an e.e. of 95% was obtained as a solid. ¹H NMR(300MHz, CDCl₃) δ 0.90 (d, J=6, 6H), 1.98(m, 2H), 2.60(m, 1H), 2.62(s, 3H), 2.90(m, 2H), 3.68(t, J=5, 1H), 3.90(m, 2H), 4.68(m, 1H); MS(NH₃-CI) Calc. for (M+1)⁺: 303. Found: 303.

35

Part D: 3-[2-[2-methyl-3(S)-(4-cyanophenyl)-isoxazolidin-5(R)-yl]acetyl]aminopropionic acid methyl ester

To a mixture of 2-[2-methyl-3(S)-(4-cyanophenyl)-isoxazolidin-5(R)-yl]acetic acid(500mg, 2.0mmol), b-alanine methyl ester HCl salt(314mg, 2.4mmol) and triethylamine(1.7ml, 12mmol) in DMF(7ml), cooled with ice-water, was added PyBOP(1.18g, 2.0mmol). After stirring for 12hrs, the reaction mixture was diluted with ethyl acetate and washed with dilute NaHCO₃ and brine, then dried. Concentration followed by chromatography with a mixture of EtOAc and hexane as the eluent gave the product as an amorphous solid(660mg, 98% yield). ¹H NMR(300MHz, CDCl₃) δ 2.00 (m, 1H), 2.40(dd, 1H), 2.56(t, 2H), 2.60(s, 3H), 2.68(dd, 1H), 2.94(m, 1H), 3.54(qt, 2H), 3.68(t, 1H), 3.70(s, 3H), 4.60(m, 1H), 6.60(s, 1H), 7.46(d, 2H), 7.64(d, 2H); MS(ESI) Calc. for (M+1)⁺: 332. Found: 332.

Part E. 3-[[4(S)-(4-cyanophenyl)tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminopropionic acid methyl ester

3-[2-[2-methyl-3(S)-(4-cyanophenyl)-isoxazolidin-5(R)-yl]acetyl]aminopropionic acid methyl ester(650mg, 1.87mmol) was dissolved in acetic acid(15ml) and zinc(1.8g, 27.7mmol) was added. The resulting suspension was stirred vigorously at rt for 8hrs, then was filtered. The filtration was evaporated to dryness. The residue was dissolved in aqueous NaHCO₃(10ml) and the cloudy solution was evaporated to dryness again. The remaining solid was extracted with ethyl acetate. Removal of ethyl acetate gave the 1,3-aminoalcohol as an oil, which was directly used in the next reaction.

The above 1,3-aminoalcohol was dissolved in anhydrous THF(15ml) and CDI(370mg, 2.2mmol) was added. The solution was stirred overnight at rt. After evaporation, the residue was taken up in ethyl acetate(100ml). The ethyl acetate solution was washed successively with 1N HCl, dilute NaHCO₃ and brine, and the dried over Na₂SO₄. Evaporation followed by chromatography using a mixture of methylene chloride and methanol gave the product as an amorphous solid(450 mg, 63% yield after two steps). ¹H NMR(300MHz, CDCl₃) δ 1.84(qt, 1H), 2.46(m, 2H), 2.54(t, 2H), 2.64(dd, 1H), 2.72(s, 3H), 3.50(qt, 2H), 3.70(s, 3H), 4.58(dd, 1H), 4.80(m, 1H), 6.38(t, 1H),

7.28(d, 2H), 7.70(d, 2H); MS(ESI) Calc. for (M+1)⁺: 360.
Found: 360.

Part F. 3-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminopropionic acid methyl ester

Dry HCl gas was bubbled through a solution of 3-[[4(S)-(4-cyanophenyl)tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminopropionic acid methyl ester (125 mg 0.35 mmol) in dry CHCl₃ containing anhydrous methanol (23 mg, 0.70 mmol), cooled with salt ice-water bath, at 0 °C for 5hrs. The resulting solution was then kept at 0 °C for 6hrs and at 15 °C for 12hrs. The flammable portion was removed and the residue was dissolved in anhydrous methanol (3 ml) followed by addition of ammonium bicarbonate (84 mg, 0.88 mmol). After stirring at rt for 4 hrs, the mixture was concentrated and purified by flush chromatography over silica gel using a mixture of methylene chloride and methanol as the eluent to give a white amorphous solid (85mg, 64% yield). ¹H NMR (300MHz, CD₃OD) δ 1.90 (m, 1H), 1.22 (m, 2H), 2.50 (t, 2H), 2.60 (dd, 1H), 2.66 (s, 3H), 3.40 (m, 2H), 3.60 (s, 3H), 4.80 (m, 2H), 7.54 (d, 2H), 7.84 (d, 2H); MS(ESI) Calc. for (M+1)⁺: 377. Found: 377.

Part G. 3-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminopropionic acid HCl salt

3-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminopropionic acid methyl ester (70mg, 0.19mmol) was dissolved in 4N HCl (3ml). The resulting solution was stirred at rt for 36 hrs and then concentrated to yield the acid as an amorphous solid (60mg, 90% yield). The acid was further purified by reverse HPLC using water and 0.1% TFA in acetonitrile as eluent. ¹H NMR (300MHz, CD₃OD) δ 1.94 (m, 1H), 1.24 (m, 2H), 2.60 (t, 2H), 2.66 (dd, 1H), 2.70 (s, 3H), 3.40 (m, 2H), 4.85 (m, 2H), 7.54 (d, 2H), 7.84 (d, 2H); MS(ESI) Calc. for (M+1)⁺: 363. Found: 363.

Example 3

3-[[4(R)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(S)-yl]acetyl]amino propionic acid HCl salt

This compound was prepared from isobutyl 2-[2-methyl-3(R)-(4-cyanophenyl)isoxazolidin-5(S)-yl]acetate. Its synthesis is similar to that of Example 1. ¹H NMR(300MHz, CD₃OD) δ 1.96 (m, 1H), 1.20(m, 2H), 2.62(t, 2H), 2.68(dd, 1H), 2.76(s, 3H), 3.50(m, 2H), 4.80(m, 2H), 7.48(d, 2H), 7.86(d, 2H); MS(ESI) Calc. for (M+1)⁺: 363. Found: 363.

10

Example 4

Trans-3-[[4-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6-yl]acetyl]amino propionic acid HCl salt

This compound was prepared from isobutyl trans-2-[2-methyl-3-(4-cyanophenyl)isoxazolidin-5-yl]acetate. Its synthesis is similar to that of Example 1. ¹H NMR(300MHz, CD₃OD) δ 2.26 (m, 6H), 2.90(s, 3H), 3.40(m, 2H), 4.56(m, 1H), 4.80(m, 1H), 7.50(d, 2H), 7.86(d, 2H); MS(ESI) Calc. for (M+1)⁺: 363. Found: 363.

20

Example 5

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminobutyric acid HCl salt

25

This compound was prepared analogously to Example 1. ¹H NMR(300MHz, DMSO-d₆) δ 1.04 (d, 3H), 1.76, dd, 1H), 2.20-2.50(m, 5H), 2.70(s, 3H), 4.20(m, 1), 4.70(m, 2H), 7.50(d, 2H), 7.80(d, 2H), 8.00(d, 1H). MS(ESI) Calc. for (M+1)⁺: 377. Found: 377.

30

Example 18

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-phenylvaleric acid HCl salt

35

This compound was prepared analogously to Example 1. ¹H NMR(300MHz, DMSO-d₆) δ 1.78 (m, 3H), 2.30-2.58(m, 5H), 2.60(s, 3H), 4.02(m, 1H), 4.70(m, 2H), 7.14(m, 3H), 7.24(m,

2H), 7.50(d, 2H), 7.84(d, 2H), 8.00(d, 1H). MS(ESI) Calc. for (M+1)⁺: 467. Found: 467.

Example 20

5 3(S)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-3-(pyridin-3-yl)propionic acid HCl salt

This compound was prepared analogously to Example 1.
1H NMR(300MHz, CD₃OD) δ 2.50(qt, 1H), 3.00(dd, 1H), 3.30(m,
10 3H), 3.36(s, 3H), 3.60(d, 2H), 5.48(m, 1H), 6.00(m, 1H), 8.24(d, 2H), 8.36(m, 1H), 8.60(d, 2H), 8.80(d, 1H), 9.38(d, 1H), 9.40(s, 1H), 9.50(d, 2H); MS(ESI) Calc. for (M+1)⁺: 440. Found: 440.

15 Example 21

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-3-(pyridin-3-yl)propionic acid HCl salt

This compound was prepared analogously to Example 1.
20 1H NMR(300MHz, CD₃OD) δ 2.00(m, 1H), 2.40(m, 1H), 2.60(m, 2H), 2.64(s, 3H), 2.90(m, 2H), 3.24((m, 1H), 4.80(m, 1H), 5.40(m, 1H), 7.50(d, 2H), 7.82(d, 2H), 8.00(m, 1H), 8.60(m, 1H), 8.70(m, 1H), 8.88(m, 1H); MS(ESI) Calc. for (M+1)⁺: 440. Found: 440.

25

Example 24

3(S)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-3-phenylpropionic acid HCl salt

30 This compound was prepared analogously to Example 1.
1H NMR(300MHz, CD₃OD) δ 1.80(qt, 1H), 2.30(m, 1H), 2.60(m, 2H), 2.66(s, 3H), 2.80(m, 2H), 4.80(m, 2H), 5.30(m, 1H), 7.30(m, 5H), 7.50(d, 2H), 7.80(d, 2H); MS(ESI) Calc. for (M+1)⁺: 439. Found: 439.

35

Example 25

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-3-phenylpropionic acid HCl salt

This compound was prepared analogously to Example 1.

- 5 ¹H NMR(300MHz, CD₃OD) δ 1.90(qt, 1H), 2.40-2.70(m, 5H), 2.72(s, 3H), 4.78(m, 2H), 5.38(t, 1H), 7.20-7.40(m, 5H), 7.50(d, 2H), 7.80(d, 2H); MS(ESI) Calc. for (M+1)⁺: 439. Found: 439.

10

Example 40

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-4-[(3-dimethylamino)-propyl]amino-4-oxobutanoic acid bis(trifluoroacetate)

15

This compound was prepared analogously to Example 1.

- ¹H NMR(300MHz, CD₃OD) δ 1.70(m, 2H), 1.90(qt, 1H), 2.38(s, 6H), 2.40-2.70(m, 6H), 2.74(s, 3H), 2.86(dd, 1H), 3.38(m, 2H), 4.60(m, 2H), 4.84(m, 1H), 7.00(d, 1H), 7.50(d, 2H), 7.80(d, 2H); MS(ESI) Calc. for (M+1)⁺: 491. Found: 491.

20

Example 317

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-indole-3-valeric acid bis(trifluoroacetate)

25

Part A. t-Butyl [2-methyl-3(S)-(4-cyanophenyl)isoxazolidin-5(R)-yl]acetate

- To a solution of [2-methyl-3(S)-(4-cyanophenyl)-isoxazolidin-5(R)-yl]acetic acid(480 mg, 1.95 mmol) in CH₂Cl₂ (30ml) cooled in an ice-water bath was added a 1.6M solution of O-tert-butyl-N, N-diisopropylisourea, cat. CuCl(3.7 ml). The resulting mixture was stirred at rt for 48 hrs. After filtration, the filtrate was concentrated in EtOAc and the residue dissolved in EtOAc. The EtOAc solution was washed with brine and then dried over Na₂SO₄. After contraction, the residue was chromatographed with a mixture of EtOAc and hexane to afford 550 mg of the product as a white solid(93%). ¹H NMR(300MHz, CDCl₃) δ 1.44(s, 9H), 1.98(m, 1H), 2.50(dd,

30

35

1H), 2.60(s, 3H), 2.80(dd, 1H), 2.98(dt, 1H), 3.70(t, 1H), 4.64(m, 1H), 7.50(d, 2H), 7.66(d, 2H); MS(ESI) Calc. for (M+1)⁺: 303. Found: 303.

5 Part B.

tert-Butyl [4(S)-(4-cyanophenyl)tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetate

The procedure is similar to Part E of Example 1. ¹H NMR(300MHz, CDCl₃) δ 1.46(s, 9H), 1.84(m, 1H), 2.50(m, 2H),
10 2.76(s, 3H), 2.80(dd, 1H), 4.60(dd, 1H), 4.70(m, 1H), 7.40(d, 2H), 7.70(d, 2H); MS(ESI) Calc. for (M+1)⁺: 331. Found: 331.

Part C.

15 [4(S)-(4-cyanophenyl)tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetic acid

The above tert-butyl ester(200 mg, 0.61 mmol) was dissolved in CH₂Cl₂(5 ml) containing 0.25 ml of TFA. The resulting solution was stirred at rt for 24 hrs and then
20 concentrated. The residue was titrated with hexane and pumped to dryness to give 160 mg of the product as a white solid. ¹H NMR(300MHz, CDCl₃) δ 1.90(m, 1H), 2.40(ddd, 1H), 2.66(m, 2H), 2.70(s, 3H), 4.80(m, 2H), 7.48(d, 2H), 7.80(d, 2H); MS(ESI) Calc. for (M+1)⁺: 275. Found: 275.

25

Part D. Methyl 1-Boc-indole-3-propionate

To a solution of methyl indole-3-propionate(5.5 g, 27.1 mmol) and Boc₂O(9.34 ml, 40.6 mmol) in dry CH₂Cl₂(50 ml) in an ice-water bath was added TEA(5.2 ml, 40.6 mmol) and DMAP(330
30 mg, 10 mol%). The mixture was then stirred overnight at rt. After removal of CH₂Cl₂, the oily residue was dissolved in EtOAc and washed with aqueous citric acid, NaHCO₃ and brine, then dried over Na₂SO₄. After concentration and flush chromatography, 7.6 g of oily product was obtained(93 %). ¹H
35 NMR(300MHz, CDCl₃) δ 1.68(s, 9H), 2.72(t, 2H), 3.04(t, 2H), 3.70(s, 3H), 7.20-7.40(m, 3H), 7.54(d, 1H), 8.10(d, 1H); MS(ESI) Calc. for (M+1)⁺: 304. Found: 304.

Part E. 1-Boc-indole-3-propionaldehyde

To a solution of methyl 1-Boc-indole-3-propionate (2.0g, 6.6 mmol) in toluene (20 ml) cooled at -78 °C was added a 1.5M toluene solution of DIBAL-H slowly so that the internal
5 temperature was kept below -65 °C. After addition, stirring was continued at -78 °C for additional 2 hrs. After quenched with 3 ml of MeOH, the mixture was poured into a NaCl solution and extracted with EtOAc. The combined organic solution was washed with a aqueous acid, NaHCO₃ and brine,
10 then dried over Na₂SO₄. Flash chromatography gave 1.4 g of oily product. ¹H NMR (300MHz, CDCl₃) δ 1.68(s, 9H), 2.84(t, 2H), 3.04(t, 2H), 7.20-7.40(m, 3H), 7.52(d, 1H), 8.14(d, 1H), 9.90(s, 1H); MS(ESI) Calc. for (M+1)⁺: 274. Found: 274.

15 Part F. t-Butyl E-5-(1-Boc-indole-3-)pent-2-enoate

A mixture of 1-Boc-indole-3-propionaldehyde (530 mg, 1.94 mmol) and (tert-butoxycarbonylmethylene)triphenylphosphorane (880 mg, 2.33 mmol) in toluene (10 ml) was stirred at rt for 24 hrs. The reaction
20 was then worked up as usual. Chromatography with hexane and ethyl acetate (19:1) gave 610 mg of the desired product as an oil (85%). ¹H NMR (300MHz, CDCl₃) δ 1.50(s, 9H), 1.70(s, 9H), 2.60(qt, 2H), 2.84(t, 2H), 5.82(d, 1H), 6.96(dt, 1H), 7.20-7.40(m, 3H), 7.50(d, 1H), 8.10(d, 1H); MS(ESI) Calc. for
25 (M+1)⁺: 372. Found: 372.

Part G. 3(R)-3-Amino-5-(1-Boc-2,3-dihydroindole-3-)valeric acid tert-butyl ester

This b-aminoester was similarly prepared according the
30 method of Davis (J. Chem. Soc. Perkin Trans I 1994, 836), obtained as a 1:1 mixture of the two diastereomers. MS(ESI) Calc. for (M+1)⁺: 389. Found: 389.

35 Part H. 3(R)-[[4(S)-(4-cyanophenyl)tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-(1-Boc-2,3-dihydroindole-3-)valeric acid tert-butyl ester

To a mixture of [4(S)-(4-cyanophenyl)tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetic acid (164 mg, 0.60

mmol), 3(R)-3-Amino-5-(1-Boc-2,3-dihydroindole-3-)valeric acid tert-butyl ester(240 mg, 0.60 mmol) and triethylamine(0.42 ml, 3.0 mmol) in DMF(5 ml), cooled in an ice-water bath, was added PyBOP(380 mg, 0.66 mmol). After stirring for 12hrs, the reaction mixture was diluted with ethyl acetate and washed with dilute NaHCO₃ and brine, then dried. Concentration followed by chromatography with a mixture of EtOAc and hexane as the eluent gave the product as an amorphous solid(270 mg, 270% yield). It was a 1:1 mixture of the two diastereomers. MS(ESI) Calc. for (M+1)⁺: 647. Found: 647.

Part H-2. 3(R)-[[4(S)-(4-cyanophenyl)tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-(1-Boc-indole-3-yl)valeric acid tert-butyl ester

A solution of 3(R)-[[4(S)-(4-cyanophenyl)tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-(1-Boc-2,3-dihydroindole-3-)valeric acid tert-butyl ester(102 mg, 0.16 mmol), DDQ(43 mg, 0.19 mmol) in toluene(5 ml) was stirred at rt for 24 hrs. The reaction was worked up as usual. Chromatography with CH₂Cl₂ and MeOH(50:1) gave the product(85 mg, 84%). ¹H NMR(300MHz, CDCl₃) δ 1.46(s, 9H), 1.68(s, 9H), 1.80(qt, 1H), 1.96(m, 2H), 2.40-2.56(m, 4H), 2.68(m, 3H), 1.70(s, 3H), 4.34(m, 1H), 4.56(dd, 1H), 4.78(m, 1H), 6.56(d, 1H), 7.16-7.48(m, 5H), 7.60(d, 2H), 8.10(d, 1H); MS(ESI) Calc. for (M+1)⁺: 645. Found: 645.

Part I. 3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-indole-3-yl)valeric acid tert-butyl ester

H₂S(g) was bubbled into a solution of 3(R)-[[4(S)-(4-cyanophenyl)tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-(1-Boc-indole-3-)valeric acid tert-butyl ester(80 mg, 0.12 mmol) in Pyr/TEA(4.8 ml, 5:1) until saturation. The solution was then sealed and stirred at rt overnight. After evaporation, the yellow solid was pumped to dryness to give the corresponding thioamide. MS(ESI) Calc. for (M+23)⁺: 701. Found: 701.

The above thioamide was dissolved in acetone(5 ml) containing 0.1 ml of iodomethane. The resulting solution was heated at 50 °C for 1.5 hrs. Evaporation gave the corresponding thioimide as an amorphous solid which was dissolved in dry MeOH(3 ml) followed by addition of ammonium acetate(14 mg). The resulting mixture was stirred at 70 °C for 4 hrs, and then worked up as usual. Chromatography with a mixture of CH₂Cl₂ and MeOH gave the amidine as a yellow powder(60 mg, 74%). ¹H NMR(300MHz, CD₃OD) δ 1.48(s, 9H), 1.64(s, 9H), 1.80-2.00(m, 2H), 2.40-2.60(m, 3H), 2.64(s, 3H), 2.70(m, 3H), 4.50(m, 1H), 4.80(m, 2H), 7.18(t, 1H), 7.24(t, 1H), 7.40-7.50(m, 4H), 7.80(d, 2H), 8.08(d, d); MS(ESI) Calc. for (M+1)⁺: 660. Found: 660.

15 Part J. 3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-indole-3-valeric acid bis(trifluoroacetate)

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-indole-3-valeric acid tert-butyl ester(50 mg, 0.076 mmol) was mixed with TFA(0.25 ml) in dry CH₂Cl₂ (5 ml). The mixture was stirred overnight at rt, and then evaporated to dryness. The residue was purified by reverse HPLC using water and 0.1% TFA in acetonitrile as eluent. MS(ESI) Calc. for (M+1)⁺: 506. Found: 506.

Example 318

3-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminopropionic acid HCl salt

This compound was prepared analogously to Example 1. ¹H NMR(300MHz, CD₃OD) δ 2.00(qt, 1H), 2.40(dd, 1H), 2.50(m, 3H), 2.60(dd, 1H), 3.40(m, 2H), 3.60(d, 1H), 4.62(dd, 1H), 4.74(m, 1H), 5.04(d, 1H), 7.04(m, 2H), 7.289m, 3H), 7.44(d, 2H), 7.809d, 2H); MS(ESI) Calc. for (M+1)⁺: 439. Found: 439.

Example 319

3-[[4(R)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(S)-yl]acetyl]aminopropionic acid HCl salt

This compound was prepared analogously to Example 1.
5 ¹H NMR(300MHz, CD₃OD) δ 1.98(qt, 1H), 2.40(dd, 1H), 2.50(m, 3H), 2.60(dd, 1H), 3.40(m, 2H), 3.60(d, 1H), 4.62(dd, 1H), 4.74(m, 1H), 5.04(d, 1H), 7.04(m, 2H), 7.289m, 3H), 7.44(d, 2H), 7.809d, 2H); MS(ESI) Calc. for (M+1)⁺: 439. Found: 439.

10

Example 320

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminobutyric acid HCl salt

15

Part A. [3-(4-cyanophenyl)isoxazolin-5(R)-yl]acetic acid

This acid was prepared according to the method of Zhang(Tetrahedron Lett. 1996. 37, 4455.).

20 Part B. tert-Butyl [3-(4-cyanophenyl)isoxazolin-5(R)-yl]acetate

To a suspension of [3-(4-cyanophenyl)isoxazolin-5(R)-yl]acetic acid(500 mg, 2.17 mmol) in CH₂Cl₂ (20 ml) cooled in an ice-water bath was added a 1.6M solution of O-tert-butyl-N, N-diisopropylisourea, cat. CuCl(4 ml). The resulting
25 mixture was stirred at rt for 48 hrs and then filtered. The filtrate was concentrated and the residue dissolved in EtOAc. The EtOAc solution was washed with brine and then dried over Na₂SO₄. After concentration, the residue was chromatographed
30 with a mixture of EtOAc and hexane to afford 600 mg of the product as a white solid(96%). ¹H NMR(300MHz, CDCl₃) δ 1.48(s, 9H), 2.60(dd, 1H), 2.60(dd, 1H), 3.16(dd, 1H), 3.52(dd, 1H), 5.169m, 1H, 7.70(d, 2H), 7.78(d, 2H); MS(ESI) Calc. for (M-1)⁺: 285. Found: 285.

35

Part C. tert-Butyl [4(S)-[4-(4-cyanophenyl)tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetate

A mixture of tert-Butyl [3-(4-cyanophenyl)isoxazolin-5(R)-yl]acetate(600 mg, 2.1 mmol), Zn(2.02 g, 31.5 mmol) in HOAc(10 ml) was vigorously stirred overnight at rt. After removal of excess Zn by filtration, the solution was
5 concentrated and pumped to dryness to give the corresponding 1,3-aminoalcohol. MS(ESI) Calc. for (M+1)⁺: 291. Found: 291.

The above 1,3-aminoalcohol was dissolved in DCE(8 ml). Benzaldehyde(0.37 ml, 3.6 mmol), HOAc(0.2 ml, 3.6 mmol) and NaB(AcO)₃H(770 mg, 3.6 mmol) were added successively. The
10 resulting mixture was stirred at rt for 2 hrs. After removal of DCE, the residue was dissolved on EtOAc and washed with NaHCO₃, brine, then dried over Na₂SO₄. After concentration, the oily residue was filtered through a short pad of Silica gel using a mixture of hexane and EtOAc as the eluent to
15 afford the desired N-benzyl-1,3-aminoalcohol as an oil. MS(ESI) Calc. for (M+1)⁺: 381. Found: 381.

The N-benzyl-1,3-aminoalcohol obtained above was mixed with CDI(340 mg, 2.1 mmol) in dry THF(12 mmol). The solution was stirred at rt for 12 hrs and then at refluxing for 24 hrs.
20 After removal of THF, the residue was worked up as usual. Chromatography with a mixture of EtOAc and hexane(1:1) gave 300 mg of the desired product(35%). ¹H NMR(300MHz, CDCl₃) δ 1.44(s, 9H), 1.86(qt, 1H), 1.42(m, 2H), 2.80(d, 1H), 3.50(d, d, 1H), 4.40(dd, 1H), 4.60(m, 1H), 5.26(d, 1H), 7.02(m, 2H),
25 7.28(m, 5H), 7.68(d, 2H); MS(ESI) Calc. for (M+1)⁺: 407. Found: 407.

Part D. [4(S)-(4-cyanophenyl)tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetic acid

30 The above tert-butyl ester(240 mg, 0.59 mmol) was dissolved in CH₂Cl₂(5 ml) containing 0.25 ml of TFA. The resulting solution was stirred at rt for 24 hrs and then concentrated. The residue was titrated with hexane and pumped to dryness to give 200 mg of the product as a
35 amorphous solid. ¹H NMR(300MHz, CDCl₃) δ 1.98(qt, 1H), 2.40(m, 1H), 2.64(dd, 1H), 2.90(dd, 1H), 3.58(d, 1H), 4.44(dd, 1H), 4.76(m, 1H), 5.20(d, 1H), 7.00(m, 2H), 7.30(m,

5H), 7.70(d, 2H); MS(ESI) Calc. for (M+1)⁺: 351. Found: 351.

Part E. 3(R)-[[4(S)-(4-cyanophenyl)tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yllacetyl]aminobutyric acid benzyl ester

The procedure was similar to Part D of Example 1. ¹H NMR (300MHz, CDCl₃) δ 1.24(d, 3H), 1.90(qt, 1H), 2.40(m, 2H), 2.56(d, 2H), 2.60(dd, 1H), 3.50(d, 1H), 4.40(m, 2H), 4.66(m, 1H), 5.10(s, 2H), 5.20(d, 1H), 6.30(d, 1H), 7.00(m, 2H), 7.20-7.40(m, 10H), 7.649d, 2H); MS(ESI) Calc. for (M+1)⁺: 526. Found: 526.

Part F. 3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yllacetyl]aminobutyric acid methyl ester

The procedure is similar to Part F of Example 1. ¹H NMR (300MHz, CD₃OD) δ 1.26(d, 3H), 1.90(m, 1H), 2.20-2.60(m, 5H), 3.40(s, 3H), 3.50(d, 1H), 4.40(m, 2H), 4.60(m, 1H), 5.20(d, 1H), 7.05(m, 2H), 7.30-7.50(m, 5H), 7.80(d, 2H); MS(ESI) Calc. for (M+1)⁺: 543. Found: 543.

Part G. 3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yllacetyl]aminobutyric acid

The procedure was similar to Part G of Example 1. ¹H NMR (300MHz, CD₃OD) δ 1.26(d, 3H), 1.90(m, 1H), 2.40(m, 2H), 2.60(m, 3H), 3.50(d, 1H), 4.50(m, 2H), 4.70(m, 1H), 5.20(d, 1H), 7.04(m, 2H), 7.40(m, 5H), 7.80(d, 2H); MS(ESI) Calc. for (M+1)⁺: 453. Found: 453.

30 Example 340

[N-[[4(S)-[4-(N-butylaminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yllacetyl]piperidin-4-yl]lactic acid HCl salt

This compound was prepared analogously to Example 320. ¹H NMR (300MHz, CD₃OD) δ 1.10-1.30(m, 2H), 1.80(m, 3H), 2.04(m, 1H), 2.24(m, 2H), 2.60(m, 3H), 2.90(dd, 1H), 3.04(m, 1H), 3.50(d, 1H), 3.80(m, 1H), 4.50(m, 2H), 4.70(m, 1H), 5.26(d,

1H), 7.02(m, 2H), 7.40(m, 5H), 7.80(d, 2H); MS(ESI) Calc. for (M+1)⁺: 493. Found: 493.

Example 411

- 5 3(R)-[[4(S)-[4-(N-butylaminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-phenylvaleric acid HCl salt

This compound was prepared analogously to Example 1.
1H NMR(300MHz, CD₃OD) δ 1.00(t, 3H), 1.46(m, 2H), 1.66-2.00(m,
10 5H), 2.40-2.60(m, 7H), 2.65(s, 3H), 3.40(t, 2H), 4.20(m, 1H),
4.80(m, 2H), 7.10-7.26(m, 5H), 7.50(d, 2H), 7.70(d, 2H),
8.08(m, 1H). MS(ESI) Calc. for (M+1)⁺: 523. Found: 523.

Example 511

- 15 3-[[2-methyl-3(S)-[4-(aminoiminomethyl)phenyl]-isoxazolidin-5(R)-yl]acetyl]aminopropionic acid HCl salt

This compound was prepared from 3-[[2-methyl-3(S)-(4-cyanophenyl)-isoxazolidin-5(R)-yl]acetyl]aminopropionic acid methyl ester through a standard Pinner reaction and a
20 hydrolysis. 1H NMR(300MHz, CD₃OD) δ 2.02(m, 1H), 2.44(dd, 1H), 2.50(t, 2H), 2.56(s, 3H), 2.64(dd, 1H), 2.96(m, 1H), 3.40(t, 2H), 3.90(t, 1H), 4.60(m, 1H), 7.60(d, 2H), 7.8(d, 2H); MS(ESI) Calc. for (M+1)⁺: 335. Found: 335.

Example 512

- 25 3-[[2-methyl-3(R)-[4-(aminoiminomethyl)phenyl]-isoxazolidin-5(S)-yl]acetyl]aminopropionic acid HCl salt

This compound was prepared analogously to Example 511.
1H NMR(300MHz, CD₃OD) δ 2.12(m, 1H), 2.42(dd, 1H), 2.50(t,
30 2H), 2.58(s, 3H), 2.66(dd, 1H), 2.94(m, 1H), 3.40(t, 2H), 3.90(t, 1H), 4.60(m, 1H), 7.60(d, 2H), 7.8(d, 2H); MS(ESI) Calc. for (M+1)⁺: 335. Found: 335.

Example 513

- 35 3(R)-[[2-methyl-3(R)-[4-(aminoiminomethyl)phenyl]-isoxazolidin-5(S)-yl]acetyl]aminobutyric acid HCl salt

This compound was prepared analogously to Example 511.
1H NMR(300MHz, CD₃OD) δ 1.22(d, 3H), 2.00(m, 1H), 2.40(dd,

1H), 2.50(d, 2H), 2.62(s, 3H), 2.70(m, 1H), 2.90(m, 1H), 3.70(m, 1H), 4.40(m, 1H), 4.60(m, 1H), 7.64(d, 2H), 7.88(d, 2H); MS(ESI) Calc. for (M+1)⁺: 349. Found: 349.

5


Example 774

[N-[[4(S)-[4-(N-butylaminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]piperidin-4-yl]acetic acid HCl salt

This compound was prepared analogously to Example 1.

10 ¹H NMR(300MHz, CD₃OD) δ 1.04-1.40(m, 4H), 1.72-2.10(m, 4H), 2.24(m, 2H), 2.50(m, 1H), 2.70(s, 3H), 2.90(m, 1H), 3.10(m, 1H), 3.96(m, 1H), 4.50(m, 1H), 4.80(m, 2H), 7.54(d, 2H), 7.86(d, 2H); MS(ESI) Calc. for (M+1)⁺: 417. Found: 417.

Table 1



Ex No.	R ¹ -A	m	R ³	X	n	R ⁵	R ⁸	Y	MS [(M+1) ⁺]
10	1 4-amidinophenyl	0	Me	C(O)	1	H	H	OH	363
	2 4-amidinophenyl	0	Me	C(O)	1	H	H	OMe	
	3 4-amidinophenyl	0	Me	C(O)	1	H	H	OH	363
	4 4-amidinophenyl 4-R, 6-S trans, racemate	0	Me	C(O)	1	H	H	OH	363
15	5 4-amidinophenyl	0	Me	C(O)	1	H	Me	OH	377
	6 4-amidinophenyl	0	Me	C(O)	1	H	Et	OH	
	7 4-amidinophenyl	0	Me	C(O)	1	H	Propyl	OH	
	8 4-amidinophenyl	0	Me	C(O)	1	H	butyl	OH	
	9 4-amidinophenyl	0	Me	C(O)	1	H	hexyl	OH	
20	10 4-amidinophenyl	0	Me	C(O)	1	H	cyclopropyl	OH	
	11 4-amidinophenyl	0	Me	C(O)	1	H	cyclohexyl	OH	
	12 4-amidinophenyl	0	Me	C(O)	1	H	acetynyl	OH	
	13 4-amidinophenyl	0	Me	C(O)	1	H	methylacetynyl	OH	
	14 4-amidinophenyl	0	Me	C(O)	1	H	cyclopropylacetynyl	OH	
25	15 4-amidinophenyl	0	Me	C(O)	1	H	ethylacetynyl	OH	
	16 4-amidinophenyl	0	Me	C(O)	1	H	butylacetynyl	OH	
	17 4-amidinophenyl	0	Me	C(O)	1	H	vinyl	OH	
	18 4-amidinophenyl	0	Me	C(O)	1	H	phenethyl	OH	467
	19 4-amidinophenyl	0	Me	C(O)	1	H	phenylmethyl	OH	
30	20 4-amidinophenyl	0	Me	C(O)	1	H	3-pyridinyl	OH	440
	21 4-amidinophenyl	0	Me	C(O)	1	H	3-pyridinyl	OH	440
	22 4-amidinophenyl	0	Me	C(O)	1	H	2-pyridinyl	OH	
	23 4-amidinophenyl	0	Me	C(O)	1	H	4-pyridinyl	OH	
	24 4-amidinophenyl	0	Me	C(O)	1	H	phenyl	OH	439
35	25 4-amidinophenyl	0	Me	C(O)	1	H	phenyl	OH	439
	26 4-amidinophenyl	0	Me	C(O)	1	H	2-fluorophenyl	OH	
	27 4-amidinophenyl	0	Me	C(O)	1	H	3-fluorophenyl	OH	
	28 4-amidinophenyl	0	Me	C(O)	1	H	4-fluorophenyl	OH	
	29 4-amidinophenyl	0	Me	C(O)	1	H	2-methylphenyl	OH	
40	30 4-amidinophenyl	0	Me	C(O)	1	H	3-methylphenyl	OH	
	31 4-amidinophenyl	0	Me	C(O)	1	H	4-methylphenyl	OH	
	32 4-amidinophenyl	0	Me	C(O)	1	H	2-methoxyphenyl	OH	
	33 4-amidinophenyl	0	Me	C(O)	1	H	3-methoxyphenyl	OH	
	34 4-amidinophenyl	0	Me	C(O)	1	H	4-methoxyphenyl	OH	
45	35 4-amidinophenyl	0	Me	C(O)	1	H	2-bromophenyl	OH	
	36 4-amidinophenyl	0	Me	C(O)	1	H	CH ₃ NHC(O)	OH	
	37 4-amidinophenyl	0	Me	C(O)	1	H	CH ₃ CH ₂ NHC(O)	OH	
	38 4-amidinophenyl	0	Me	C(O)	1	H	cyclopropyl-NHC(O)	OH	
	39 4-amidinophenyl	0	Me	C(O)	1	H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH	
50	40 4-amidinophenyl	0	Me	C(O)	1	H	Me ₂ N(CH ₂) ₃ NHC(O)	OH	491
	41 4-amidinophenyl	0	Me	C(O)	1	H	PhNHC(O)	OH	
	42 4-amidinophenyl	0	Me	C(O)	1	H	2-MeOPhNH(CO)	OH	
	43 4-amidinophenyl	0	Me	C(O)	1	H	Me ₂ NC(O)	OH	
	44 4-amidinophenyl	0	Et	C(O)	1	H	H	OH	

	45	4-amidinophenyl	0	Et	C(O)	1	H	H	OMe
	46	4-amidinophenyl	0	Et	C(O)	1	H	Me	OH
	47	4-amidinophenyl	0	Et	C(O)	1	H	Et	OH
	48	4-amidinophenyl	0	Et	C(O)	1	H	Propyl	OH
5	49	4-amidinophenyl	0	Et	C(O)	1	H	butyl	OH
	50	4-amidinophenyl	0	Et	C(O)	1	H	hexyl	OH
	51	4-amidinophenyl	0	Et	C(O)	1	H	cyclopropyl	OH
	52	4-amidinophenyl	0	Et	C(O)	1	H	cyclohexyl	OH
	53	4-amidinophenyl	0	Et	C(O)	1	H	acetynyl	OH
10	54	4-amidinophenyl	0	Et	C(O)	1	H	methylacetynyl	OH
	55	4-amidinophenyl	0	Et	C(O)	1	H	cyclopropylacetynyl	OH
	56	4-amidinophenyl	0	Et	C(O)	1	H	ethylacetynyl	OH
	57	4-amidinophenyl	0	Et	C(O)	1	H	butylacetynyl	OH
	58	4-amidinophenyl	0	Et	C(O)	1	H	vinyl	OH
15	59	4-amidinophenyl	0	Et	C(O)	1	H	phenethyl	OH
	60	4-amidinophenyl	0	Et	C(O)	1	H	phenylmethyl	OH
	61	4-amidinophenyl	0	Et	C(O)	1	H	3-pyridinyl	OH
	62	4-amidinophenyl	0	Et	C(O)	1	H	2-pyridinyl	OH
	63	4-amidinophenyl	0	Et	C(O)	1	H	4-pyridinyl	OH
20	64	4-amidinophenyl	0	Et	C(O)	1	H	phenyl	OH
	65	4-amidinophenyl	0	Et	C(O)	1	H	2-fluorophenyl	OH
	66	4-amidinophenyl	0	Et	C(O)	1	H	3-fluorophenyl	OH
	67	4-amidinophenyl	0	Et	C(O)	1	H	4-fluorophenyl	OH
	68	4-amidinophenyl	0	Et	C(O)	1	H	2-methylphenyl	OH
25	69	4-amidinophenyl	0	Et	C(O)	1	H	3-methylphenyl	OH
	70	4-amidinophenyl	0	Et	C(O)	1	H	4-methylphenyl	OH
	71	4-amidinophenyl	0	Et	C(O)	1	H	2-methoxyphenyl	OH
	72	4-amidinophenyl	0	Et	C(O)	1	H	3-methoxyphenyl	OH
	73	4-amidinophenyl	0	Et	C(O)	1	H	4-methoxyphenyl	OH
30	74	4-amidinophenyl	0	Et	C(O)	1	H	2-bromophenyl	OH
	75	4-amidinophenyl	0	Et	C(O)	1	H	CH ₃ NHC(O)	OH
	76	4-amidinophenyl	0	Et	C(O)	1	H	CH ₃ CH ₂ NHC(O)	OH
	77	4-amidinophenyl	0	Et	C(O)	1	H	cyclopropyl-NHC(O)	OH
	78	4-amidinophenyl	0	Et	C(O)	1	H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH
35	79	4-amidinophenyl	0	Et	C(O)	1	H	Me ₂ N(CH ₂) ₃ NHC(O)	OH
	80	4-amidinophenyl	0	Et	C(O)	1	H	PhNHC(O)	OH
	81	4-amidinophenyl	0	Et	C(O)	1	H	2-MeOPhNH(CO)	OH
	82	4-amidinophenyl	0	Et	C(O)	1	H	Me ₂ NHC(O)	OH
	83	4-amidinophenyl	0	H	C(O)	1	H	H	OH
40	84	4-amidinophenyl	0	H	C(O)	1	H	H	OMe
	85	4-amidinophenyl	0	H	C(O)	1	H	Me	OH
	86	4-amidinophenyl	0	H	C(O)	1	H	Et	OH
	87	4-amidinophenyl	0	H	C(O)	1	H	Propyl	OH
	88	4-amidinophenyl	0	H	C(O)	1	H	butyl	OH
45	89	4-amidinophenyl	0	H	C(O)	1	H	hexyl	OH
	90	4-amidinophenyl	0	H	C(O)	1	H	cyclopropyl	OH
	91	4-amidinophenyl	0	H	C(O)	1	H	cyclohexyl	OH
	92	4-amidinophenyl	0	H	C(O)	1	H	acetynyl	OH
	93	4-amidinophenyl	0	H	C(O)	1	H	methylacetynyl	OH
50	94	4-amidinophenyl	0	H	C(O)	1	H	cyclopropylacetynyl	OH
	95	4-amidinophenyl	0	H	C(O)	1	H	ethylacetynyl	OH
	96	4-amidinophenyl	0	H	C(O)	1	H	butylacetynyl	OH
	97	4-amidinophenyl	0	H	C(O)	1	H	vinyl	OH
	98	4-amidinophenyl	0	H	C(O)	1	H	phenethyl	OH
55	99	4-amidinophenyl	0	H	C(O)	1	H	phenylmethyl	OH
	100	4-amidinophenyl	0	H	C(O)	1	H	3-pyridinyl	OH
	101	4-amidinophenyl	0	H	C(O)	1	H	2-pyridinyl	OH
	102	4-amidinophenyl	0	H	C(O)	1	H	4-pyridinyl	OH
	103	4-amidinophenyl	0	H	C(O)	1	H	phenyl	OH
60	104	4-amidinophenyl	0	H	C(O)	1	H	2-fluorophenyl	OH
	105	4-amidinophenyl	0	H	C(O)	1	H	3-fluorophenyl	OH

	106	4-amidinophenyl	0	H	C(O)	1	H	4-fluorophenyl	OH
	107	4-amidinophenyl	0	H	C(O)	1	H	2-methylphenyl	OH
	108	4-amidinophenyl	0	H	C(O)	1	H	3-methylphenyl	OH
	109	4-amidinophenyl	0	H	C(O)	1	H	4-methylphenyl	OH
5	110	4-amidinophenyl	0	H	C(O)	1	H	2-methoxyphenyl	OH
	111	4-amidinophenyl	0	H	C(O)	1	H	3-methoxyphenyl	OH
	112	4-amidinophenyl	0	H	C(O)	1	H	4-methoxyphenyl	OH
	113	4-amidinophenyl	0	H	C(O)	1	H	2-bromophenyl	OH
	114	4-amidinophenyl	0	H	C(O)	1	H	CH ₃ NHC(O)	OH
10	115	4-amidinophenyl	0	H	C(O)	1	H	CH ₃ CH ₂ NHC(O)	OH
	116	4-amidinophenyl	0	H	C(O)	1	H	cyclopropyl-NHC(O)	OH
	117	4-amidinophenyl	0	H	C(O)	1	H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH
	118	4-amidinophenyl	0	H	C(O)	1	H	Me ₂ N(CH ₂) ₃ NHC(O)	OH
	119	4-amidinophenyl	0	H	C(O)	1	H	PhNHC(O)	OH
15	120	4-amidinophenyl	0	H	C(O)	1	H	2-MeOPhNH(CO)	OH
	121	4-amidinophenyl	0	H	C(O)	1	H	Me ₂ NHC(O)	OH
	122	4-amidinophenyl	0	H	C(O)	1	Me	H	OH
	123	4-amidinophenyl	0	H	C(O)	1	Me	H	OMe
	124	4-amidinophenyl	0	H	C(O)	1	Me	Me	OH
20	125	4-amidinophenyl	0	H	C(O)	1	Me	Et	OH
	126	4-amidinophenyl	0	H	C(O)	1	Me	Propyl	OH
	127	4-amidinophenyl	0	H	C(O)	1	Me	butyl	OH
	128	4-amidinophenyl	0	H	C(O)	1	Me	hexyl	OH
	129	4-amidinophenyl	0	H	C(O)	1	Me	cyclopropyl	OH
25	130	4-amidinophenyl	0	H	C(O)	1	Me	cyclohexyl	OH
	131	4-amidinophenyl	0	H	C(O)	1	Me	acetynyl	OH
	132	4-amidinophenyl	0	H	C(O)	1	Me	methylacetynyl	OH
	133	4-amidinophenyl	0	H	C(O)	1	Me	cyclopropylacetynyl	OH
	134	4-amidinophenyl	0	H	C(O)	1	Me	ethylacetynyl	OH
30	135	4-amidinophenyl	0	H	C(O)	1	Me	butylacetynyl	OH
	136	4-amidinophenyl	0	H	C(O)	1	Me	vinyl	OH
	137	4-amidinophenyl	0	H	C(O)	1	Me	phenethyl	OH
	138	4-amidinophenyl	0	H	C(O)	1	Me	phenylmethyl	OH
	139	4-amidinophenyl	0	H	C(O)	1	Me	3-pyridinyl	OH
35	140	4-amidinophenyl	0	H	C(O)	1	Me	2-pyridinyl	OH
	141	4-amidinophenyl	0	H	C(O)	1	Me	4-pyridinyl	OH
	142	4-amidinophenyl	0	H	C(O)	1	Me	phenyl	OH
	143	4-amidinophenyl	0	H	C(O)	1	Me	2-fluorophenyl	OH
	144	4-amidinophenyl	0	H	C(O)	1	Me	3-fluorophenyl	OH
40	145	4-amidinophenyl	0	H	C(O)	1	Me	4-fluorophenyl	OH
	146	4-amidinophenyl	0	H	C(O)	1	Me	2-methylphenyl	OH
	147	4-amidinophenyl	0	H	C(O)	1	Me	3-methylphenyl	OH
	148	4-amidinophenyl	0	H	C(O)	1	Me	4-methylphenyl	OH
	149	4-amidinophenyl	0	H	C(O)	1	Me	2-methoxyphenyl	OH
45	150	4-amidinophenyl	0	H	C(O)	1	Me	3-methoxyphenyl	OH
	151	4-amidinophenyl	0	H	C(O)	1	Me	4-methoxyphenyl	OH
	152	4-amidinophenyl	0	H	C(O)	1	Me	2-bromophenyl	OH
	153	4-amidinophenyl	0	H	C(O)	1	Me	CH ₃ NHC(O)	OH
	154	4-amidinophenyl	0	H	C(O)	1	Me	CH ₃ CH ₂ NHC(O)	OH
50	155	4-amidinophenyl	0	H	C(O)	1	Me	cyclopropyl-NHC(O)	OH
	156	4-amidinophenyl	0	H	C(O)	1	Me	CH ₃ OCH ₂ CH ₂ NHC(O)	OH
	157	4-amidinophenyl	0	H	C(O)	1	Me	Me ₂ N(CH ₂) ₃ NHC(O)	OH
	158	4-amidinophenyl	0	H	C(O)	1	Me	PhNHC(O)	OH
	159	4-amidinophenyl	0	H	C(O)	1	Me	2-MeOPhNH(CO)	OH
55	160	4-amidinophenyl	0	H	C(O)	1	Me	Me ₂ NHC(O)	OH
	161	4-amidinophenyl	0	c-propyl	C(O)	1	H	H	OH
	162	4-amidinophenyl	0	c-propyl	C(O)	1	H	H	OMe
	163	4-amidinophenyl	0	c-propyl	C(O)	1	H	Me	OH
60	164	4-amidinophenyl	0	c-propyl	C(O)	1	H	Et	OH
	165	4-amidinophenyl	0	c-propyl	C(O)	1	H	Propyl	OH

	166	4-amidinophenyl	0	c-propyl	C(O)	1	H	butyl	OH
	167	4-amidinophenyl	0	c-propyl	C(O)	1	H	hexyl	OH
	168	4-amidinophenyl	0	c-propyl	C(O)	1	H	cyclopropyl	OH
	169	4-amidinophenyl	0	c-propyl	C(O)	1	H	cyclohexyl	OH
5	170	4-amidinophenyl	0	c-propyl	C(O)	1	H	acetynyl	OH
	171	4-amidinophenyl	0	c-propyl	C(O)	1	H	methylacetynyl	OH
	172	4-amidinophenyl	0	c-propyl	C(O)	1	H	cyclopropylacetynyl	OH
	173	4-amidinophenyl	0	c-propyl	C(O)	1	H	ethylacetynyl	OH
	174	4-amidinophenyl	0	c-propyl	C(O)	1	H	butylacetynyl	OH
10	175	4-amidinophenyl	0	c-propyl	C(O)	1	H	vinyl	OH
	176	4-amidinophenyl	0	c-propyl	C(O)	1	H	phenethyl	OH
	177	4-amidinophenyl	0	c-propyl	C(O)	1	H	phenylmethyl	OH
	178	4-amidinophenyl	0	c-propyl	C(O)	1	H	3-pyridinyl	OH
	179	4-amidinophenyl	0	c-propyl	C(O)	1	H	2-pyridinyl	OH
15	180	4-amidinophenyl	0	c-propyl	C(O)	1	H	4-pyridinyl	OH
	181	4-amidinophenyl	0	c-propyl	C(O)	1	H	phenyl	OH
	182	4-amidinophenyl	0	c-propyl	C(O)	1	H	2-fluorophenyl	OH
	183	4-amidinophenyl	0	c-propyl	C(O)	1	H	3-fluorophenyl	OH
	184	4-amidinophenyl	0	c-propyl	C(O)	1	H	4-fluorophenyl	OH
20	185	4-amidinophenyl	0	c-propyl	C(O)	1	H	2-methylphenyl	OH
	186	4-amidinophenyl	0	c-propyl	C(O)	1	H	3-methylphenyl	OH
	187	4-amidinophenyl	0	c-propyl	C(O)	1	H	4-methylphenyl	OH
	188	4-amidinophenyl	0	c-propyl	C(O)	1	H	2-methoxyphenyl	OH
	189	4-amidinophenyl	0	c-propyl	C(O)	1	H	3-methoxyphenyl	OH
25	190	4-amidinophenyl	0	c-propyl	C(O)	1	H	4-methoxyphenyl	OH
	191	4-amidinophenyl	0	c-propyl	C(O)	1	H	2-bromophenyl	OH
	192	4-amidinophenyl	0	c-propyl	C(O)	1	H	CH ₃ NHC(O)	OH
	193	4-amidinophenyl	0	c-propyl	C(O)	1	H	CH ₃ CH ₂ NHC(O)	OH
	194	4-amidinophenyl	0	c-propyl	C(O)	1	H	cyclopropyl-NHC(O)	OH
30	195	4-amidinophenyl	0	c-propyl	C(O)	1	H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH
	195	4-amidinophenyl	0	c-propyl	C(O)	1	H	Me ₂ N(CH ₂) ₃ NHC(O)	OH
	197	4-amidinophenyl	0	c-propyl	C(O)	1	H	PhNHC(O)	OH
	198	4-amidinophenyl	0	c-propyl	C(O)	1	H	2-MeOPhNH(CO)	OH
	199	4-amidinophenyl	0	c-propyl	C(O)	1	H	Me ₂ NHC(O)	OH
35									
	200	4-amidinophenyl	0	Me	C(O)	0	H	H	OH
	201	4-amidinophenyl	0	Me	C(O)	0	H	H	OMe
	201	4-amidinophenyl	0	Me	C(O)	0	H	Me	OH
	203	4-amidinophenyl	0	Me	C(O)	0	H	Et	OH
40	204	4-amidinophenyl	0	Me	C(O)	0	H	Propyl	OH
	205	4-amidinophenyl	0	Me	C(O)	0	H	butyl	OH
	206	4-amidinophenyl	0	Me	C(O)	0	H	hexyl	OH
	207	4-amidinophenyl	0	Me	C(O)	0	H	cyclopropyl	OH
	208	4-amidinophenyl	0	Me	C(O)	0	H	cyclohexyl	OH
45	209	4-amidinophenyl	0	Me	C(O)	0	H	acetynyl	OH
	210	4-amidinophenyl	0	Me	C(O)	0	H	methylacetynyl	OH
	211	4-amidinophenyl	0	Me	C(O)	0	H	cyclopropylacetynyl	OH
	212	4-amidinophenyl	0	Me	C(O)	0	H	ethylacetynyl	OH
	213	4-amidinophenyl	0	Me	C(O)	0	H	butylacetynyl	OH
50	214	4-amidinophenyl	0	Me	C(O)	0	H	vinyl	OH
	215	4-amidinophenyl	0	Me	C(O)	0	H	phenethyl	OH
	216	4-amidinophenyl	0	Me	C(O)	0	H	phenylmethyl	OH
	217	4-amidinophenyl	0	Me	C(O)	0	H	3-pyridinyl	OH
	218	4-amidinophenyl	0	Me	C(O)	0	H	2-pyridinyl	OH
55	219	4-amidinophenyl	0	Me	C(O)	0	H	4-pyridinyl	OH
	220	4-amidinophenyl	0	Me	C(O)	0	H	phenyl	OH
	221	4-amidinophenyl	0	Me	C(O)	0	H	2-fluorophenyl	OH
	222	4-amidinophenyl	0	Me	C(O)	0	H	3-fluorophenyl	OH
	223	4-amidinophenyl	0	Me	C(O)	0	H	4-fluorophenyl	OH
60	224	4-amidinophenyl	0	Me	C(O)	0	H	2-methylphenyl	OH
	225	4-amidinophenyl	0	Me	C(O)	0	H	3-methylphenyl	OH

5	226	4-amidinophenyl	0	Me	C(O) 0 H	4-methylphenyl	OH
	227	4-amidinophenyl	0	Me	C(O) 0 H	2-methoxyphenyl	OH
	228	4-amidinophenyl	0	Me	C(O) 0 H	3-methoxyphenyl	OH
	229	4-amidinophenyl	0	Me	C(O) 0 H	4-methoxyphenyl	OH
	230	4-amidinophenyl	0	Me	C(O) 0 H	2-bromophenyl	OH
10	231	4-amidinophenyl	0	Me	C(O) 0 H	CH ₃ NHC(O)	OH
	232	4-amidinophenyl	0	Me	C(O) 0 H	CH ₃ CH ₂ NHC(O)	OH
	233	4-amidinophenyl	0	Me	C(O) 0 H	cyclopropyl-NHC(O)	OH
	234	4-amidinophenyl	0	Me	C(O) 0 H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH
	235	4-amidinophenyl	0	Me	C(O) 0 H	Me ₂ N(CH ₂) ₃ NHC(O)	OH
15	236	4-amidinophenyl	0	Me	C(O) 0 H	PhNHC(O)	OH
	237	4-amidinophenyl	0	Me	C(O) 0 H	2-MeOPhNH(CO)	OH
	238	4-amidinophenyl	0	Me	C(O) 0 H	Me ₂ NHC(O)	OH
	239	4-amidinophenyl	1	Me	C(O) 0 H	H	OH
	240	4-amidinophenyl	1	Me	C(O) 0 H	H	OMe
20	241	4-amidinophenyl	1	Me	C(O) 0 H	Me	OH
	242	4-amidinophenyl	1	Me	C(O) 0 H	Et	OH
	243	4-amidinophenyl	1	Me	C(O) 0 H	Propyl	OH
	244	4-amidinophenyl	1	Me	C(O) 0 H	butyl	OH
	245	4-amidinophenyl	1	Me	C(O) 0 H	hexyl	OH
25	246	4-amidinophenyl	1	Me	C(O) 0 H	cyclopropyl	OH
	247	4-amidinophenyl	1	Me	C(O) 0 H	cyclohexyl	OH
	248	4-amidinophenyl	1	Me	C(O) 0 H	acetynyl	OH
	249	4-amidinophenyl	1	Me	C(O) 0 H	methylacetynyl	OH
	250	4-amidinophenyl	1	Me	C(O) 0 H	cyclopropylacetynyl	OH
30	251	4-amidinophenyl	1	Me	C(O) 0 H	ethylacetynyl	OH
	252	4-amidinophenyl	1	Me	C(O) 0 H	butylacetynyl	OH
	253	4-amidinophenyl	1	Me	C(O) 0 H	vinyl	OH
	254	4-amidinophenyl	1	Me	C(O) 0 H	phenethyl	OH
	255	4-amidinophenyl	1	Me	C(O) 0 H	phenylmethyl	OH
35	256	4-amidinophenyl	1	Me	C(O) 0 H	3-pyridinyl	OH
	257	4-amidinophenyl	1	Me	C(O) 0 H	2-pyridinyl	OH
	258	4-amidinophenyl	1	Me	C(O) 0 H	4-pyridinyl	OH
	259	4-amidinophenyl	1	Me	C(O) 0 H	phenyl	OH
	260	4-amidinophenyl	1	Me	C(O) 0 H	2-fluorophenyl	OH
40	261	4-amidinophenyl	1	Me	C(O) 0 H	3-fluorophenyl	OH
	262	4-amidinophenyl	1	Me	C(O) 0 H	4-fluorophenyl	OH
	263	4-amidinophenyl	1	Me	C(O) 0 H	2-methylphenyl	OH
	264	4-amidinophenyl	1	Me	C(O) 0 H	3-methylphenyl	OH
	265	4-amidinophenyl	1	Me	C(O) 0 H	4-methylphenyl	OH
45	266	4-amidinophenyl	1	Me	C(O) 0 H	2-methoxyphenyl	OH
	267	4-amidinophenyl	1	Me	C(O) 0 H	3-methoxyphenyl	OH
	268	4-amidinophenyl	1	Me	C(O) 0 H	4-methoxyphenyl	OH
	269	4-amidinophenyl	1	Me	C(O) 0 H	2-bromophenyl	OH
	270	4-amidinophenyl	1	Me	C(O) 0 H	CH ₃ NHC(O)	OH
50	271	4-amidinophenyl	1	Me	C(O) 0 H	CH ₃ CH ₂ NHC(O)	OH
	272	4-amidinophenyl	1	Me	C(O) 0 H	cyclopropyl-NHC(O)	OH
	273	4-amidinophenyl	1	Me	C(O) 0 H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH
	274	4-amidinophenyl	1	Me	C(O) 0 H	Me ₂ N(CH ₂) ₃ NHC(O)	OH
	275	4-amidinophenyl	1	Me	C(O) 0 H	PhNHC(O)	OH
55	276	4-amidinophenyl	1	Me	C(O) 0 H	2-MeOPhNH(CO)	OH
	277	4-amidinophenyl	1	Me	C(O) 0 H	Me ₂ NHC(O)	OH
	278	4-amidinophenyl	0	Me	C(O) 2 H	H	OH
	279	4-amidinophenyl	0	Me	C(O) 2 H	H	OMe
	280	4-amidinophenyl	0	Me	C(O) 2 H	Me	OH
60	281	4-amidinophenyl	0	Me	C(O) 2 H	Et	OH
	282	4-amidinophenyl	0	Me	C(O) 2 H	Propyl	OH
	283	4-amidinophenyl	0	Me	C(O) 2 H	butyl	OH
	284	4-amidinophenyl	0	Me	C(O) 2 H	hexyl	OH

	285	4-amidinophenyl	0	Me	C(O) 2 H	cyclopropyl	OH	
	286	4-amidinophenyl	0	Me	C(O) 2 H	cyclohexyl	OH	
	287	4-amidinophenyl	0	Me	C(O) 2 H	acetynyl	OH	
	288	4-amidinophenyl	0	Me	C(O) 2 H	methylacetynyl	OH	
5	289	4-amidinophenyl	0	Me	C(O) 2 H	cyclopropylacetynyl	OH	
	290	4-amidinophenyl	0	Me	C(O) 2 H	ethylacetynyl	OH	
	291	4-amidinophenyl	0	Me	C(O) 2 H	butylacetynyl	OH	
	292	4-amidinophenyl	0	Me	C(O) 2 H	vinyl	OH	
	293	4-amidinophenyl	0	Me	C(O) 2 H	phenethyl	OH	
10	294	4-amidinophenyl	0	Me	C(O) 2 H	phenylmethyl	OH	
	295	4-amidinophenyl	0	Me	C(O) 2 H	3-pyridinyl	OH	
	296	4-amidinophenyl	0	Me	C(O) 2 H	2-pyridinyl	OH	
	297	4-amidinophenyl	0	Me	C(O) 2 H	4-pyridinyl	OH	
	298	4-amidinophenyl	0	Me	C(O) 2 H	phenyl	OH	
15	299	4-amidinophenyl	0	Me	C(O) 2 H	2-fluorophenyl	OH	
	300	4-amidinophenyl	0	Me	C(O) 2 H	3-fluorophenyl	OH	
	301	4-amidinophenyl	0	Me	C(O) 2 H	4-fluorophenyl	OH	
	302	4-amidinophenyl	0	Me	C(O) 2 H	2-methylphenyl	OH	
	303	4-amidinophenyl	0	Me	C(O) 2 H	3-methylphenyl	OH	
20	304	4-amidinophenyl	0	Me	C(O) 2 H	4-methylphenyl	OH	
	305	4-amidinophenyl	0	Me	C(O) 2 H	2-methoxyphenyl	OH	
	306	4-amidinophenyl	0	Me	C(O) 2 H	3-methoxyphenyl	OH	
	307	4-amidinophenyl	0	Me	C(O) 2 H	4-methoxyphenyl	OH	
	308	4-amidinophenyl	0	Me	C(O) 2 H	2-bromophenyl	OH	
25	309	4-amidinophenyl	0	Me	C(O) 2 H	CH ₃ NHC(O)	OH	
	310	4-amidinophenyl	0	Me	C(O) 2 H	CH ₃ CH ₂ NHC(O)	OH	
	311	4-amidinophenyl	0	Me	C(O) 2 H	cyclopropyl-NHC(O)	OH	
	312	4-amidinophenyl	0	Me	C(O) 2 H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH	
	313	4-amidinophenyl	0	Me	C(O) 2 H	Me ₂ N(CH ₂) ₃ NHC(O)	OH	
30	314	4-amidinophenyl	0	Me	C(O) 2 H	PhNHC(O)	OH	
	315	4-amidinophenyl	0	Me	C(O) 2 H	2-MeOPhNH(CO)	OH	
	316	4-amidinophenyl	0	Me	C(O) 2 H	Me ₂ NHC(O)	OH	
	317	4-amidinophenyl	0	Me	C(O) 1 H	indole-3-ethyl	OH	506
35	318	4-amidinophenyl	0	benzyl	C(O) 1 H	H	OH	439
	319	4-amidinophenyl	0	benzyl	C(O) 1 H	H	OH	439
		4-R, 6-S						
	320	4-amidinophenyl	0	benzyl	C(O) 1 H	Me	OH	453
	321	4-amidinophenyl	0	benzyl	C(O) 1 H	Et	OH	
40	322	4-amidinophenyl	0	benzyl	C(O) 1 H	Propyl	OH	
	323	4-amidinophenyl	0	benzyl	C(O) 1 H	butyl	OH	
	324	4-amidinophenyl	0	benzyl	C(O) 1 H	hexyl	OH	
	325	4-amidinophenyl	0	benzyl	C(O) 1 H	cyclopropyl	OH	
	326	4-amidinophenyl	0	benzyl	C(O) 1 H	cyclohexyl	OH	
45	327	4-amidinophenyl	0	benzyl	C(O) 1 H	acetynyl	OH	
	328	4-amidinophenyl	0	benzyl	C(O) 1 H	methylacetynyl	OH	
	329	4-amidinophenyl	0	benzyl	C(O) 1 H	cyclopropylacetynyl	OH	
	330	4-amidinophenyl	0	benzyl	C(O) 1 H	ethylacetynyl	OH	
	331	4-amidinophenyl	0	benzyl	C(O) 1 H	butylacetynyl	OH	
50	332	4-amidinophenyl	0	benzyl	C(O) 1 H	vinyl	OH	
	333	4-amidinophenyl	0	benzyl	C(O) 1 H	phenethyl	OH	
	334	4-amidinophenyl	0	benzyl	C(O) 1 H	phenylmethyl	OH	
	335	4-amidinophenyl	0	benzyl	C(O) 1 H	3-pyridinyl	OH	
	336	4-amidinophenyl	0	benzyl	C(O) 1 H	2-pyridinyl	OH	
55	337	4-amidinophenyl	0	benzyl	C(O) 1 H	4-pyridinyl	OH	
	338	4-amidinophenyl	0	benzyl	C(O) 1 H	phenyl	OH	
	339	4-amidinophenyl	0	benzyl	C(O) 1 H	2-fluorophenyl	OH	
	340	4-amidinophenyl	0	benzyl	C(O) 1 H	3-fluorophenyl	OH	471
	341	4-amidinophenyl	0	benzyl	C(O) 1 H	4-fluorophenyl	OH	
60	342	4-amidinophenyl	0	benzyl	C(O) 1 H	2-methylphenyl	OH	
	343	4-amidinophenyl	0	benzyl	C(O) 1 H	3-methylphenyl	OH	

5	344	4-amidinophenyl	0	benzyl	C(O) 1 H	4-methylphenyl	OH
	345	4-amidinophenyl	0	benzyl	C(O) 1 H	2-methoxyphenyl	OH
	346	4-amidinophenyl	0	benzyl	C(O) 1 H	3-methoxyphenyl	OH
	347	4-amidinophenyl	0	benzyl	C(O) 1 H	4-methoxyphenyl	OH
	348	4-amidinophenyl	0	benzyl	C(O) 1 H	2-bromophenyl	OH
10	349	4-amidinophenyl	0	benzyl	C(O) 1 H	CH ₃ NHC(O)	OH
	350	4-amidinophenyl	0	benzyl	C(O) 1 H	CH ₃ CH ₂ NHC(O)	OH
	351	4-amidinophenyl	0	benzyl	C(O) 1 H	cyclopropyl-NHC(O)	OH
	352	4-amidinophenyl	0	benzyl	C(O) 1 H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH
	353	4-amidinophenyl	0	benzyl	C(O) 1 H	Me ₂ N(CH ₂) ₃ NHC(O)	OH
15	354	4-amidinophenyl	0	benzyl	C(O) 1 H	PhNHC(O)	OH
	355	4-amidinophenyl	0	benzyl	C(O) 1 H	2-MeOPhNH(CO)	OH
	356	4-amidinophenyl	0	benzyl	C(O) 1 H	Me ₂ NHC(O)	OH
	357	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	H	OH
	358	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	H	OMe
20	359	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	Me	OH
	360	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	Et	OH
	361	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	Propyl	OH
	362	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	butyl	OH
	363	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	hexyl	OH
25	364	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	cyclopropyl	OH
	365	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	cyclohexyl	OH
	366	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	acetynyl	OH
	367	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	methylacetynyl	OH
	368	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	cyclopropylacetynyl	OH
30	369	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	ethylacetynyl	OH
	370	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	butylacetynyl	OH
	371	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	vinyl	OH
	372	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	phenethyl	OH
	373	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	phenylmethyl	OH
35	374	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	3-pyridinyl	OH
	375	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	2-pyridinyl	OH
	376	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	4-pyridinyl	OH
	377	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	phenyl	OH
	378	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	2-fluorophenyl	OH
40	379	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	3-fluorophenyl	OH
	380	4-(N-methylamidino) phenyl	0	Me	C(O) 1 H	4-fluorophenyl	OH

5	381	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	2-methylphenyl	OH
	382	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	3-methylphenyl	OH
	383	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	4-methylphenyl	OH
	384	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	2-methoxyphenyl	OH
10	385	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	3-methoxyphenyl	OH
	386	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	4-methoxyphenyl	OH
	387	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	2-bromophenyl	OH
	388	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	CH ₃ NHC(O)	OH
15	389	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	CH ₃ CH ₂ NHC(O)	OH
	390	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	cyclopropyl-NHC(O)	OH
	391	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH
	392	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	Me ₂ N(CH ₂) ₃ NHC(O)	OH
25	393	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	PhNHC(O)	OH
	394	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	2-MeOPhNH(CO)	OH
	395	phenyl 4-(N-methylamidino)	0	Me	C(O)	1	H	Me ₂ NHC(O)	OH
	396	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	H	OH
35	397	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	H	OMe
	398	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	Me	OH
	399	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	Et	OH
	400	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	Propyl	OH
40	401	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	butyl	OH
	402	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	hexyl	OH
	403	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	cyclopropyl	OH
	404	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	cyclohexyl	OH
50	405	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	acetyl	OH
	406	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	methylacetyl	OH
	407	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	cyclopropylacetyl	OH
	408	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	ethylacetyl	OH
55	409	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	butylacetyl	OH
	410	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	vinyl	OH

	411	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	phenethyl	OH	523
	412	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	phenylmethyl	OH	
5	413	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	3-pyridinyl	OH	
	414	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	2-pyridinyl	OH	
10	415	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	4-pyridinyl	OH	
	416	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	phenyl	OH	
	417	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	2-fluorophenyl	OH	
15	418	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	3-fluorophenyl	OH	
	419	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	4-fluorophenyl	OH	
20	420	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	2-methylphenyl	OH	
	421	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	3-methylphenyl	OH	
	422	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	4-methylphenyl	OH	
25	423	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	2-methoxyphenyl	OH	
	424	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	3-methoxyphenyl	OH	
30	425	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	4-methoxyphenyl	OH	
	426	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	2-bromophenyl	OH	
	427	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	CH ₃ NHC(O)	OH	
35	428	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	CH ₃ CH ₂ NHC(O)	OH	
	429	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	cyclopropyl-NHC(O)	OH	
40	430	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH	
	431	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	Me ₂ N(CH ₂) ₃ NHC(O)	OH	
	432	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	PhNHC(O)	OH	
45	433	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	2-MeOPhNH(CO)	OH	
	434	phenyl 4-(N-butylamidino)	0	Me	C(O)	1	H	Me ₂ NHC(O)	OH	
50	435	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	H	OH	
	436	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	H	OMe	
55	437	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	Me	OH	
	438	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	Et	OH	
	439	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	Propyl	OH	
60	440	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	butyl	OH	

	441	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	hexyl	OH	
	442	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	cyclopropyl	OH	
5	443	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	cyclohexyl	OH	
	444	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	acetynyl	OH	
10	445	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	methylacetynyl	OH	
	446	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	cyclopropylacetynyl	OH	
	447	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	ethylacetynyl	OH	
15	448	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	butylacetynyl	OH	
	449	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	vinyl	OH	
20	450	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	phenethyl	OH	523
	451	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	phenylmethyl	OH	
	452	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	3-pyridinyl	OH	
25	453	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	2-pyridinyl	OH	
	454	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	4-pyridinyl	OH	
30	455	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	phenyl	OH	
	456	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	2-fluorophenyl	OH	
	457	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	3-fluorophenyl	OH	
35	458	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	4-fluorophenyl	OH	
	459	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	2-methylphenyl	OH	
40	460	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	3-methylphenyl	OH	
	461	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	4-methylphenyl	OH	
	462	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	2-methoxyphenyl	OH	
45	463	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	3-methoxyphenyl	OH	
	464	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	4-methoxyphenyl	OH	
50	465	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	2-bromophenyl	OH	
	466	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	CH ₃ NHC(O)	OH	
	467	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	CH ₃ CH ₂ NHC(O)	OH	
55	468	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	cyclopropyl-NHC(O)	OH	
	469	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH	
60	470	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	H	Me ₂ N(CH ₂) ₃ NHC(O)	OH	

	471	4-(N-butylamidino) phenyl	0	benzyl	C(O)	1	H	PhNHC(O)	OH	
	472	4-(N-butylamidino) phenyl	0	benzyl	C(O)	1	H	2-MeOPhNH(CO)	OH	
5	473	4-(N-butylamidino) pheny	0	benzyl	C(O)	1	H	Me ₂ NHC(O)	OH	
	474	4-piperidinyl	2	benzyl	C(O)	1	H	Me	OH	
	475	4-piperidinyl	2	benzyl	C(O)	1	H	Et	OH	
10	476	4-piperidinyl	2	benzyl	C(O)	1	H	Propyl	OH	
	477	4-piperidinyl	2	benzyl	C(O)	1	H	butyl	OH	
	478	4-piperidinyl	2	benzyl	C(O)	1	H	hexyl	OH	
	479	4-piperidinyl	2	benzyl	C(O)	1	H	cyclopropyl	OH	
	480	4-piperidinyl	2	benzyl	C(O)	1	H	cyclohexyl	OH	
15	481	4-piperidinyl	2	benzyl	C(O)	1	H	acetyl	OH	
	482	4-piperidinyl	2	benzyl	C(O)	1	H	methylacetyl	OH	
	483	4-piperidinyl	2	benzyl	C(O)	1	H	cyclopropylacetyl	OH	
	484	4-piperidinyl	2	benzyl	C(O)	1	H	ethylacetyl	OH	
	485	4-piperidinyl	2	benzyl	C(O)	1	H	butylacetyl	OH	
20	486	4-piperidinyl	2	benzyl	C(O)	1	H	vinyl	OH	
	487	4-piperidinyl	2	benzyl	C(O)	1	H	phenethyl	OH	
	488	4-piperidinyl	2	benzyl	C(O)	1	H	phenylmethyl	OH	
	489	4-piperidinyl	2	benzyl	C(O)	1	H	3-pyridinyl	OH	
	490	4-piperidinyl	2	benzyl	C(O)	1	H	2-pyridinyl	OH	
25	491	4-piperidinyl	2	benzyl	C(O)	1	H	4-pyridinyl	OH	
	492	4-piperidinyl	2	benzyl	C(O)	1	H	phenyl	OH	
	493	4-piperidinyl	2	benzyl	C(O)	1	H	2-fluorophenyl	OH	
	494	4-piperidinyl	2	benzyl	C(O)	1	H	3-fluorophenyl	OH	
	495	4-piperidinyl	2	benzyl	C(O)	1	H	4-fluorophenyl	OH	
30	496	4-piperidinyl	2	benzyl	C(O)	1	H	2-methylphenyl	OH	
	497	4-piperidinyl	2	benzyl	C(O)	1	H	3-methylphenyl	OH	
	498	4-piperidinyl	2	benzyl	C(O)	1	H	4-methylphenyl	OH	
	499	4-piperidinyl	2	benzyl	C(O)	1	H	2-methoxyphenyl	OH	
	500	4-piperidinyl	2	benzyl	C(O)	1	H	3-methoxyphenyl	OH	
35	501	4-piperidinyl	2	benzyl	C(O)	1	H	4-methoxyphenyl	OH	
	502	4-piperidinyl	2	benzyl	C(O)	1	H	2-bromophenyl	OH	
	503	4-piperidinyl	2	benzyl	C(O)	1	H	CH ₃ NHC(O)	OH	
	504	4-piperidinyl	2	benzyl	C(O)	1	H	CH ₃ CH ₂ NHC(O)	OH	
	505	4-piperidinyl	2	benzyl	C(O)	1	H	cyclopropyl-NHC(O)	OH	
40	506	4-piperidinyl	2	benzyl	C(O)	1	H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH	
	507	4-piperidinyl	2	benzyl	C(O)	1	H	Me ₂ N(CH ₂) ₃ NHC(O)	OH	
	508	4-piperidinyl	2	benzyl	C(O)	1	H	PhNHC(O)	OH	
	509	4-piperidinyl	2	benzyl	C(O)	1	H	2-MeOPhNH(CO)	OH	
	510	4-piperidinyl	2	benzyl	C(O)	1	H	Me ₂ NHC(O)	OH	
45										
	511	4-amidinophenyl	0	Me	none	1	H	H	OH	335
	512	4-amidinophenyl 4-R, 6-S	0	Me	none	1	H	H	OH	335
50	514	4-amidinophenyl	0	Me	none	1	H	Me	OH	349
	515	4-amidinophenyl	0	Me	none	1	H	Et	OH	
	516	4-amidinophenyl	0	Me	none	1	H	Propyl	OH	
	517	4-amidinophenyl	0	Me	none	1	H	butyl	OH	
	518	4-amidinophenyl	0	Me	none	1	H	hexyl	OH	
55	519	4-amidinophenyl	0	Me	none	1	H	cyclopropyl	OH	
	520	4-amidinophenyl	0	Me	none	1	H	cyclohexyl	OH	
	521	4-amidinophenyl	0	Me	none	1	H	acetyl	OH	
	522	4-amidinophenyl	0	Me	none	1	H	methylacetyl	OH	
	523	4-amidinophenyl	0	Me	none	1	H	cyclopropylacetyl	OH	

	524	4-amidinophenyl	0	Me	none	1	H	ethylacetynyl	OH
	525	4-amidinophenyl	0	Me	none	1	H	butylacetynyl	OH
	526	4-amidinophenyl	0	Me	none	1	H	vinyl	OH
	527	4-amidinophenyl	0	Me	none	1	H	phenethyl	OH
5	528	4-amidinophenyl	0	Me	none	1	H	phenylmethyl	OH
	529	4-amidinophenyl	0	Me	none	1	H	3-pyridinyl	OH
	530	4-amidinophenyl	0	Me	none	1	H	2-pyridinyl	OH
	531	4-amidinophenyl	0	Me	none	1	H	4-pyridinyl	OH
	532	4-amidinophenyl	0	Me	none	1	H	phenyl	OH
10	533	4-amidinophenyl	0	Me	none	1	H	2-fluorophenyl	OH
	534	4-amidinophenyl	0	Me	none	1	H	3-fluorophenyl	OH
	535	4-amidinophenyl	0	Me	none	1	H	4-fluorophenyl	OH
	536	4-amidinophenyl	0	Me	none	1	H	2-methylphenyl	OH
	537	4-amidinophenyl	0	Me	none	1	H	3-methylphenyl	OH
15	538	4-amidinophenyl	0	Me	none	1	H	4-methylphenyl	OH
	539	4-amidinophenyl	0	Me	none	1	H	2-methoxyphenyl	OH
	540	4-amidinophenyl	0	Me	none	1	H	3-methoxyphenyl	OH
	541	4-amidinophenyl	0	Me	none	1	H	4-methoxyphenyl	OH
	542	4-amidinophenyl	0	Me	none	1	H	2-bromophenyl	OH
20	543	4-amidinophenyl	0	Me	none	1	H	CH ₃ NHC(O)	OH
	544	4-amidinophenyl	0	Me	none	1	H	CH ₃ CH ₂ NHC(O)	OH
	545	4-amidinophenyl	0	Me	none	1	H	cyclopropyl-NHC(O)	OH
	546	4-amidinophenyl	0	Me	none	1	H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH
	547	4-amidinophenyl	0	Me	none	1	H	Me ₂ N(CH ₂) ₃ NHC(O)	OH
25	548	4-amidinophenyl	0	Me	none	1	H	PhNHC(O)	OH
	549	4-amidinophenyl	0	Me	none	1	H	2-MeOPhNH(CO)	OH
	550	4-amidinophenyl	0	Me	none	1	H	Me ₂ NC(O)	OH
	551	4-amidinophenyl	0	Et	none	1	H	H	OH
30	552	4-amidinophenyl	0	Et	none	1	H	Me	OH
	553	4-amidinophenyl	0	Et	none	1	H	Et	OH
	554	4-amidinophenyl	0	Et	none	1	H	Propyl	OH
	555	4-amidinophenyl	0	Et	none	1	H	butyl	OH
	556	4-amidinophenyl	0	Et	none	1	H	hexyl	OH
35	557	4-amidinophenyl	0	Et	none	1	H	cyclopropyl	OH
	558	4-amidinophenyl	0	Et	none	1	H	cyclohexyl	OH
	559	4-amidinophenyl	0	Et	none	1	H	acetynyl	OH
	560	4-amidinophenyl	0	Et	none	1	H	methylacetynyl	OH
	561	4-amidinophenyl	0	Et	none	1	H	cyclopropylacetynyl	OH
40	562	4-amidinophenyl	0	Et	none	1	H	ethylacetynyl	OH
	563	4-amidinophenyl	0	Et	none	1	H	butylacetynyl	OH
	564	4-amidinophenyl	0	Et	none	1	H	vinyl	OH
	565	4-amidinophenyl	0	Et	none	1	H	phenethyl	OH
	566	4-amidinophenyl	0	Et	none	1	H	phenylmethyl	OH
45	567	4-amidinophenyl	0	Et	none	1	H	3-pyridinyl	OH
	568	4-amidinophenyl	0	Et	none	1	H	2-pyridinyl	OH
	569	4-amidinophenyl	0	Et	none	1	H	4-pyridinyl	OH
	570	4-amidinophenyl	0	Et	none	1	H	phenyl	OH
	571	4-amidinophenyl	0	Et	none	1	H	2-fluorophenyl	OH
50	572	4-amidinophenyl	0	Et	none	1	H	3-fluorophenyl	OH
	573	4-amidinophenyl	0	Et	none	1	H	4-fluorophenyl	OH
	574	4-amidinophenyl	0	Et	none	1	H	2-methylphenyl	OH
	575	4-amidinophenyl	0	Et	none	1	H	3-methylphenyl	OH

	576	4-amidinophenyl	0	Et	none	1	H	4-methylphenyl	OH
	577	4-amidinophenyl	0	Et	none	1	H	2-methoxyphenyl	OH
	578	4-amidinophenyl	0	Et	none	1	H	3-methoxyphenyl	OH
	578	4-amidinophenyl	0	Et	none	1	H	4-methoxyphenyl	OH
5	579	4-amidinophenyl	0	Et	none	1	H	2-bromophenyl	OH
	580	4-amidinophenyl	0	Et	none	1	H	CH ₃ NHC(O)	OH
	581	4-amidinophenyl	0	Et	none	1	H	CH ₃ CH ₂ NHC(O)	OH
	582	4-amidinophenyl	0	Et	none	1	H	cyclopropyl-NHC(O)	OH
	583	4-amidinophenyl	0	Et	none	1	H	CH ₃ OCH ₂ CH ₂ NHC(O)	OH
10	584	4-amidinophenyl	0	Et	none	1	H	Me ₂ N(CH ₂) ₃ NHC(O)	OH
	585	4-amidinophenyl	0	Et	none	1	H	PhNHC(O)	OH
	586	4-amidinophenyl	0	Et	none	1	H	2-MeOPhNH(CO)	OH
	587	4-amidinophenyl	0	Et	none	1	H	Me ₂ NHC(O)	OH
15	588	4-amidinophenyl	0	H	none	1	H	Me	OH
	589	4-amidinophenyl	0	H	none	1	H	Et	OH
	590	4-amidinophenyl	0	H	none	1	H	Propyl	OH
	591	4-amidinophenyl	0	H	none	1	H	butyl	OH
	592	4-amidinophenyl	0	H	none	1	H	hexyl	OH
20	593	4-amidinophenyl	0	H	none	1	H	cyclopropyl	OH
	594	4-amidinophenyl	0	H	none	1	H	cyclohexyl	OH
	595	4-amidinophenyl	0	H	none	1	H	acetynyl	OH
	596	4-amidinophenyl	0	H	none	1	H	methylacetynyl	OH
	597	4-amidinophenyl	0	H	none	1	H	cyclopropylacetynyl	OH
25	598	4-amidinophenyl	0	H	none	1	H	ethylacetynyl	OH
	599	4-amidinophenyl	0	H	none	1	H	butylacetynyl	OH
	600	4-amidinophenyl	0	H	none	1	H	vinyl	OH
30	601	4-amidinophenyl	0	H	none	1	Me	Me	OH
	602	4-amidinophenyl	0	H	none	1	Me	Et	OH
	603	4-amidinophenyl	0	H	none	1	Me	Propyl	OH
	604	4-amidinophenyl	0	H	none	1	Me	butyl	OH
	605	4-amidinophenyl	0	H	none	1	Me	hexyl	OH
35	606	4-amidinophenyl	0	H	none	1	Me	cyclopropyl	OH
	607	4-amidinophenyl	0	H	none	1	Me	cyclohexyl	OH
	608	4-amidinophenyl	0	H	none	1	Me	acetynyl	OH
	609	4-amidinophenyl	0	H	none	1	Me	methylacetynyl	OH
	610	4-amidinophenyl	0	H	none	1	Me	cyclopropylacetynyl	OH
	611	4-amidinophenyl	0	H	none	1	Me	ethylacetynyl	OH
40	612	4-amidinophenyl	0	H	none	1	Me	butylacetynyl	OH
	613	4-amidinophenyl	0	H	none	1	Me	vinyl	OH
	614	4-amidinophenyl	0	H	none	1	Me	phenethyl	OH
	615	4-amidinophenyl	0	H	none	1	Me	phenylmethyl	OH
	616	4-amidinophenyl	0	H	none	1	Me	3-pyridinyl	OH
45	617	4-amidinophenyl	0	H	none	1	Me	2-pyridinyl	OH
	618	4-amidinophenyl	0	H	none	1	Me	4-pyridinyl	OH
	619	4-amidinophenyl	0	H	none	1	Me	phenyl	OH
	620	4-amidinophenyl	0	H	none	1	Me	2-fluorophenyl	OH
	621	4-amidinophenyl	0	H	none	1	Me	3-fluorophenyl	OH
50	622	4-amidinophenyl	0	H	none	1	Me	4-fluorophenyl	OH
	623	4-amidinophenyl	0	H	none	1	Me	2-methylphenyl	OH
	624	4-amidinophenyl	0	H	none	1	Me	3-methylphenyl	OH
	625	4-amidinophenyl	0	H	none	1	Me	4-methylphenyl	OH
	626	4-amidinophenyl	0	H	none	1	Me	2-methoxyphenyl	OH
55	627	4-amidinophenyl	0	c-propyl	none	1	H	Me	OH
	628	4-amidinophenyl	0	c-propyl	none	1	H	Et	OH
	629	4-amidinophenyl	0	c-propyl	none	1	H	Propyl	OH
	630	4-amidinophenyl	0	c-propyl	none	1	H	butyl	OH
	631	4-amidinophenyl	0	c-propyl	none	1	H	hexyl	OH
60	632	4-amidinophenyl	0	c-propyl	none	1	H	cyclopropyl	OH
	633	4-amidinophenyl	0	c-propyl	none	1	H	cyclohexyl	OH


	634	4-amidinophenyl	0	c-propyl	none	1	H	acetynyl	OH
	635	4-amidinophenyl	0	c-propyl	none	1	H	methylacetynyl	OH
	636	4-amidinophenyl	0	c-propyl	none	1	H	cyclopropylacetynyl	OH
	637	4-amidinophenyl	0	c-propyl	none	1	H	ethylacetynyl	OH
5	638	4-amidinophenyl	0	c-propyl	none	1	H	butylacetynyl	OH
	639	4-amidinophenyl	0	c-propyl	none	1	H	vinyl	OH
	640	4-amidinophenyl	0	c-propyl	none	1	H	phenethyl	OH
	641	4-amidinophenyl	0	c-propyl	none	1	H	phenylmethyl	OH
	642	4-amidinophenyl	0	c-propyl	none	1	H	3-pyridinyl	OH
10	643	4-amidinophenyl	0	c-propyl	none	1	H	2-pyridinyl	OH
	644	4-amidinophenyl	0	c-propyl	none	1	H	4-pyridinyl	OH
	645	4-amidinophenyl	0	c-propyl	none	1	H	phenyl	OH
	646	4-amidinophenyl	0	c-propyl	none	1	H	2-fluorophenyl	OH
	647	4-amidinophenyl	0	c-propyl	none	1	H	3-fluorophenyl	OH
15	648	4-amidinophenyl	0	c-propyl	none	1	H	4-fluorophenyl	OH
	649	4-amidinophenyl	0	c-propyl	none	1	H	2-methylphenyl	OH
	650	4-amidinophenyl	0	c-propyl	none	1	H	3-methylphenyl	OH
	651	4-amidinophenyl	0	c-propyl	none	1	H	4-methylphenyl	OH
	652	4-amidinophenyl	0	c-propyl	none	1	H	2-methoxyphenyl	OH
20	653	4-amidinophenyl	0	c-propyl	none	1	H	3-methoxyphenyl	OH
	654	4-amidinophenyl	0	c-propyl	none	1	H	4-methoxyphenyl	OH
	655	4-amidinophenyl	0	Me	none	0	H	Me	OH
	656	4-amidinophenyl	0	Me	none	0	H	Et	OH
	657	4-amidinophenyl	0	Me	none	0	H	Propyl	OH
25	658	4-amidinophenyl	0	Me	none	0	H	butyl	OH
	659	4-amidinophenyl	0	Me	none	0	H	hexyl	OH
	660	4-amidinophenyl	0	Me	none	0	H	cyclopropyl	OH
	661	4-amidinophenyl	0	Me	none	0	H	cyclohexyl	OH
	662	4-amidinophenyl	0	Me	none	0	H	acetynyl	OH
30	663	4-amidinophenyl	0	Me	none	0	H	methylacetynyl	OH
	664	4-amidinophenyl	0	Me	none	0	H	cyclopropylacetynyl	OH
	665	4-amidinophenyl	0	Me	none	0	H	ethylacetynyl	OH
	666	4-amidinophenyl	0	Me	none	0	H	butylacetynyl	OH
	667	4-amidinophenyl	0	Me	none	0	H	vinyl	OH
35	668	4-amidinophenyl	0	Me	none	0	H	phenethyl	OH
	669	4-amidinophenyl	0	Me	none	0	H	phenylmethyl	OH
	670	4-amidinophenyl	0	Me	none	0	H	3-pyridinyl	OH
	671	4-amidinophenyl	0	Me	none	0	H	2-pyridinyl	OH
	672	4-amidinophenyl	0	Me	none	0	H	4-pyridinyl	OH
40	673	4-amidinophenyl	0	Me	none	0	H	phenyl	OH
	674	4-amidinophenyl	0	Me	none	0	H	2-fluorophenyl	OH
	675	4-amidinophenyl	0	Me	none	0	H	3-fluorophenyl	OH
	676	4-amidinophenyl	0	Me	none	0	H	4-fluorophenyl	OH
	677	4-amidinophenyl	0	Me	none	0	H	2-methylphenyl	OH
45	678	4-amidinophenyl	0	Me	none	0	H	3-methylphenyl	OH
	679	4-amidinophenyl	0	Me	none	0	H	4-methylphenyl	OH
	680	4-amidinophenyl	0	Me	none	0	H	2-methoxyphenyl	OH
	681	4-amidinophenyl	0	Me	none	0	H	3-methoxyphenyl	OH
	682	4-amidinophenyl	0	Me	none	0	H	4-methoxyphenyl	OH
50	683	4-amidinophenyl	0	Me	none	0	H	2-bromophenyl	OH
	684	4-amidinophenyl	1	Me	none	0	H	Me	OH
	685	4-amidinophenyl	1	Me	none	0	H	Et	OH
	686	4-amidinophenyl	1	Me	none	0	H	Propyl	OH
55	687	4-amidinophenyl	1	Me	none	0	H	butyl	OH
	688	4-amidinophenyl	1	Me	none	0	H	hexyl	OH
	689	4-amidinophenyl	1	Me	none	0	H	cyclopropyl	OH
	690	4-amidinophenyl	1	Me	none	0	H	cyclohexyl	OH
	691	4-amidinophenyl	1	Me	none	0	H	acetynyl	OH
60	692	4-amidinophenyl	1	Me	none	0	H	methylacetynyl	OH
	693	4-amidinophenyl	1	Me	none	0	H	cyclopropylacetynyl	OH
	694	4-amidinophenyl	1	Me	none	0	H	ethylacetynyl	OH

5	695	4-amidinophenyl	1	Me	none	0	H	butylacetynyl	OH
	696	4-amidinophenyl	1	Me	none	0	H	vinyl	OH
	697	4-amidinophenyl	1	Me	none	0	H	phenethyl	OH
	698	4-amidinophenyl	1	Me	none	0	H	phenylmethyl	OH
	699	4-amidinophenyl	1	Me	none	0	H	3-pyridinyl	OH
	700	4-amidinophenyl	1	Me	none	0	H	2-pyridinyl	OH
	701	4-amidinophenyl	1	Me	none	0	H	4-pyridinyl	OH
	702	4-amidinophenyl	1	Me	none	0	H	phenyl	OH
10	703	4-amidinophenyl	1	Me	none	0	H	2-fluorophenyl	OH
	704	4-amidinophenyl	0	Me	none	2	H	Me	OH
	705	4-amidinophenyl	0	Me	none	2	H	Et	OH
	706	4-amidinophenyl	0	Me	none	2	H	Propyl	OH
15	707	4-amidinophenyl	0	Me	none	2	H	butyl	OH
	708	4-amidinophenyl	0	Me	none	2	H	hexyl	OH
	709	4-amidinophenyl	0	Me	none	2	H	cyclopropyl	OH
	710	4-amidinophenyl	0	Me	none	2	H	cyclohexyl	OH
20	711	4-amidinophenyl	0	Me	none	2	H	acetynyl	OH
	712	4-amidinophenyl	0	Me	none	2	H	methylacetynyl	OH
	713	4-amidinophenyl	0	Me	none	2	H	cyclopropylacetynyl	OH
	714	4-amidinophenyl	0	Me	none	2	H	ethylacetynyl	OH
25	715	4-amidinophenyl	0	Me	none	2	H	butylacetynyl	OH
	716	4-amidinophenyl	0	Me	none	2	H	vinyl	OH
	717	4-amidinophenyl	0	Me	none	2	H	phenethyl	OH
	718	4-amidinophenyl	0	Me	none	2	H	phenylmethyl	OH
30	719	4-amidinophenyl	0	Me	none	2	H	3-pyridinyl	OH
	720	4-amidinophenyl	0	Me	none	2	H	2-pyridinyl	OH
	721	4-amidinophenyl	0	Me	none	2	H	4-pyridinyl	OH
	722	4-amidinophenyl	0	Me	none	2	H	phenyl	OH
35	723	4-amidinophenyl	0	Me	none	2	H	2-fluorophenyl	OH
	724	4-amidinophenyl	0	Me	none	2	H	3-fluorophenyl	OH
	725	4-amidinophenyl	0	benzyl	none	1	H	Et	OH
	726	4-amidinophenyl	0	benzyl	none	1	H	Propyl	OH
40	727	4-amidinophenyl	0	benzyl	none	1	H	butyl	OH
	728	4-amidinophenyl	0	benzyl	none	1	H	hexyl	OH
	729	4-amidinophenyl	0	benzyl	none	1	H	cyclopropyl	OH
	730	4-amidinophenyl	0	benzyl	none	1	H	cyclohexyl	OH
45	731	4-amidinophenyl	0	benzyl	none	1	H	acetynyl	OH
	732	4-amidinophenyl	0	benzyl	none	1	H	methylacetynyl	OH
	733	4-amidinophenyl	0	benzyl	none	1	H	cyclopropylacetynyl	OH
	734	4-amidinophenyl	0	benzyl	none	1	H	ethylacetynyl	OH
50	735	4-amidinophenyl	0	benzyl	none	1	H	butylacetynyl	OH
	736	4-amidinophenyl	0	benzyl	none	1	H	vinyl	OH
	737	4-amidinophenyl	0	benzyl	none	1	H	phenethyl	OH
	738	4-amidinophenyl	0	benzyl	none	1	H	phenylmethyl	OH
55	739	4-amidinophenyl	0	benzyl	none	1	H	3-pyridinyl	OH
	740	4-amidinophenyl	0	benzyl	none	1	H	2-pyridinyl	OH
	741	4-amidinophenyl	0	benzyl	none	1	H	4-pyridinyl	OH
	742	4-amidinophenyl	0	benzyl	none	1	H	phenyl	OH
60	743	4-amidinophenyl	0	benzyl	none	1	H	2-fluorophenyl	OH
	744	4-(N-methylamidino) phenyl	0	Me	none	1	H	Me	OH
	745	4-(N-methylamidino) phenyl	0	Me	none	1	H	Et	OH
	746	4-(N-methylamidino) phenyl	0	Me	none	1	H	Propyl	OH
60	747	4-(N-methylamidino) phenyl	0	Me	none	1	H	butyl	OH
	748	4-(N-methylamidino) phenyl	0	Me	none	1	H	hexyl	OH

	749	4-(N-methylamidino) 0 Me	none	1	H	cyclopropyl	OH
	750	phenyl 4-(N-methylamidino) 0 Me	none	1	H	cyclohexyl	OH
5	751	phenyl 4-(N-methylamidino) 0 Me	none	1	H	acetynyl	OH
	752	phenyl 4-(N-methylamidino) 0 Me	none	1	H	methylacetynyl	OH
10	753	phenyl 4-(N-methylamidino) 0 Me	none	1	H	cyclopropylacetynyl	OH
	754	phenyl 4-(N-methylamidino) 0 Me	none	1	H	ethylacetynyl	OH
	755	phenyl 4-(N-methylamidino) 0 Me	none	1	H	butylacetynyl	OH
15	756	phenyl 4-(N-butylamidino) 0 Me	none	1	H	Me	OH
	757	phenyl 4-(N-butylamidino) 0 Me	none	1	H	Et	OH
20	758	phenyl 4-(N-butylamidino) 0 Me	none	1	H	Propyl	OH
	759	phenyl 4-(N-butylamidino) 0 Me	none	1	H	butyl	OH
25	760	phenyl 4-(N-butylamidino) 0 Me	none	1	H	hexyl	OH
	761	phenyl 4-(N-butylamidino) 0 Me	none	1	H	cyclopropyl	OH
	762	phenyl 4-(N-butylamidino) 0 Me	none	1	H	cyclohexyl	OH
30	763	phenyl 4-(N-butylamidino) 0 Me	none	1	H	acetynyl	OH
	764	phenyl 4-(N-butylamidino) 0 Me	none	1	H	methylacetynyl	OH
35	765	phenyl 4-(N-butylamidino) 0 Me	none	1	H	cyclopropylacetynyl	OH
	766	phenyl 4-(N-butylamidino) 0 Me	none	1	H	ethylacetynyl	OH
	767	phenyl 4-(N-butylamidino) 0 Me	none	1	H	butylacetynyl	OH
40	768	phenyl 4-(N-butylamidino) 0 Me	none	1	H	vinyl	OH

45

Table 2



Ex No.	R ¹ -A	m	R ³	X	n	U	V	j	Y	MS [(M+1) ⁺]
5										
10	769	4-amidinophenyl	0	Me	C(O)	1	N	none	1	OH
	770	4-amidinophenyl	0	Me	C(O)	1	N	none	1	OMe
	771	4-amidinophenyl	0	Me	C(O)	1	N	none	1	OH
		4-R, 6-S								
	772	4-amidinophenyl	0	Me	C(O)	1	N	none	2	OH
	773	4-amidinophenyl	0	Me	C(O)	1	N	none	3	OH
15	774	4-amidinophenyl	0	Me	C(O)	1	CH	none	1	OH
	775	4-amidinophenyl	0	Me	C(O)	1	CH	none	2	OH
	776	4-amidinophenyl	0	Me	C(O)	1	CH	none	3	OH
	777	4-amidinophenyl	0	Me	C(O)	1	CH	O	1	OH
	778	4-amidinophenyl	0	Me	C(O)	1	CH	O	2	OH
20	779	4-amidinophenyl	0	Me	C(O)	1	CH	O	3	OH
	780	4-amidinophenyl	0	Me	C(O)	1	N	O	1	OH
	781	4-amidinophenyl	0	Me	C(O)	1	N	O	2	OH
	782	4-amidinophenyl	0	Me	C(O)	1	N	NH	1	OH
25	783	4-amidinophenyl	0	Me	C(O)	0	N	none	1	OH
	784	4-amidinophenyl	0	Me	C(O)	0	N	none	1	OMe
	785	4-amidinophenyl	0	Me	C(O)	0	N	none	2	OH
	786	4-amidinophenyl	0	Me	C(O)	0	N	none	3	OH
	787	4-amidinophenyl	0	Me	C(O)	0	CH	none	1	OH
30	788	4-amidinophenyl	0	Me	C(O)	0	CH	none	2	OH
	789	4-amidinophenyl	0	Me	C(O)	0	CH	none	3	OH
	790	4-amidinophenyl	0	Me	C(O)	0	CH	O	1	OH
	791	4-amidinophenyl	0	Me	C(O)	0	CH	O	2	OH
	792	4-amidinophenyl	0	Me	C(O)	0	N	O	1	OH
35	793	4-amidinophenyl	0	Me	C(O)	0	N	O	2	OH
	794	4-amidinophenyl	0	Me	C(O)	0	N	NH	1	OH
	795	4-amidinophenyl	1	Me	C(O)	0	N	none	1	OH
	796	4-amidinophenyl	1	Me	C(O)	0	N	none	1	OMe
40	797	4-amidinophenyl	1	Me	C(O)	0	N	none	2	OH
	798	4-amidinophenyl	1	Me	C(O)	0	N	none	3	OH
	799	4-amidinophenyl	1	Me	C(O)	0	CH	none	1	OH
	800	4-amidinophenyl	1	Me	C(O)	0	CH	none	2	OH
	801	4-amidinophenyl	1	Me	C(O)	0	CH	none	3	OH
45	802	4-amidinophenyl	1	Me	C(O)	0	CH	O	1	OH
	803	4-amidinophenyl	1	Me	C(O)	0	CH	O	2	OH
	804	4-amidinophenyl	1	Me	C(O)	0	CH	O	3	OH
	805	4-amidinophenyl	1	Me	C(O)	0	N	O	1	OH
	806	4-amidinophenyl	1	Me	C(O)	0	N	O	2	OH
50	807	4-amidinophenyl	1	Me	C(O)	0	N	NH	1	OH
	808	4-amidinophenyl	1	Et	C(O)	0	N	none	1	OH
	809	4-amidinophenyl	1	Et	C(O)	0	N	none	1	OMe
	810	4-amidinophenyl	1	Et	C(O)	0	N	none	2	OH

5	811	4-amidinophenyl	1	Et	C(O)	0	N	none	3	OH
	812	4-amidinophenyl	1	Et	C(O)	0	CH	none	1	OH
	813	4-amidinophenyl	1	Et	C(O)	0	CH	none	2	OH
	814	4-amidinophenyl	1	Et	C(O)	0	CH	none	3	OH
	815	4-amidinophenyl	1	Et	C(O)	0	CH	O	1	OH
	816	4-amidinophenyl	1	Et	C(O)	0	CH	O	2	OH
	817	4-amidinophenyl	1	Et	C(O)	0	CH	O	3	OH
	818	4-amidinophenyl	1	Et	C(O)	0	N	O	1	OH
10	819	4-amidinophenyl	1	Et	C(O)	0	N	O	2	OH
	820	4-amidinophenyl	1	Et	C(O)	0	N	NH	1	OH
15	821	4-amidinophenyl	1	benzyl	C(O)	0	N	none	1	OH
	822	4-amidinophenyl	1	benzyl	C(O)	0	N	none	1	OMe
	823	4-amidinophenyl	1	benzyl	C(O)	0	N	none	2	OH
	824	4-amidinophenyl	1	benzyl	C(O)	0	N	none	3	OH
	825	4-amidinophenyl	1	benzyl	C(O)	0	CH	none	1	OH
	826	4-amidinophenyl	1	benzyl	C(O)	0	CH	none	2	OH
	827	4-amidinophenyl	1	benzyl	C(O)	0	CH	none	3	OH
	828	4-amidinophenyl	1	benzyl	C(O)	0	CH	O	1	OH
20	829	4-amidinophenyl	1	benzyl	C(O)	0	CH	O	2	OH
	830	4-amidinophenyl	1	benzyl	C(O)	0	CH	O	3	OH
	831	4-amidinophenyl	1	benzyl	C(O)	0	N	O	1	OH
	832	4-amidinophenyl	1	benzyl	C(O)	0	N	O	2	OH
	833	4-amidinophenyl	1	benzyl	C(O)	0	N	NH	1	OH
25	834	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	N	none	1	OH
	835	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	N	none	1	OMe
30	836	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	N	none	2	OH
	837	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	N	none	3	OH
35	838	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	CH	none	1	OH
	839	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	CH	none	2	OH
	840	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	CH	none	3	OH
40	841	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	CH	O	1	OH
	842	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	CH	O	2	OH
45	843	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	CH	O	3	OH
	844	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	N	O	1	OH
	845	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	N	O	2	OH
50	846	4-(N-methylamidino) phenyl	1	benzyl	C(O)	0	N	NH	1	OH
55	847	4-(N-butylamidino) phenyl	1	benzyl	C(O)	0	N	none	1	OH
	848	4-(N-butylamidino) phenyl	1	benzyl	C(O)	0	N	none	1	OMe
	849	4-(N-butylamidino) phenyl	1	benzyl	C(O)	0	N	none	2	OH
60	850	4-(N-butylamidino) phenyl	1	benzyl	C(O)	0	N	none	3	OH
	851	4-(N-butylamidino)	1	benzyl	C(O)	0	CH	none	1	OH

5	852	phenyl 4-(N-butylamidino)	1	benzyl	C(O)	0	CH	none	2	OH
	853	phenyl 4-(N-butylamidino)	1	benzyl	C(O)	0	CH	none	3	OH
	854	phenyl 4-(N-butylamidino)	1	benzyl	C(O)	0	CH	O	1	OH
	855	phenyl 4-(N-butylamidino)	1	benzyl	C(O)	0	CH	O	2	OH
10	856	phenyl 4-(N-butylamidino)	1	benzyl	C(O)	0	CH	O	3	OH
	857	phenyl 4-(N-butylamidino)	1	benzyl	C(O)	0	N	O	1	OH
15	858	phenyl 4-(N-butylamidino)	1	benzyl	C(O)	0	N	O	2	OH
	859	phenyl 4-(N-butylamidino)	1	benzyl	C(O)	0	N	NH	1	OH
20	860	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	N	none	1	OH
	861	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	N	none	1	OMe
	862	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	N	none	2	OH
25	863	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	N	none	3	OH
	864	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	CH	none	1	OH
30	865	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	CH	none	2	OH
	866	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	CH	none	3	OH
	867	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	CH	O	1	O
35	868	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	CH	O	2	OH
	869	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	CH	O	3	OH
40	870	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	N	O	1	OH
	871	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	1	N	O	2	OH
	872	phenyl 4-(N-butylamidino)	0	benzyl	C(O)	0	N	NH	1	OH
45	873	4-piperidinyl	1	benzyl	C(O)	0	N	none	1	OH
	874	4-piperidinyl	1	benzyl	C(O)	0	N	none	1	OMe
	875	4-piperidinyl	1	benzyl	C(O)	0	N	none	2	OH
	876	4-piperidinyl	1	benzyl	C(O)	0	N	none	3	OH
	877	4-piperidinyl	1	benzyl	C(O)	0	CH	none	1	OH
	878	4-piperidinyl	1	benzyl	C(O)	0	CH	none	2	OH
	879	4-piperidinyl	1	benzyl	C(O)	0	CH	none	3	OH
	880	4-piperidinyl	1	benzyl	C(O)	0	CH	O	1	OH
	881	4-piperidinyl	1	benzyl	C(O)	0	CH	O	2	OH
	882	4-piperidinyl	1	benzyl	C(O)	0	CH	O	3	OH
55	883	4-piperidinyl	1	benzyl	C(O)	0	N	O	1	OH
	884	4-piperidinyl	1	benzyl	C(O)	0	N	O	2	OH
	885	4-piperidinyl	1	benzyl	C(O)	0	N	NH	1	OH
60	886	4-piperidinyl	2	benzyl	C(O)	0	N	none	1	OH
	887	4-piperidinyl	2	benzyl	C(O)	0	N	none	1	OMe

5	888	4-piperidinyl	2	benzyl	C(O)	0	N	none	2	OH
	889	4-piperidinyl	2	benzyl	C(O)	0	N	none	3	OH
	890	4-piperidinyl	2	benzyl	C(O)	0	CH	none	1	OH
	891	4-piperidinyl	2	benzyl	C(O)	0	CH	none	2	OH
	892	4-piperidinyl	2	benzyl	C(O)	0	CH	none	3	OH
	893	4-piperidinyl	2	benzyl	C(O)	0	CH	O	1	OH
	894	4-piperidinyl	2	benzyl	C(O)	0	CH	O	2	OH
	895	4-piperidinyl	2	benzyl	C(O)	0	CH	O	3	OH
	896	4-piperidinyl	2	benzyl	C(O)	0	N	O	1	OH
	897	4-piperidinyl	2	benzyl	C(O)	0	N	O	2	OH
10	898	4-piperidinyl	2	benzyl	C(O)	0	N	NH	1	OH
15	899	4-piperidinyl	2	benzyl	C(O)	1	N	none	1	OH
	900	4-piperidinyl	2	benzyl	C(O)	1	N	none	1	OMe
	901	4-piperidinyl	2	benzyl	C(O)	1	N	none	2	OH
	902	4-piperidinyl	2	benzyl	C(O)	1	N	none	3	OH
	903	4-piperidinyl	2	benzyl	C(O)	1	CH	none	1	OH
	904	4-piperidinyl	2	benzyl	C(O)	1	CH	none	2	OH
	905	4-piperidinyl	2	benzyl	C(O)	1	CH	none	3	OH
	906	4-piperidinyl	2	benzyl	C(O)	1	CH	O	1	OH
	907	4-piperidinyl	2	benzyl	C(O)	1	CH	O	2	OH
	908	4-piperidinyl	2	benzyl	C(O)	1	CH	O	3	OH
20	909	4-piperidinyl	2	benzyl	C(O)	1	N	O	1	OH
	910	4-piperidinyl	2	benzyl	C(O)	1	N	O	2	OH
	911	4-piperidinyl	2	benzyl	C(O)	1	N	NH	1	OH
	912	4-amidinophenyl	0	Me	none	1	N	none	1	OH
	913	4-amidinophenyl	0	Me	none	1	N	none	1	OMe
	914	4-amidinophenyl	0	Me	none	1	N	none	1	OH
		4-R, 6-S								
	915	4-amidinophenyl	0	Me	none	1	N	none	2	OH
	916	4-amidinophenyl	0	Me	none	1	N	none	3	OH
	917	4-amidinophenyl	0	Me	none	1	CH	none	1	OH
35	918	4-amidinophenyl	0	Me	none	1	CH	none	2	OH
	919	4-amidinophenyl	0	Me	none	1	CH	none	3	OH
	920	4-amidinophenyl	0	Me	none	1	CH	O	1	OH
	921	4-amidinophenyl	0	Me	none	1	CH	O	2	OH
	922	4-amidinophenyl	0	Me	none	1	CH	O	3	OH
	923	4-amidinophenyl	0	Me	none	1	N	O	1	OH
	924	4-amidinophenyl	0	Me	none	1	N	O	2	OH
	925	4-amidinophenyl	0	Me		1	N	NH	1	OH
	926	4-amidinophenyl	0	Me	none	0	N	none	1	OH
	927	4-amidinophenyl	0	Me	none	0	N	none	1	OMe
40	928	4-amidinophenyl	0	Me	none	0	N	none	2	OH
	929	4-amidinophenyl	0	Me	none	0	N	none	3	OH
	930	4-amidinophenyl	0	Me	none	0	CH	none	1	OH
	931	4-amidinophenyl	0	Me	none	0	CH	none	2	OH
	932	4-amidinophenyl	0	Me	none	0	CH	none	3	OH
	933	4-amidinophenyl	0	Me	none	0	CH	O	1	OH
	934	4-amidinophenyl	0	Me	none	0	CH	O	2	OH
	935	4-amidinophenyl	0	Me	none	0	CH	O	3	OH
	936	4-amidinophenyl	0	Me	none	0	N	O	1	OH
	937	4-amidinophenyl	0	Me	none	0	N	O	2	OH
50	938	4-amidinophenyl	0	Me	none	0	N	NH	1	OH
	939	4-amidinophenyl	1	Me		0	N	none	1	OH
	940	4-amidinophenyl	1	Me	none	0	N	none	1	OMe
	941	4-amidinophenyl	1	Me	none	0	N	none	2	OH
	942	4-amidinophenyl	1	Me	none	0	N	none	3	OH
55										
60										

5	943	4-amidinophenyl	1	Me	none	0	CH	none	1	OH
	944	4-amidinophenyl	1	Me	none	0	CH	none	2	OH
	945	4-amidinophenyl	1	Me	none	0	CH	none	3	OH
	946	4-amidinophenyl	1	Me	none	0	CH	O	1	OH
	948	4-amidinophenyl	1	Me	none	0	CH	O	2	OH
	949	4-amidinophenyl	1	Me	none	0	CH	O	3	OH
	950	4-amidinophenyl	1	Me	none	0	N	O	1	OH
	951	4-amidinophenyl	1	Me	none	0	N	O	2	OH
10	952	4-amidinophenyl	1	Me	none	0	N	NH	1	OH
	953	4-amidinophenyl	1	Et	none	0	N	none	1	OH
	954	4-amidinophenyl	1	Et	none	0	N	none	1	OMe
	955	4-amidinophenyl	1	Et	none	0	N	none	2	OH
	956	4-amidinophenyl	1	Et	none	0	N	none	3	OH
	957	4-amidinophenyl	1	Et	none	0	CH	none	1	OH
	958	4-amidinophenyl	1	Et	none	0	CH	none	2	OH
	959	4-amidinophenyl	1	Et	none	0	CH	none	3	OH
15	960	4-amidinophenyl	1	Et	none	0	CH	O	1	OH
	961	4-amidinophenyl	1	Et	none	0	CH	O	2	OH
	962	4-amidinophenyl	1	Et	none	0	CH	O	3	OH
	963	4-amidinophenyl	1	Et	none	0	N	O	1	OH
	964	4-amidinophenyl	1	Et	none	0	N	O	2	OH
	965	4-amidinophenyl	1	Et	none	0	N	NH	1	OH
20	966	4-amidinophenyl	1	benzyl	none	0	N	none	1	OH
	967	4-amidinophenyl	1	benzyl	none	0	N	none	1	OMe
	968	4-amidinophenyl	1	benzyl	none	0	N	none	2	OH
	969	4-amidinophenyl	1	benzyl	none	0	N	none	3	OH
	970	4-amidinophenyl	1	benzyl	none	0	CH	none	1	OH
	971	4-amidinophenyl	1	benzyl	none	0	CH	none	2	OH
	972	4-amidinophenyl	1	benzyl	none	0	CH	none	3	OH
	973	4-amidinophenyl	1	benzyl	none	0	CH	O	1	OH
30	974	4-amidinophenyl	1	benzyl	none	0	CH	O	2	OH
	975	4-amidinophenyl	1	benzyl	none	0	CH	O	3	OH
	976	4-amidinophenyl	1	benzyl	none	0	N	O	1	OH
	977	4-amidinophenyl	1	benzyl	none	0	N	O	2	OH
	978	4-amidinophenyl	1	benzyl	none	0	N	NH	1	OH
35	979	4-(N-methylamidino) phenyl	1	benzyl	none	0	N	none	1	OH
	980	4-(N-methylamidino) phenyl	1	benzyl	none	0	N	none	1	OMe
	981	4-(N-methylamidino) phenyl	1	benzyl	none	0	N	none	2	OH
	982	4-(N-methylamidino) phenyl	1	benzyl	none	0	N	none	3	OH
	983	4-(N-methylamidino) phenyl	1	benzyl	none	0	CH	none	1	OH
	984	4-(N-methylamidino) phenyl	1	benzyl	none	0	CH	none	2	OH
	985	4-(N-methylamidino) phenyl	1	benzyl	none	0	CH	none	3	OH
	986	4-(N-methylamidino) phenyl	1	benzyl	none	0	CH	O	1	OH
40	987	4-(N-methylamidino) phenyl	1	benzyl	none	0	CH	O	2	OH
	988	4-(N-methylamidino) phenyl	1	benzyl	none	0	CH	O	3	OH
	989	4-(N-methylamidino) phenyl	1	benzyl	none	0	N	O	1	OH
	990	4-(N-methylamidino) phenyl	1	benzyl	none	0	N	O	2	OH

	991	phenyl 4-(N-methylamidino) phenyl	1	benzyl	none	0	N	NH	1	OH
5	992	4-(N-butylamidino) phenyl	1	benzyl	none	0	N	none	1	OH
	993	4-(N-butylamidino) phenyl	1	benzyl	none	0	N	none	1	OMe
10	994	4-(N-butylamidino) phenyl	1	benzyl	none	0	N	none	2	OH
	995	4-(N-butylamidino) phenyl	1	benzyl	none	0	N	none	3	OH
	996	4-(N-butylamidino) phenyl	1	benzyl	none	0	CH	none	1	OH
15	997	4-(N-butylamidino) phenyl	1	benzyl	none	0	CH	none	2	OH
	998	4-(N-butylamidino) phenyl	1	benzyl	none	0	CH	none	3	OH
	999	4-(N-butylamidino) phenyl	1	benzyl	none	0	CH	O	1	OH
20	1000	4-(N-butylamidino) phenyl	1	benzyl	none	0	CH	O	2	OH
	1001	4-(N-butylamidino) phenyl	1	benzyl	none	0	CH	O	3	OH
25	1002	4-(N-butylamidino) phenyl	1	benzyl	none	0	N	O	1	OH
	1003	4-(N-butylamidino) phenyl	1	benzyl	none	0	N	O	2	OH
30	1004	4-(N-butylamidino) phenyl	1	benzyl	none	0	N	NH	1	OH
	1005	4-(N-butylamidino) phenyl	0	benzyl	none	1	N	none	1	OH
35	1006	4-(N-butylamidino) phenyl	0	benzyl	none	1	N	none	1	OMe
	1007	4-(N-butylamidino) phenyl	0	benzyl	none	1	N	none	2	OH
	1008	4-(N-butylamidino) phenyl	0	benzyl	none	1	N	none	3	OH
40	1009	4-(N-butylamidino) phenyl	0	benzyl	none	1	CH	none	1	OH
	1010	4-(N-butylamidino) phenyl	0	benzyl	none	1	CH	none	2	OH
45	1011	4-(N-butylamidino) phenyl	0	benzyl	none	1	CH	none	3	OH
	1012	4-(N-butylamidino) phenyl	0	benzyl	none	1	CH	O	1	OH
	1013	4-(N-butylamidino) phenyl	0	benzyl	none	1	CH	O	2	OH
50	1014	4-(N-butylamidino) phenyl	0	benzyl	none	1	CH	O	3	OH
	1015	4-(N-butylamidino) phenyl	0	benzyl	none	1	N	O	1	OH
55	1016	4-(N-butylamidino) phenyl	0	benzyl	none	1	N	O	2	OH
	1017	4-(N-butylamidino) phenyl	0	benzyl	none	0	N	NH	1	OH
60	1018	4-piperidinyl	1	benzyl	none	0	N	none	1	OH
	1019	4-piperidinyl	1	benzyl	none	0	N	none	1	OMe
	1020	4-piperidinyl	1	benzyl	none	0	N	none	2	OH

5	1021	4-piperidiny1	1	benzyl	none	0	N	none	3	OH
	1022	4-piperidiny1	1	benzyl	none	0	CH	none	1	OH
	1023	4-piperidiny1	1	benzyl	none	0	CH	none	2	OH
	1024	4-piperidiny1	1	benzyl	none	0	CH	none	3	OH
	1025	4-piperidiny1	1	benzyl	none	0	CH	O	1	OH
10	1026	4-piperidiny1	1	benzyl	none	0	CH	O	2	OH
	1027	4-piperidiny1	1	benzyl	none	0	CH	O	3	OH
	1028	4-piperidiny1	1	benzyl	none	0	N	O	1	OH
	1029	4-piperidiny1	1	benzyl	none	0	N	O	2	OH
	1030	4-piperidiny1	1	benzyl	none	0	N	NH	1	OH
15	1031	4-piperidiny1	2	benzyl	none	0	N	none	1	OH
	1032	4-piperidiny1	2	benzyl	none	0	N	none	1	OMe
	1033	4-piperidiny1	2	benzyl	none	0	N	none	2	OH
	1034	4-piperidiny1	2	benzyl	none	0	N	none	3	OH
	1035	4-piperidiny1	2	benzyl	none	0	CH	none	1	OH
20	1036	4-piperidiny1	2	benzyl	none	0	CH	none	2	OH
	1037	4-piperidiny1	2	benzyl	none	0	CH	none	3	OH
	1038	4-piperidiny1	2	benzyl	none	0	CH	O	1	OH
	1039	4-piperidiny1	2	benzyl	none	0	CH	O	2	OH
	1040	4-piperidiny1	2	benzyl	none	0	CH	O	3	OH
25	1041	4-piperidiny1	2	benzyl	none	0	N	O	1	OH
	1042	4-piperidiny1	2	benzyl	none	0	N	O	2	OH
	1043	4-piperidiny1	2	benzyl	none	0	N	NH	1	OH
	1044	4-piperidiny1	2	benzyl	none	1	N	none	1	OH
	1045	4-piperidiny1	2	benzyl	none	1	N	none	1	OMe
30	1046	4-piperidiny1	2	benzyl	none	1	N	none	2	OH
	1048	4-piperidiny1	2	benzyl	none	1	N	none	3	OH
	1049	4-piperidiny1	2	benzyl	none	1	CH	none	1	OH
	1050	4-piperidiny1	2	benzyl	none	1	CH	none	2	OH
	1051	4-piperidiny1	2	benzyl	none	1	CH	none	3	OH
35	1052	4-piperidiny1	2	benzyl	none	1	CH	O	1	OH
	1053	4-piperidiny1	2	benzyl	none	1	CH	O	2	OH
	1054	4-piperidiny1	2	benzyl	none	1	CH	O	3	OH
	1055	4-piperidiny1	2	benzyl	none	1	N	O	1	OH
	1056	4-piperidiny1	2	benzyl	none	1	N	O	2	OH
40	1057	4-piperidiny1	2	benzyl	none	1	N	NH	1	OH

Utility

The compounds of this invention possess antiplatelet efficacy, as evidenced by their activity in standard platelet aggregation assays or platelet fibrinogen binding assays, as described below. A compound is considered to be active in these assays if it has an IC₅₀ value of less than about 1 mM. Platelet aggregation and fibrinogen binding assays which may be used to demonstrate the antiplatelet activity of the compounds of the invention are described below.

Platelet Aggregation Assay: Venous blood was obtained from the arm of a healthy human donor who was drug-free and aspirin-free for at least two weeks prior to blood collection. Blood was collected into 10 mL citrated Vacutainer tubes. The blood was centrifuged for 15 minutes at 150 x g at room temperature, and platelet-rich plasma (PRP) was removed. The remaining blood was centrifuged for 15 minutes at 1500 x g at room temperature, and platelet-poor plasma (PPP) was removed. Samples were assayed on a aggregometer (PAP-4 Platelet Aggregation Profiler), using PPP as the blank (100% transmittance). 200 µL of PRP was added to each micro test tube, and transmittance was set to 0%. 20 µL of various agonists (ADP, collagen, arachidonate, epinephrine, thrombin) were added to each tube, and the aggregation profiles were plotted (% transmittance versus time). The results are expressed as % inhibition of agonist-induced platelet aggregation. For the IC₅₀ evaluation, the test compounds were added at various concentrations prior to the activation of the platelets.

Ester prodrugs were preincubated (10⁻³ M F.C.) with 100 IU/mL Porcine liver esterase (Sigma Chemical Co., St. Louis, MO, #E-3128) for 2 hours at 37 °C. Aliquots are then diluted in 0.1 M Tris, pH 7.4, to the desired concentrations. Aliquots of 20 µl of the esterase pretreated prodrugs are added to 200 µl of human platelet rich plasma. Samples were placed in platelet profiler (aggregometer) for 8 minutes at 37 °C, followed by the addition of 100 µM Adenosine

Diphosphate, (Sigma Chemical Co., St. Louis, MO, #A-6521), to induce platelet aggregation. Platelet aggregation was allowed to proceed for 5 minutes. Percent inhibition is calculated using percent aggregation in the presence of the test compound divided by percent aggregation of control, times 100. This value is subtracted from 100, yielding percent inhibition. Calculation of IC₅₀ is performed on a Texas Instruments TI59 with an IC₅₀ program.

Compounds of the present invention have demonstrated IC₅₀ values less than 1 mM.

Purified GPIIb/IIIa-Fibrinogen Binding ELISA

The following reagents are used in the GPIIb/IIIa-fibrinogen binding ELISA:

- 15 purified GPIIb/IIIa (148.8 µg/mL);
- biotinylated fibrinogen (~ 1 mg/mL or 3000 nM);
- anti-biotin alkaline phosphatase conjugate (Sigma no. A7418);
- flat-bottom, high binding, 96-well plates (Costar Cat. no. 3590);
- 20 phosphatase substrate (Sigma 104) (40 mg capsules);
- bovine serum albumin (BSA) (Sigma no. A3294);
- Alkaline Phosphatase buffer - 0.1 M glycine-HCl, 1 mM MgCl₂·6H₂O, 1 mM ZnCl₂, pH 10.4;
- 25 Binding buffer - 20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl₂·2H₂O, 0.02% NaN₃, pH 7.0;
- Buffer A - 50 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl₂·2H₂O, 0.02% NaN₃, pH 7.4;
- Buffer A + 3.5% BSA (Blocking buffer);
- 30 Buffer A + 0.1% BSA (Dilution buffer);
- 2N NaOH.

The following method steps are used in the GPIIb/IIIa-fibrinogen binding ELISA:

- 35 Coat plates with GPIIb/IIIa in Binding buffer (125 ng/100 µL/well) overnight at 4 °C (Leave first column uncoated for non-specific binding). Cover and freeze plates at -70 °C until used. Thaw plate 1 hour at room temperature

or overnight at 4 °C. Discard coating solution and wash once with 200 µL Binding buffer per well. Block plate 2 hours at room temperature on shaker with 200 µL Buffer A + 3.5% BSA (Blocking buffer) per well. Discard Blocking buffer and wash
5 once with 200 µL Buffer A + 0.1% BSA (Dilution buffer) per well. Pipet 11 µL of test compound (10X the concentration to be tested in Dilution buffer) into duplicate wells. Pipet 11 µL Dilution buffer into non-specific and total binding wells. Add 100 µL Biotinylated fibrinogen (1/133 in Dilution
10 buffer, final concentration = 20 nM) to each well. Incubate plates for 3 hours at room temperature on a plate shaker. Discard assay solution and wash twice with 300 µL Binding buffer per well. Add 100 µL Anti-biotin alkaline phosphatase conjugate (1/1500 in Dilution buffer) to each well. Incubate
15 plates for 1 hour at room temperature on plate shaker. Discard conjugate and wash twice with 300 µL Binding buffer per well. Add 100 µL Phosphatase substrate (1.5 mg/mL in Alkaline phosphatase buffer) to each well. Incubate plate at room temperature on shaker until color develops. Stop color
20 development by adding 25 µL 2N NaOH per well. Read plate at 405 nm. Blank against non-specific binding (NSB) well. % Inhibition is calculated as $100 - (\text{Test Compound Abs} / \text{Total Abs}) \times 100$.

25 Platelet-Fibrinogen Binding Assay: Binding of ^{125}I -fibrinogen to platelets was performed as described by Bennett et al. (1983) Proc. Natl. Acad. Sci. USA 80: 2417-2422, with some modifications as described below. Human PRP (h-PRP) was applied to a Sepharose column for the purification of
30 platelet fractions. Aliquots of platelets (5×10^8 cells) along with 1 mM calcium chloride were added to removable 96 well plates prior to the activation of the human gel purified platelets (h-GPP). Activation of the human gel purified platelets was achieved using ADP, collagen, arachidonate,
35 epinephrine, and/or thrombin in the presence of the ligand, ^{125}I -fibrinogen. The ^{125}I -fibrinogen bound to the activated platelets was separated from the free form by centrifugation and then counted on a gamma counter. For an IC_{50} evaluation,

the test compounds were added at various concentrations prior to the activation of the platelets.

The compounds of Formula (I) of the present invention may also possess thrombolytic efficacy, that is, they are capable of lysing (breaking up) already formed platelet-rich fibrin blood clots, and thus are useful in treating a thrombus formation, as evidenced by their activity in the tests described below. Preferred compounds of the present invention for use in thrombolysis include those compounds having an IC_{50} value (that is, the molar concentration of the compound capable of achieving 50% clot lysis) of less than about 1 μM , more preferably an IC_{50} value of less than about 0.1 μM .

Thrombolytic Assay: Venous blood was obtained from the arm of a healthy human donor who was drug-free and aspirin free for at least two weeks prior to blood collection, and placed into 10 ml citrated Vacutainer tubes. The blood was centrifuged for 15 minutes at 1500 x g at room temperature, and platelet rich plasma (PRP) was removed. To the PRP was then added 1×10^{-3} M of the agonist ADP, epinephrine, collagen, arachidonate, serotonin or thrombin, or a mixture thereof, and the PRP incubated for 30 minutes. The PRP was centrifuged for 12 minutes at 2500 x g at room temperature. The supernatant was then poured off, and the platelets remaining in the test tube were resuspended in platelet poor plasma (PPP), which served as a plasminogen source. The suspension was then assayed on a Coulter Counter (Coulter Electronics, Inc., Hialeah, FL), to determine the platelet count at the zero time point. After obtaining the zero time point, test compounds were added at various concentrations. Test samples were taken at various time points and the platelets were counted using the Coulter Counter. To determine the percent of lysis, the platelet count at a time point subsequent to the addition of the test compound was subtracted from the platelet count at the zero time point, and the resulting number divided by the platelet count at the zero time point. Multiplying this result by 100 yielded the percentage of clot lysis achieved by the test compound. For

the IC₅₀ evaluation, the test compounds were added at various concentrations, and the percentage of lysis caused by the test compounds was calculated.

The compounds of Formula (I) of the present invention are also useful for administration in combination with anti-coagulant agents such as warfarin or heparin, or anti-platelet agents such as aspirin, piroxicam or ticlopidine, or thrombin inhibitors such as boro peptides, hirudin or argatroban, or thrombolytic agents such as tissue plasminogen activator, anistreplase, urokinase or streptokinase, or combinations thereof.

The compounds of Formula (I) of the present invention may also be useful as antagonists of other integrins such as for example, the α_v/β_3 or vitronectin receptor, α_4/β_1 or α_5/β_1 and as such may also have utility in the treatment and diagnosis of osteoporosis, cancer metastasis, diabetic retinopathy, rheumatoid arthritis, inflammation, and autoimmune disorders. The compounds of Formula (I) of the present invention may be useful for the treatment or prevention of other diseases which involve cell adhesion processes, including, but not limited to, inflammation, bone degradation, rheumatoid arthritis, asthma, allergies, adult respiratory distress syndrome, graft versus host disease, organ transplantation, septic shock, psoriasis, eczema, contact dermatitis, osteoporosis, osteoarthritis, atherosclerosis, metastasis, wound healing, diabetic retinopathy, inflammatory bowel disease and other autoimmune diseases.

30

Dosage and Formulation

The compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in

the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an anti-aggregation agent. Finally, the compounds of the invention may also be administered intranasally.

5 The compounds of this invention can be administered by any means that produces contact of the active agent with the agent's site of action, glycoprotein IIb/IIIa (GPIIb/IIIa), in the body of a mammal. They can be administered by any conventional means available for use in conjunction with
10 pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents, such as a second antiplatelet agent such as aspirin or ticlopidine which are agonist-specific. They can be administered alone, but generally administered with a pharmaceutical carrier selected
15 on the basis of the chosen route of administration and standard pharmaceutical practice.

 The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular
20 agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the
25 patient, and the effect desired. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

 By way of general guidance, the daily oral dosage of
30 each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. Intravenously, the most preferred doses will range from about
35 1 to about 10 mg/kg/minute during a constant rate infusion. Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily

dosage may be administered in divided doses of two, three, or four times daily.

The compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as carrier materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.

Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.

Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.

The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.

Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained

release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.

Representative useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

Capsules

A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 1-20 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.

Soft Gelatin Capsules

A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 1-20

milligrams of the active ingredient. The capsules are washed and dried.

Tablets

A large number of tablets are prepared by conventional procedures so that the dosage unit was 1-20 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

Injectable

A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.

Suspension

An aqueous suspension is prepared for oral administration so that each 5 mL contain 1-20 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025 mL of vanillin.

The compounds of the present invention may be administered in combination with a second therapeutic agent selected from: an anti-coagulant agent such as warfarin or heparin; an anti-platelet agent such as aspirin, piroxicam or ticlopidine; a thrombin inhibitor such as a boro peptide thrombin inhibitor, or hirudin; or a thrombolytic agent such as plasminogen activators, such as tissue plasminogen activator, anistreplase, urokinase or streptokinase. The compound of Formula (I) and such second therapeutic agent can be administered separately or as a physical combination in a single dosage unit, in any dosage form and by various routes of administration, as described above.

The compound of Formula (I) may be formulated together with the second therapeutic agent in a single dosage unit (that is, combined together in one capsule, tablet, powder,

or liquid, etc.). When the compound of Formula (I) and the second therapeutic agent are not formulated together in a single dosage unit, the compound of Formula (I) and the second therapeutic agent (anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent) may be administered essentially at the same time, or in any order; for example the compound of Formula (I) may be administered first, followed by administration of the second agent (anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent). When not administered at the same time, preferably the administration of the compound of Formula (I) and the second therapeutic agent occurs less than about one hour apart.

A preferable route of administration of the compound of Formula (I) is oral. Although it is preferable that the compound of Formula (I) and the second therapeutic agent (anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent) are both administered by the same route (that is, for example, both orally), if desired, they may each be administered by different routes and in different dosage forms (that is, for example, one component of the combination product may be administered orally, and another component may be administered intravenously).

The dosage of the compound of Formula (I) when administered alone or in combination with a second therapeutic agent may vary depending upon various factors such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration, the age, health and weight of the recipient, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, and the effect desired, as described above.

Although the proper dosage of the compound of Formula (I) when administered in combination with the second therapeutic agent will be readily ascertainable by a medical practitioner skilled in the art, once armed with the present disclosure, by way of general guidance, where the compounds of this invention are combined with anti-coagulant agents,

for example, a daily dosage may be about 0.1 to 100 milligrams of the compound of Formula (I) and about 1 to 7.5 milligrams of the anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the novel compounds of this invention generally may be present in an amount of about 1 to 10 milligrams per dosage unit, and the anti-coagulant in an amount of about 1 to 5 milligrams per dosage unit.

Where the compounds of Formula (I) are administered in combination with a second anti-platelet agent, by way of general guidance, typically a daily dosage may be about 0.01 to 25 milligrams of the compound of Formula (I) and about 50 to 150 milligrams of the additional anti-platelet agent, preferably about 0.1 to 1 milligrams of the compound of Formula (I) and about 1 to 3 milligrams of antiplatelet agents, per kilogram of patient body weight.

Further, by way of general guidance, where the compounds of Formula (I) are administered in combination with thrombolytic agent, typically a daily dosage may be about 0.1 to 1 milligrams of the compound of Formula (I), per kilogram of patient body weight and, in the case of the thrombolytic agents, the usual dosage of the thrombolytic agent when administered alone may be reduced by about 70-80% when administered with a compound of Formula (I).

Where two or more of the foregoing second therapeutic agents are administered with the compound of Formula (I), generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination.

Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of Formula (I) and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced). For example,

one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. One of the active ingredients may also be coated with a sustained-release material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients.

Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a lowviscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.

These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.

The present invention also includes pharmaceutical kits useful, for example, in the inhibition of platelet aggregation, the treatment of blood clots, and/or the treatment of thromboembolic disorders, which comprise one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I). Such kits may further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers,


etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing
5 the components, may also be included in the kit.

In the present disclosure it should be understood that the specified materials and conditions are important in practicing the invention but that unspecified materials and conditions are not excluded so long as they do not prevent
10 the benefits of the invention from being realized.

Claims

What is claimed is:

1. A compound of the Formula (I):



(I)

or their pharmaceutically acceptable salts thereof, wherein:

- 10 A is selected from R¹;
 phenyl substituted with R¹ and 0-2 R⁶;
 piperidinyl substituted with 0-1 R¹ and 0-2 R⁶; and
 pyridyl substituted with 0-1 R¹ and 0-2 R⁶;
- 15 R¹ is -NHR², -C(=NR²)NHR², -Z(CH₂)_qNHR², -Z(CH₂)_qC(=NR²)NHR²,
 -N(R²)C(=NR²)NHR², -C(=O)NHR², -C(=NR²)N(OR^{2A})R², or
 -C(=NOR^{2A})NHR²;
- q is 1, 2, or 3;
- 20 Z is a bond, O, S, S(=O), or S(=O)₂;
- R² is, independently at each occurrence, H, C₁-C₄ alkyl, C₂-C₆
 alkenyl, C₁-C₁₀ alkoxy carbonyl, or aryl(C₁-C₁₀
 25 alkoxy) carbonyl;
- R^{2A} is H or C₁-C₁₀ alkyl substituted with 0-1 R⁴;
- R³ is H,
- 30 C₁-C₆ alkyl substituted with 0-1 R⁶,
 C₂-C₆ alkenyl substituted with 0-1 R⁶,
 C₂-C₆ alkynyl substituted with 0-1 R⁶,
 C₃-C₇ cycloalkyl substituted with 0-2 R^{6A},
 phenyl substituted with 0-2 R^{6A}, or

pyridyl substituted with 0-2 R^{6A};

X is -C(=O)- or a single bond;

5 R⁴ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇
cycloalkyl, C₇-C₁₄ bicycloalkyl, hydroxy, C₁-C₆ alkoxy,
C₁-C₆ alkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆
alkylsulfonyl, nitro, C₁-C₆ alkylcarbonyl, C₆-C₁₀ aryl,
-N(R¹²)R¹³; halo, CF₃, CN, NO₂, C₁-C₆ alkoxycarbonyl,
10 carboxy, piperidinyl, morpholinyl, or pyridinyl;

R⁵ is H or C₁-C₁₀ alkyl substituted with 0-1 R⁴;

R⁶ is C₃-C₇ cycloalkyl substituted with 0-2 R^{6A} or 0-1 R¹;
15 phenyl substituted with 0-2 R^{6A} or 0-1 R¹; or
pyridyl substituted with 0-2 R^{6A} or 0-1 R¹;

R^{6A} is C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, CF₃, NO₂ or NR¹²R¹³;

20 U is -C(R⁷)(R^{7A})- or -N(R⁷)-;

R⁷ is selected from:

H,
C₁-C₄ alkyl substituted with 0-2 R¹⁶,
25 C₂-C₄ alkenyl substituted with 0-2 R¹⁶,
C₂-C₄ alkynyl substituted with 0-2 R¹⁶,
C₃-C₆ cycloalkyl substituted with 0-2 R¹⁶,
C₃-C₆ cycloalkyl(C₁-C₄ alkyl) substituted with 0-2 R¹⁶,
aryl substituted with 0-4 R¹⁶,
30 aryl(C₁-C₄ alkyl) substituted with 0-4 R¹⁶,
a 5-6 membered heterocyclic ring system having 1-3
heteroatoms selected independently from O, S, and N,
said heterocyclic ring being substituted with 0-4
R¹⁶, and
35 C₁-C₄ alkyl substituted with a 5-6 membered heterocyclic
ring system having 1-3 heteroatoms selected
independently from O, S, and N, said heterocyclic
ring being substituted with 0-4 R¹⁶;

alternatively, R⁵ and R⁷ are taken together to form a 5-6
membered heterocyclic ring system having 1 or 2 nitrogen
atoms;

5

R^{7A} is selected from:

H,

C₁-C₄ alkyl substituted with 0-2 R¹⁶,

C₂-C₄ alkenyl substituted with 0-2 R¹⁶, and

10

C₂-C₄ alkynyl substituted with 0-2 R¹⁶;

R⁸ is selected from:

H,

-C(=O)N(R²⁰)₂,

15

C₁-C₆ alkyl substituted with 0-2 R¹⁶,

C₂-C₄ alkenyl substituted with 0-2 R¹⁶,

C₂-C₄ alkynyl substituted with 0-2 R¹⁶,

C₃-C₆ cycloalkyl substituted with 0-2 R¹⁶,

aryl substituted with 0-4 R¹⁶,

20

aryl(C₁-C₄ alkyl) substituted with 0-4 R¹⁶,

a 5-6 membered heterocyclic ring system having 1-3

heteroatoms selected independently from O, S, and N,

said heterocyclic ring being substituted with 0-4

R¹⁶, and

25

C₁-C₄ alkyl substituted with a 5-10 membered heterocyclic
ring system having 1-3 heteroatoms selected
independently from O, S, and N, said heterocyclic
ring being substituted with 0-4 R¹⁶;

30 alternatively, R⁵ and R⁸ are taken together to form a
piperidiny1 or a pyrrolidinyl ring;

alternatively, R⁷ and R⁸ are taken together to form a 5-6
membered carbocyclic ring, wherein said carbocyclic ring
35 is either saturated, partially unsaturated or aromatic;

R^{8A} is selected from:

H,

C₁-C₄ alkyl substituted with 0-2 R¹⁶,
C₂-C₄ alkenyl substituted with 0-2 R¹⁶, and
C₂-C₄ alkynyl substituted with 0-2 R¹⁶;

5 k is 0 or 1;

j is 0, 1, 2, or 3;

V is O, NH, or a single bond;

10

Q is -C(=O)Y, -SO₃H, or -PO₃H;

Y is hydroxy,

15 C₁-C₁₀ alkyloxy,
C₃-C₁₁ cycloalkyloxy,
C₆-C₁₀ aryloxy,
C₇-C₁₁ aralkyloxy,
C₃-C₁₀ alkylcarbonyloxyalkyloxy,
C₃-C₁₀ alkoxy carbonyloxyalkyloxy,
20 C₂-C₁₀ alkoxy carbonylalkyloxy,
C₅-C₁₀ cycloalkylcarbonyloxyalkyloxy,
C₅-C₁₀ cycloalkoxy carbonyloxyalkyloxy,
C₅-C₁₀ cycloalkoxy carbonylalkyloxy,
C₇-C₁₁ aryloxy carbonylalkyloxy,
25 C₈-C₁₂ aryloxy carbonyloxyalkyloxy,
C₈-C₁₂ arylcarbonyloxyalkyloxy,
C₅-C₁₀ alkoxyalkylcarbonyloxyalkyloxy,
C₅-C₁₀ (5-alkyl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy,
C₁₀-C₁₄ (5-aryl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy,
30 or
(R²)HN-(C₁-C₁₀ alkyl)oxy;

m is 0, 1, or 2;

35 n is 0, 1, 2, 3, or 4;

R⁹ and R¹⁰ are each independently H, C₁-C₆ alkyl, C₂-C₆
alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl,

phenyl substituted with 0-2 R^{6A}, or
pyridyl substituted with 0-2 R^{6A};

5 R¹² and R¹³ are each independently H, C₁-C₁₀ alkyl, C₁-C₁₀
alkoxycarbonyl, C₁-C₁₀ alkylcarbonyl, C₁-C₁₀
alkylsulfonyl, heteroaryl(C₁-C₄ alkyl)sulfonyl,
aryl(C₁-C₁₀ alkyl)sulfonyl, arylsulfonyl, aryl,
heteroarylcarbonyl, heteroarylsulfonyl, or
heteroarylalkylcarbonyl, wherein said aryls and
10 heteroaryls are optionally substituted with 0-3
substituents selected from the group consisting of C₁-C₄
alkyl, C₁-C₄ alkoxy, halo, CF₃, and NO₂;

15 R¹⁶ is H, halogen, -CF₃, -CN, -NO₂, -NR¹⁷R¹⁸, methyl, ethyl,
propyl, butyl, cyclopropyl, methoxy, ethoxy, propoxy,
butoxy, or C₁-C₄ alkoxy carbonyl;

R¹⁷ and R¹⁸ are each independently H, methyl, ethyl, propyl,
or butyl;

20 alternatively, R¹⁷ and R¹⁸ can be taken together to form
-(CH₂)₄-, -(CH₂)₅-, or -CH₂CH₂NHCH₂CH₂-;

R²⁰ is selected from:
25 H,
C₁-C₄ alkyl substituted with 0-1 R²¹,
C₃-C₆ cycloalkyl substituted with 0-2 R²¹,
aryl substituted with 0-3 R²¹, and
aryl(C₁-C₄ alkyl) substituted with 0-4 R²¹; and

30 R²¹ is H, halogen, -CF₃, -CN, -NR¹⁷R¹⁸, methyl, ethyl, propyl,
butyl, cyclopropyl, methoxy, ethoxy, propoxy, or butoxy;

provided that m and n are chosen such that the number of
35 atoms connecting R¹ and Y is in the range of 10-18.

2. A compound according to Claim 1, wherein:

- A is selected from R¹;
phenyl substituted with R¹ and 0-2 R⁶;
piperidinyl substituted with 0-1 R¹ and 0-2 R⁶; and
5 pyridyl substituted with 0-1 R¹ and 0-2 R⁶;
- R¹ is -NHR², -C(=NR²)NHR², -Z(CH₂)_qNHR², -Z(CH₂)_qC(=NR²)NHR²,
-N(R²)C(=NR²)NHR², -C(=NR²)N(OR^{2A})R², or -C(=NOR^{2A})NHR²;
- 10 q is 1, 2 or, 3;
- Z is a bond or O;
- R² is, independently at each occurrence, H, C₁-C₄ alkyl, C₂-C₄
15 alkenyl, C₁-C₆ alkoxy carbonyl, or aryl(C₁-C₆
alkoxy)carbonyl;
- R^{2A} is H or C₁-C₆ alkyl substituted with 0-1 R⁴;
- 20 R³ is H,
C₁-C₄ alkyl substituted with 0-1 R⁶,
C₂-C₄ alkenyl substituted with 0-1 R⁶,
C₂-C₄ alkynyl substituted with 0-1 R⁶,
C₃-C₆ cycloalkyl substituted with 0-2 R^{6A},
25 phenyl substituted with 0-2 R^{6A}, or
pyridyl substituted with 0-2 R^{6A};
- X is -C(=O)-;
- 30 R⁴ is C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆
cycloalkyl, C₇-C₁₂ bicycloalkyl, hydroxy, C₁-C₄ alkoxy,
C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄
alkylsulfonyl, nitro, C₁-C₄ alkylcarbonyl, C₆-C₁₀ aryl,
-N(R¹²)R¹³; halo, CF₃, CN, NO₂, C₁-C₅ alkoxy carbonyl,
35 carboxy, piperidinyl, morpholinyl, or pyridinyl;
- R⁵ is H or C₁-C₆ alkyl substituted with 0-1 R⁴;

R⁶ is C₃-C₇ cycloalkyl substituted with 0-2 R^{6A} or 0-1 R¹;
phenyl substituted with 0-2 R^{6A} or 0-1 R¹; or
pyridyl substituted with 0-2 R^{6A} or 0-1 R¹;

5 R^{6A} is C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, CF₃, NO₂, or NR¹²R¹³;

U is -C(R⁷)(R^{7A})- or -N(R⁷)-;

R⁷ is selected from:

- 10 H,
C₁-C₄ alkyl substituted with 0-1 R¹⁶,
C₂-C₄ alkenyl substituted with 0-1 R¹⁶,
C₂-C₄ alkynyl substituted with 0-1 R¹⁶,
C₃-C₆ cycloalkyl substituted with 0-2 R¹⁶,
15 C₃-C₆ cycloalkyl(C₁-C₄ alkyl) substituted with 0-1 R¹⁶,
aryl substituted with 0-4 R¹⁶, and
aryl(C₁-C₄ alkyl) substituted with 0-4 R¹⁶;

alternatively, R⁵ and R⁷ are taken together to form a
20 piperidinyl, pyrrolidinyl, or piperazinyl ring;

R^{7A} is H;

R⁸ is selected from:

- 25 H,
-C(=O)NHR²⁰,
C₁-C₆ alkyl substituted with 0-1 R¹⁶,
C₂-C₄ alkenyl substituted with 0-1 R¹⁶,
C₂-C₄ alkynyl substituted with 0-1 R¹⁶,
30 C₃-C₆ cycloalkyl substituted with 0-2 R¹⁶,
aryl substituted with 0-4 R¹⁶,
aryl(C₁-C₄ alkyl) substituted with 0-4 R¹⁶,
a 5-6 membered heterocyclic ring system having 1-3
heteroatoms selected independently from O, S, and N,
35 said heterocyclic ring being substituted with 0-4
R¹⁶, and
C₁-C₄ alkyl substituted with a 5-10 membered heterocyclic
ring system having 1-3 heteroatoms selected

independently from O, S, and N, said heterocyclic ring being substituted with 0-4 R¹⁶;

alternatively, R⁵ and R⁸ are taken together to form a
5 piperidinyl or a pyrrolidinyl ring;

alternatively, R⁷ and R⁸ are taken together to form a 5-6
membered carbocyclic ring, wherein said carbocyclic ring
is selected from phenyl, cyclohexyl, cyclopentyl,
10 cyclohexenyl, or cyclopentenyl;

R^{8A} is H or C₁-C₄ alkyl substituted with 0-1 R¹⁶;

k is 0 or 1;

15

j is 0, 1, or 2;

V is O or a single bond;

20 Q is -C(=O)Y or -SO₃H;

Y is hydroxy,

C₁-C₁₀ alkyloxy,

C₃-C₁₁ cycloalkyloxy,

25

C₆-C₁₀ aryloxy,

C₇-C₁₁ aralkyloxy,

C₃-C₁₀ alkylcarbonyloxyalkyloxy,

C₃-C₁₀ alkoxy carbonyloxyalkyloxy,

C₂-C₁₀ alkoxy carbonylalkyloxy,

30

C₅-C₁₀ cycloalkylcarbonyloxyalkyloxy,

C₅-C₁₀ cycloalkoxy carbonyloxyalkyloxy,

C₅-C₁₀ cycloalkoxy carbonylalkyloxy,

C₇-C₁₁ aryloxy carbonylalkyloxy,

C₈-C₁₂ aryloxy carbonyloxyalkyloxy,

35

C₈-C₁₂ arylcarbonyloxyalkyloxy,

C₅-C₁₀ alkoxyalkylcarbonyloxyalkyloxy,

C₅-C₁₀ (5-alkyl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy,

C₁₀-C₁₄ (5-aryl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy,
or
(R²)HN-(C₁-C₁₀ alkyl)oxy;

5 m is 0, 1, or 2;

n is 0, 1, 2, or 3;

10 R⁹ is H, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆
cycloalkyl, phenyl substituted with 0-2 R^{6A}, or pyridyl
substituted with 0-2 R^{6A};

R¹⁰ is H, methyl, ethyl, propyl, or butyl;

15 R¹² and R¹³ are each independently H, C₁-C₆ alkyl, C₁-C₆
alkoxycarbonyl, C₁-C₆ alkylcarbonyl, C₁-C₆ alkylsulfonyl,
heteroaryl(C₁-C₄ alkyl)sulfonyl,
aryl(C₁-C₆ alkyl)sulfonyl, arylsulfonyl, aryl,
heteroarylcarbonyl, heteroarylsulfonyl, or
20 heteroarylalkylcarbonyl, wherein said aryls and
heteroaryls are optionally substituted with 0-3
substituents selected from the group consisting of C₁-C₄
alkyl, C₁-C₄ alkoxy, halo, CF₃, and NO₂;

25 R¹⁶ is H, halogen, -CF₃, -CN, -NO₂, -NR¹⁷R¹⁸, methyl, ethyl,
propyl, butyl, cyclopropyl, methoxy, ethoxy, propoxy,
butoxy, or C₁-C₄ alkoxycarbonyl;

30 R¹⁷ and R¹⁸ are each independently H, methyl, ethyl, propyl,
or butyl;

alternatively, R¹⁷ and R¹⁸ can be taken together to form
-(CH₂)₄-, -(CH₂)₅-, or -CH₂CH₂NHCH₂CH₂-;

35 R²⁰ is selected from:

H,

C₁-C₄ alkyl substituted with 0-1 R²¹,

C₃-C₆ cycloalkyl substituted with 0-2 R²¹,

aryl substituted with 0-3 R²¹, and
aryl(C₁-C₄ alkyl) substituted with 0-3 R²¹; and

5 R²¹ is H, halogen, -CF₃, -CN, -NR¹⁷R¹⁸, methyl, ethyl, propyl,
butyl, cyclopropyl, methoxy, ethoxy, propoxy, or butoxy;

provided that m and n are chosen such that the number of
atoms connecting R¹ and Y is in the range of 10-18.

10

3. A compound according to Claim 1, wherein:

A is phenyl substituted with R¹ and 0-1 R⁶, or
piperidinyl substituted with 0-1 R⁶;

15

R¹ is -NHR², -C(=NR²)NHR², -(CH₂)_qNHR², -(CH₂)_qC(=NR²)NHR², or
-N(R²)C(=NR²)NHR²;

q is 1, 2, or 3;

20

R² is, independently at each occurrence, H, methyl, ethyl,
propyl, butyl, or C₂-C₄ alkenyl;

R³ is H,

25

C₁-C₄ alkyl substituted with 0-1 R⁶ or
C₂-C₄ alkenyl substituted with 0-1 R⁶;

X is -C(=O)-;

30

R⁴ is methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy,
or butoxy, fluoro, chloro, bromo, iodo, CF₃, NO₂, NH₂,
or N(CH₃)₂;

R⁵ is H or C₁-C₂ alkyl substituted with 0-1 R⁴;

35

R⁶ is C₃-C₆ cycloalkyl substituted with 0-2 R^{6A};
phenyl substituted with 0-2 R^{6A}; or
pyridyl substituted with 0-2 R^{6A};

R^{6A} is methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy,
or butoxy, fluoro, chloro, bromo, iodo, CF₃, NO₂, NH₂,
N(CH₃)₂, or N(CH₂CH₃)₂;

5

U is -C(R⁷)(R^{7A})- or -N(R⁷)-;

R⁷ is selected from:

H, methyl, ethyl, propyl, and butyl;

10

R^{7A} is H;

R⁸ is selected from:

H,

15

-C(=O)NHR²⁰,

C₁-C₆ alkyl substituted with 0-1 R¹⁶,

C₂-C₄ alkenyl substituted with 0-1 R¹⁶,

C₂-C₄ alkynyl substituted with 0-1 R¹⁶,

C₃-C₆ cycloalkyl substituted with 0-2 R¹⁶,

20

aryl substituted with 0-4 R¹⁶,

aryl(C₁-C₄ alkyl) substituted with 0-2 R¹⁶,

a 5-6 membered heterocyclic ring system having 1-3

heteroatoms selected independently from O, S, and N,

said heterocyclic ring being substituted with 0-2

25

R¹⁶, and

C₁-C₄ alkyl substituted with a 5-10 membered heterocyclic

ring system having 1-3 heteroatoms selected

independently from O, S, and N, said heterocyclic

ring being substituted with 0-2 R¹⁶;

30

R^{8A} is H, methyl, ethyl, propyl, or butyl;

k is 0;

35 j is 0;

V is a single bond;

Q is -C(=O)Y;

Y is hydroxy-,

C₁-C₄ alkoxy-,

5 methylcarbonyloxymethoxy-,

ethylcarbonyloxymethoxy-,

t-butylcarbonyloxymethoxy-,

cyclohexylcarbonyloxymethoxy-,

1-(methylcarbonyloxy)ethoxy-,

10 1-(ethylcarbonyloxy)ethoxy-,

1-(t-butylcarbonyloxy)ethoxy-,

1-(cyclohexylcarbonyloxy)ethoxy-,

t-butyloxy carbonyloxymethoxy-,

i-propyloxy carbonyloxymethoxy-,

15 1-(i-propyloxy carbonyloxy)ethoxy-,

1-(cyclohexyloxy carbonyloxy)ethoxy-,

1-(t-butyloxy carbonyloxy)ethoxy-,

dimethylaminoethoxy-,

diethylaminoethoxy-,

20 (5-methyl-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,

(5-(t-butyl)-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,

(1,3-dioxo-5-phenyl-cyclopenten-2-on-4-yl)methoxy-,

1-(2-(2-methoxypropyl)carbonyloxy)ethoxy-,

(R²)HN-(C₁-C₆ alkyl)oxy-, morpholinoethoxy-, or

25 pyrrolidinoethoxy;

m is 0 or 1;

n is 0 or 1;

30

R⁹ is H, methyl, ethyl, propyl, butyl, phenyl substituted with
0-2 R⁶, or pyridyl substituted with 0-2 R⁶;

R¹⁰ is H;

35

R¹⁶ is H, halogen, -CF₃, -CN, -NO₂, -NR¹⁷R¹⁸, methyl, ethyl,
propyl, butyl, cyclopropyl, methoxy, ethoxy, propoxy or
butoxy;

R^{17} and R^{18} are each independently H, methyl, ethyl, propyl or butyl.


5 R^{20} is selected from:

H,
 C_1 - C_3 alkyl substituted with 0-1 R^{21} ,
 C_3 - C_6 cycloalkyl substituted with 0-1 R^{21} ,
 aryl substituted with 0-2 R^{21} , and
 10 aryl(C_1 - C_2 alkyl) substituted with 0-2 R^{21} ; and

R^{21} is H, F, Cl, Br, I, $-CF_3$, $-CN$, NH_2 , $N(CH_3)_2$, $N(CH_2CH_3)_2$,
 methyl, ethyl, cyclopropyl, methoxy, or ethoxy.

15

4. A compound according to Claim 3 of Formula (Ia),
 wherein:



20

(Ia)

R^1 is $-C(=NR^2)NHR^2$, $-(CH_2)_qC(=NR^2)NHR^2$ or
 $-N(R^2)C(=NR^2)NHR^2$;

25 q is 1 or 2;

R^2 is, independently at each occurrence, H, methyl or ethyl;

R^3 is H,

30 methyl substituted with 0-1 R^6 , or
 ethyl substituted with 0-1 R^6 ;

R^5 is H, methyl or ethyl;

R⁶ is C₃-C₆ cycloalkyl substituted with 0-2 R^{6A};
phenyl substituted with 0-2 R^{6A}; or
pyridyl substituted with 0-2 R^{6A};

5

R^{6A} is methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy,
or butoxy, fluoro, chloro, bromo, iodo, CF₃, NO₂, NH₂ or
N(CH₃)₂;

10 R⁸ is selected from:

H,
-C(=O)NHCH₂R²¹,
-C(=O)NH(CH₂)₂R²¹,
-C(=O)NH(CH₂)₃R²¹,

15

methyl substituted with 0-1 R¹⁶,
ethyl substituted with 0-1 R¹⁶,
phenyl substituted with 0-2 R¹⁶,
phenyl(CH₂)- substituted with 0-2 R¹⁶,
phenyl(CH₂CH₂)- substituted with 0-2 R¹⁶,

20

a 5-6 membered heterocyclic ring system selected from
pyrrolyl, indolyl, 2-isobenzazolyl-, indazolyl,
isoindazolyl, pyridinyl, quinolinyl, isoquinolinyl,
and piperidinyl;

25

methyl substituted with a 5-6 membered heterocyclic ring
system selected from pyrrolyl, indolyl, 2-
isobenzazolyl-, indazolyl, isoindazolyl, pyridinyl,
quinolinyl, isoquinolinyl, and piperidinyl; and

30

ethyl substituted with a 5-6 membered heterocyclic ring
system selected from pyrrolyl, indolyl, 2-
isobenzazolyl-, indazolyl, isoindazolyl, pyridinyl,
quinolinyl, isoquinolinyl, and piperidinyl;

35

Y is hydroxy-, methoxy-, ethoxy-, n-butoxy-, isopropoxy-,
isobutoxy-, benzyloxy-, methylcarbonyloxymethoxy-,
ethylcarbonyloxymethoxy-, tert-butylcarbonyloxymethoxy-,
cyclohexylcarbonyloxymethoxy-,
tert-butyloxycarbonyloxymethoxy-, dimethylaminoethoxy-,

diethylaminoethoxy-, morpholinoethoxy-, or
pyrrolidinoethoxy-;

5 R^{16} is H, halogen, $-CF_3$, methyl, ethyl, methoxy, ethoxy, $-NH_2$,
 $-N(CH_3)_2$, or $-N(CH_2CH_3)_2$;

R^{17} and R^{18} are each independently H, methyl, or ethyl; and

10 R^{21} is H, F, Cl, Br, I, $-CF_3$, $-CN$, NH_2 , $N(CH_3)_2$, $N(CH_2CH_3)_2$,
 methyl, ethyl, cyclopropyl, methoxy, or ethoxy.

5. A compound of Claim 1 selected from the group
consisting of:

15

3-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-
oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminopropionic acid;

20

3-[[4(R)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-
oxo-2H-1,3-oxazin-6(S)-yl]acetyl]amino propionic acid;

Trans-3-[[4-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-
2-oxo-2H-1,3-oxazin-6-yl]acetyl]amino propionic acid;

25

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-
2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminobutyric acid;

30

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-
2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-phenylvaleric
acid;

35

3(S)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-
2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-3-(pyridin-3-
yl)propionic acid;

3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-
2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-3-(pyridin-3-
yl)propionic acid;

- 3(S)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-3-phenylpropionic acid;
- 5
- 3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-3-phenylpropionic acid;
- 10
- 3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-4-[(3-dimethylamino)propyl]amino-4-oxobutanoic acid;
- 15
- 3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-indole-3-valeric acid;
- 20
- 3-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminopropionic acid;
- 25
- 3(R)-[[4(S)-[4-(aminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]aminobutyric acid;
- 30
- [N-[[4(S)-[4-(N-butylaminoiminomethyl)phenyl]tetrahydro-3-benzyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]piperidin-4-yl]acetic acid;
- 35
- 3(R)-[[4(S)-[4-(N-butylaminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]amino-5-phenylvaleric acid;
- 3-[[2-methyl-3(S)-[4-(aminoiminomethyl)phenyl]-isoxazolidin-5(R)-yl]acetyl]aminopropionic acid;


3-[[2-methyl-3(R)-[4-(aminoiminomethyl)phenyl]-isoxazolidin-5(S)-yl]acetyl]aminopropionic acid;

3(R)-[[2-methyl-3(R)-[4-(aminoiminomethyl)phenyl]-isoxazolidin-5(S)-yl]acetyl]aminobutyric acid; and

[N-[[4(S)-[4-(N-butylaminoiminomethyl)phenyl]tetrahydro-3-methyl-2-oxo-2H-1,3-oxazin-6(R)-yl]acetyl]piperidin-4-yl]acetic acid.

10


6. A compound of Claim 1 of formula (II)



(II)

15 or their pharmaceutically acceptable salts thereof.

7. A compound of Claim 2 of formula (II)




(II)

20

or their pharmaceutically acceptable salts thereof.

8. A compound of Claim 3 of formula (II)




(II)

25

or their pharmaceutically acceptable salts thereof.


9. A compound of Claim 4 of formula (IIa)



(IIa)

5 or their pharmaceutically acceptable salts thereof.

10. A compound of Claim 1 of formula (III)



(III)

10 or their pharmaceutically acceptable salts thereof.

11. A pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically effective amount of a compound according to one of Claims 1-10 or a pharmaceutically acceptable salt from thereof.

12. A method of inhibiting the aggregation of blood platelets which comprises administering to a host in need of such inhibition a therapeutically effective amount of a compound according to one of Claims 1-10.

13. A method of treating thromboembolic disorders selected from thrombus or embolus formation, harmful platelet aggregation, reocclusion following thrombolysis, reperfusion injury, restenosis, atherosclerosis, stroke, myocardial infarction, and unstable angina, which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound according to one of Claims 1-10.

14. A method of treating metastatic cancer which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound according to one of Claims 1-10.
- 5

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/14392

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D265/10 C07D261/02 C07D413/12 C07D413/06 A61K31/535
A61K31/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 14682 A (DU PONT MERCK PHARMA) 1 June 1995 (1995-06-01) claims	1-14
Y	WO 95 14683 A (DU PONT MERCK PHARMA) 1 June 1995 (1995-06-01) claims	1-14
Y	WO 98 06707 A (DU PONT MERCK PHARMA) 19 February 1998 (1998-02-19) claims	1-14
Y	WO 98 06694 A (DU PONT MERCK PHARMA) 19 February 1998 (1998-02-19) claims	1-14

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"A" document member of the same patent family

Date of the actual completion of the international search

7 October 1999

Date of mailing of the international search report

19/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 apo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chouly, J

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 14392

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 12-14
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 12-14
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC/US 99/14392

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9514682 A	01-06-1995	US 5446056 A	29-08-1995
		AT 168106 T	15-07-1998
		AU 677481 B	24-04-1997
		AU 1097895 A	13-06-1995
		CA 2174415 A	01-06-1995
		DE 69411584 D	13-08-1998
		DE 69411584 T	17-12-1998
		EP 0730589 A	11-09-1996
		ES 2120713 T	01-11-1998
		JP 9505589 T	03-06-1997
		NZ 276631 A	24-06-1995
		ZA 9409291 A	23-05-1996
WO 9514683 A	01-06-1995	AU 695853 B	27-08-1998
		AU 1098095 A	13-06-1995
		BR 9408137 A	12-08-1997
		CA 2174838 A	01-06-1995
		CZ 9601419 A	13-11-1996
		EP 0730590 A	11-09-1996
		FI 962184 A	23-05-1996
		HR 940952 A	30-04-1997
		HU 74690 A	28-01-1997
		JP 9505590 T	03-06-1997
		NO 962096 A	23-05-1996
		NZ 276633 A	27-04-1998
		PL 314591 A	16-09-1996
		SK 66696 A	06-11-1996
		US 5849736 A	15-12-1998
		ZA 9409337 A	24-05-1996
WO 9806707 A	19-02-1998	AU 3970697 A	06-03-1998
		EP 0922039 A	16-06-1999
WO 9806694 A	19-02-1998	AU 4064597 A	06-03-1998
		EP 0934265 A	11-08-1999